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ABSTRACT 
Genomic stability relies on the faithful chromosome segregation in mitosis, under 
the control of the Spindle Assembly Checkpoint (SAC). This surveillance mechanism 
monitors the nature of kinetochore-microtubule attachments (KT-MT) and prevents 
premature anaphase onset until all chromosomes achieve proper bipolar attachments and 
come under tension. To initiate anaphase and promote mitotic exit, the silencing of SAC 
is required.  
In this study, we proposed to shed light into the function and regulation of the SAC 
mechanism and to explore its potential as therapeutic target for cancer therapy. For that, 
two questions were asked that define the main objectives of the present thesis: i) how 
SAC proteins are functionally related to motor proteins to regulate KT-MT attachments 
and SAC silencing? and ii) to what extent could SAC proteins constitute relevant cancer 
biomarkers and/or relevant targets to kill cancer cells, either alone or in combination 
with currently used antimitotics? 
We found that RNAi-mediated co-depletion of the SAC protein Bub3 and the motor 
protein dynein partially restored functional KT-MT attachment, otherwise severely 
affect by individual depletion of each of the two proteins, leading to chromosome 
congression. An antagonistic relationship between Bub3 and dynein is suggested to 
ensure stable KT-MT attachments. In addition, we demonstrated that upon chromosome 
alignment at the metaphase plate, the core SAC proteins Mad1, Mad2, Bub1, BubR1, 
and Bub3 and the KMN components Hec1 and Mis12 are poleward transported by 
dynein, suggesting a role in SAC silencing.  
Second, and in a therapeutic perspective, we dissected the dual role of Spindly 
(kinetochore regulator of dynein), in chromosome attachment and SAC silencing, as a 
strategy to potentiate tumor cell killing. We found an upregulation of Spindly in human 
cancer cell lines and in patient samples which are correlated with tumor proliferation. 
Interestingly, Spindly inhibition enhanced the cytotoxic response of paclitaxel- and 
cisplatin-mediated chemotherapy, and sensitized human tumor cells to death.  
Overall, we provide new insight into the regulation of kinetochore-microtubule 
interactions by establishing a functional antagonistic relationship between Bub3 and 
dynein in regulating KT-MT attachment. Also, we provide new insight as to SAC 
components that are removed from the kinetochore by dynein during SAC silencing. 
ABSTRACT 
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Finally, we propose Spindly as relevant target for cancer treatment and as a new 
biomarker for cancer proliferation and prognosis.   
 
Keywords: spindle assembly checkpoint, kinetochore-microtubule interactions, Bub3, 
dynein, Spindly, cancer therapy.  
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RESUMO 
A estabilidade genómica depende da fidelidade da segregação dos cromossomas, 
durante a mitose, sob o controlo do checkpoint mitótico. Este sofisticado mecanismo de 
controlo monitoriza o estado das ligações cinetocoro-microtúbulos e inibe o início 
prematuro da anafase até que todos os cromossomas estabeleçam uma ligação bipolar, 
através dos seus cinetocoros irmãos, com os microtúbulos provenientes de pólos 
opostos do fuso mitótico, culminando no seu alinhamento na placa metafásica, 
fenómeno designado de congressão. Nos cinetocoros não ligados ou ligados de forma 
incorrecta, a formação do complexo do checkpoint mitótico (MCC), constituído pela 
associação das proteínas Mad2, BubR1, Bub3 e Cdc20, inibe a activação do complexo 
promotor da anafase/ciclossoma (APC/C). A inibição do APC/C evita a degradação 
proteossómica dos substratos mitóticos ciclina B e securina, induzindo uma paragem na 
mitose e evitando a separação prematura das cromátides irmãs. Por sua vez, o início da 
anafase e a saída da mitose requerem o silenciamento do checkpoint mitótico. 
A expressão anormal de componentes do checkpoint mitótico tem sido amplamente 
associada a vários tipos de cancro. Assim, a mitose como alvo no tratamento do cancro 
emergiu como um área de rápido avanço científico e várias proteínas envolvidas na sua 
regulação têm vindo a ser identificadas como possíveis alvos terapêuticos. Até à data, os 
fármacos que afectam a dinâmica dos microtúbulos como o paclitaxel, permanecem 
entre os quimioterápicos mais efetivos na clínica. Ao interferirem com a instabilidade 
dinâmica dos microtúbulos, estes agentes levam a uma activação crónica do checkpoint 
mitótico que ativaria o programa de morte celular. Infelizmente, o destino das células 
paradas em mitose sobre ação dos agentes anti-microtúbulos varia consideravelmente 
entre uma população de células tumorais e algumas células saem da mitose, escapando à 
morte celular. Não obstante, a resistência adquirida e a toxicidade, associada aos 
fármacos quimioterápicos em uso, permanecem uma preocupante limitação no sucesso 
da terapia do cancro. Assim, torna-se urgente compreender o mecanismo através do qual 
estes compostos atuam e travam a progressão das células tumorais, de forma a potenciar 
a sua acção e/ou desenvolver novas abordagens terapêuticas. Igualmente importante é a 
identificação de biomarcadores específicos que promovam uma detecção precoce e um 
diagnóstico efectivo.   
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No presente estudo propusemo-nos promover o conhecimento acerca da função e 
regulação do mecanismo do checkpoint mitótico e explorar o seu papel como potencial 
alvo terapêutico no tratamento do cancro. Para isso, duas questões principais foram 
colocadas, que definem os objetivos desta tese: (i) de que forma as proteínas do 
checkpoint mitótico estão funcionalmente relacionadas com as proteínas motoras dos 
microtúbulos, na regulação da ligação cinetocoro-microtúbulos e no silenciamento do 
checkpoint mitótico? e (ii) até que ponto as proteínas do checkpoint mitótico podem 
constituir relevantes biomarcadores e/ou alvos terapêuticos para eliminar as células 
tumorais, quer de forma isolada ou em combinação com os agentes anti-mitóticos 
correntemente em uso?  
Para responder ao primeiro objetivo, propusemo-nos caracterizar, em células 
humanas em cultura, a relação funcional entre a proteína do checkpoint mitótico Bub3 e 
a proteína motora dineína, na ligação cinetocoro-microtúbulos, recorrendo à técnica de 
RNA de interferência, a ensaios funcionais e microscopia de alta resolução. A depleção, 
quer da proteína Bub3 quer da proteínas dineína, originou placas metafásicas 
incompletas com vários cromossomas desalinhados, confirmando o papel destas 
proteínas na ligação cinetocoro-microtúbulos. Surpreendentemente, a depleção 
simultânea das duas proteínas resultou na supressão parcial do fenótipo de 
desalinhamento e restaurou a congressão dos cromossomas. Consistente com estas 
observações, as ligações cinetocoro-microtúbulos estabelecidas nas células co-
depletadas mostraram ser estáveis, produzindo tensão inter- e intra-cinetocoros, 
indicando que são funcionais. Sugerimos a existência de uma relação antagonística entre 
as proteínas Bub3 e dineína na regulação da estabilidade das ligações cinetocoro-
microtúbulos. Ainda, propusemo-nos clarificar o papel da proteína dineína no 
silenciamento do checkpoint mitótico, nomeadamente no transporte de componentes do 
checkpoint dos cinetocoros ligados para os pólos do fuso mitótico. Recorrendo a dois 
ensaios de redução de ATP que mantêm a atividade motora da dineína mas que previne 
a libertação no pólo da proteína transportada, verificamos que os componentes do 
checkpoint mitótico Mad1, Mad2, Bub1, BubR1, and Bub3 são redistribuídos dos 
cinetocoros ligados para os pólos do fuso, pela ação motora da dineína. Esta 
redistribuição continua a ocorrer em células paradas em metafase, após tratamento com 
o inibidor do proteossoma MG-132, situação em que checkpoint deveria estar 
silenciado, indicando que estas células são capazes de reativar este mecanismo. Estes 
resultados foram corroborados “in vivo” pela observação em tempo real deste processo 
RESUMO  
xix 
recorrendo a uma proteína de fusão EGFP-Bub3. Curiosamente, foi verificado que um 
pool das proteínas Hec1 e Mis12 é igualmente transportado pela dineína para os pólos, 
sugerindo uma contribuição do complexo KMN (complexo proteico necessário para o 
estabelecimento da ligação cinetocoro-microtúbulo) no silenciamento do checkpoint 
mitótico. 
Para responder ao segundo objetivo, e numa perspetiva terapêutica, exploramos o 
papel da proteína Spindly como potencial alvo terapêutico no tratamento do cancro. A 
Spindly é uma proteína necessária para a localização da dineína nos cinetocoros e está 
implicada na ligação dos cromossomas e no silenciamento do checkpoint mitótico. 
Inicialmente, verificamos uma sobreexpressão da Spindly quer em linhas celulares 
tumorais (PCR em tempo real) quer em amostras tumorais de pacientes 
(imunohistoquímica). Da análise imunohistoquímica verificou-se que a sobreexpressão 
da Spindly (+75% dos pacientes com carcinoma oral) estava correlacionada com um 
aumento da proliferação tumoral e com um mau prognóstico. As análises uni e 
multivariadas demonstraram que esta sobreexpressão constitui um indicador 
independente de prognóstico para a sobrevivência específica de cancro. Por outro lado, 
a depleção da Spindly, por RNA de interferência, revelou um aumento do efeito 
citotóxico de fármacos correntemente utilizados em quimioterapia, como o paclitaxel e 
a cisplatina, demonstrando sensibilizar as células tumorais para a morte celular. Estes 
resultados indicam que a supressão da Spindly poderá constituir uma estratégia válida e 
efectiva no tratamento do cancro. Como as concentrações utilizadas de paclitaxel e 
cisplatina utilizadas foram efetivamente reduzidas, esta estratégia poderá trazer 
benefícios clínicos, nomeadamente na superação dos efeitos secundários inerentes ao 
tratamento com estes fármacos. Estes resultados reforçam o potencial clinico da Spindly 
como um importante marcador de proliferação tumoral e o benefício de um co-
tratamento com paclitaxel ou cisplatina na inibição da proliferação tumoral e na indução 
da morte celular.  
Globalmente, o trabalho apresentado nesta tese contribuiu para estabelecer uma 
relação entre proteínas envolvidas na sinalização do checkpoint mitótico e as proteínas 
da maquinaria da ligação cinetocoro-microtúbulos; clarificou quais as proteínas 
transportadas dos cinetocoros para os pólos do fuso, pela dineína na promoção do 
silenciamento do checkpoint mitótico e identificou novos componentes sujeitos a este 
transporte; e identificou a proteína Spindly como potencial biomarcador e alvo 
terapêutico no tratamento do cancro, como adjuvante dos fármacos quimioterápicos em 
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uso. Permitiu, ainda, estabelecer uma ponte sólida entre a investigação fundamental e a 
investigação aplicada ao relacionar aspetos da função e regulação do mecanismo do 
checkpoint mitótico com as implicações terapêuticas resultantes da sua modelação.   
 
Palavras-chave: checkpoint mitótico, interações cinetocoro-microtúbulos, Bub3, 
dynein, Spindly, terapia anti-cancro. 
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THESIS OUTLINE 
 
This thesis is organized into six chapters and one appendix.  
Chapter 1 provides a general introduction in light of the current literature. An 
overview of the cell cycle, its regulation and control are addressed. A particular 
emphasis is given to mitosis, from the description of the events to the molecular 
machinery of the mitotic spindle. Kinetochore-microtubules interactions and error 
correction are described in detail. Spindle Assembly Checkpoint (SAC) activation and 
silencing mechanisms are presented, together with the link between SAC and 
tumorigenesis. Lastly, targeting mitosis for cancer therapy was focused, providing an 
overview of the current approaches, their limitations and future directions.  
Chapter 2 describes the project motivation and the specific aims.  
Chapters 3 and 4 are related to the experimental work and are structured according 
to two main aims. In chapter 3 we describe the work performed on the regulation and 
function of SAC. In particular, chapter 3 unveils a functional interaction between the 
SAC protein Bub3 and the microtubule motor dynein in regulating kinetochore-
microtubule attachments and elucidates the role of kinetochore dynein in SAC silencing 
mechanism. In chapter 4 we describe the work concerning the relevance of SAC 
components in cancer therapy. In this chapter, we explore the dual role of Spindly 
protein in chromosome attachment and SAC silencing as a strategy to potentiate tumor 
cell killing. The consequences of Spindly depletion on the viability of tumor cells 
treated with clinically relevant doses of paclitaxel and cisplatin are reported. 
Importantly, the pattern of Spindly expression in patient samples from oral cancer and 
its potential correlation to clinicopathologic significance are stated. A rationale for 
combination chemotherapy is discussed, providing a novel and possibly effective 
approach for therapeutic intervention in cancer. 
Chapter 5 provides overall conclusions and perspectives for future research. 
In Chapter 6 a list of all cited references is available.  
Lastly, the Appendix contains the legends of the movies that were provided in 
digital support. 
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1. THE EUKARYOTIC CELL DIVISION CYCLE  
1.1. Cell cycle overview  
The cell cycle can be defined as a highly ordered and tightly regulated process by 
which a parental cell reproduces and gives rise to two genetically identical daughter 
cells. Therefore, it is a vital process during the development of multicellular organisms 
and for the maintenance of adult tissues, by providing the renewal of old or damaged 
cells.  
Classically, the eukaryotic cell cycle can be divided in two major phases: the 
longest, called interphase, during which the cell grows and replicates the chromosomal 
DNA; and the shorter phase, mitosis, where the segregation of replicated chromosomes 
and their equal distribution takes place (Figure 1.1).  
 
Figure 1.1. Illustration of the eukaryotic cell cycle. Resting non-dividing cells are called in 
G0 and may entre G1 phase, pass the restriction point (R) and go through cell cycle under 
mitogen stimuli. The cell cycle is divided in two major phases, the interphase (I, dark blue), 
which comprises the G1-, S- and G2-phases, and mitosis (M, green). During the Gap phases, G1 
and G2, the cell continuously grows and synthetizes components for the S-phase and mitosis, 
respectively. At the S-phase the DNA and centrosomes are replicated. At mitosis (M phase) the 
cell contents are equally distributed between the two new daughter cells.  
 
The interphase is the period between two consecutive mitosis and contemplates the 
orderly phases Gap1 (G1), the synthesis-phase (S-phase), and the Gap2 (G2). During 
the G1, the biosynthetic activity of the cell is quite pronounced, namely the synthesis of 
enzymes required for the following S-phase. The membrane, structural proteins, 
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cytoplasmic organelles and RNAs are duplicated, resulting in the cell size doubling, 
although the chromosomes are in only single copies per cell. The major control of cell 
proliferation is positioned at late G1 and is called restriction point. Regulated primarily 
by extracellular growth factors, the fate of the most cells is dictated at this point. In the 
presence of suitable growth factors, cells go past the restriction point, and become 
committed to proceed through S-phase and continuing cycling. In contrast, if proper 
growth factors are not available, cells exit from the cell cycle becoming quiescent, a 
reversible non-proliferating resting state called Gap0 (G0). Some cells can stay for long 
periods without proliferating, remaining metabolically active, although they cease 
growth and have reduced rates of protein synthesis; while others remain at G0 for their 
entire lifespan. During the S-phase, centrosomes and DNA are replicated, and each 
chromosome has now two sister chromatids. At the G2 phase, the cell continues to grow 
and synthetize macromolecules in preparation for mitosis.  
Mitosis, or M-phase, culminates into the nuclear division, and is followed by the 
cytoplasmic division, or cytokinesis, where the formed daughter cells are completely 
individualized.  
1.2. Cell cycle regulation and control 
The ordering of cell cycle events is orchestrated by a complex regulatory network 
that controls the accurate timing and direction of duplication and division of cellular 
components. By ensuring the unidirectionality, the occurrence of later events is 
dependent of the successful completion of earlier events. For instance, DNA replication 
should begin and end before the distribution of cell contents at mitosis. Through signal 
transduction pathways, the cell cycle control system allows events separated either in 
time or space to be connected between the different phases.  
Cell cycle central regulators are a family of serine/threonine kinases known as 
Cyclin-dependent kinases (Cdks) [1, 2], which catalyze the phosphorylation of protein 
substrates inducing changes in their enzymatic activity or the interaction with other 
proteins. Cdks concentration is constant throughout the cell cycle and regulation of their 
activity depends primarily on fluctuations in levels of the regulatory subunits termed 
cyclins. These bind tightly to Cdks and stimulate their catalytic activity. In addition to 
cyclin binding, complete activation of Cdks requires a phosphorylation of a threonine 
residue 160 (Thr 160) adjacent to the kinase active site, catalyzed by Cdk-activating 
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kinases (CAKs). In contrast, Cdks inhibition could be modulated by interactions with 
Cdk inhibitors (CKIs), working as brakes to halt cell cycle progression under adverse 
conditions, and by inhibitory phosphorylation at tyrosine residue 15 (Tyr 15) and 
threonine residue 14 (Thr 14) of Cdks. Changes in the phosphorylation of these sites are 
particularly critical in the activation of mitotic Cdks, at the onset of mitosis. 
Phosphorylation of Tyr 15 by kinase Wee1, or phosphorylation of both Tyr 15 and Thr 
14 by kinase Myt1, inactivates the M-phase cyclin-Cdk complex. In turn, 
dephosphorylation of the inhibitory sites by the phosphatase Cdc25C leads to complex 
reactivation and allows entry into mitosis [3, 4].  
Cyclins are produced and degraded according to the cell cycle stage, resulting in the 
formation of specific complexes cyclin-Cdk which controls the progression of cell cycle 
(Figure 1.2). Cyclins can be divided in four classes: G1 cyclins (D in vertebrates), G1/S 
cyclins (E in vertebrates), S cyclins (A in vertebrates) and G2/M cyclins (A and B in 
vertebrates) [5, 6].  
 
 
Figure 1.2. Different cyclin-Cdk complexes formed along the cell cycle stages in 
vertebrates. Cyclin D-Cdk4 or -Cdk6 controls the cell cycle entry at G1; Cyclin E-Cdk2 
monitors the G1/S phase, initiating the process of DNA replication; Cyclin A-Cdk1 or -Cdk2 
stimulates the DNA replication at S-phase and promotes early mitotic events; Cyclin B-Cdk1 
promotes mitosis entrance and its degradation is required for mitotic exit.  
 
G1 cyclins contributes to stimulate and control the cell cycle entrance in response to 
extracellular factors. G1/S cyclins rise in late G1 and fall in early S-phase, triggering 
cell progression through restriction point and initiating the process that leads to DNA 
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and centrosomes replication. S cyclins are responsible for stimulate the DNA 
replication, remaining high throughout S-phase, and also at G2 and early mitosis to 
promote the initial mitotic events. The association between cyclin B with Cdk1 (initially 
known as p34Cdc2) forms a complex called Mitosis-Promoting Factor (MPF), critical 
for mitosis onset. Cyclin B rises as the cell approaches mitosis and it is responsible for 
the cellular changes that occur in early stages (described in the next section), while their 
degradation leads to the mitotic exit. Cyclin levels regulation depends on cyclin gene 
expression and their degradation by the ubiquitin-proteolytic system, thereby 
modulating different Cdks activity [7]. Indeed, the irreversibility of the cell cycle is 
achieved by proteolytic destruction of cyclins and this post-translational mechanism is 
particularly important at the metaphase to anaphase transition, during mitosis, where the 
sister chromatids separation and mitosis exit are triggered by cyclin B destruction and 
consequent inactivation of Cdk1. Cyclin B is targeted for degradation after 
ubiquitination (addition of multiple copies of ubiquitin) by the anaphase-promoting 
complex/cyclosome (APC), followed by destruction on the proteasome. 
To ensure that genetically normal cells are produced, there are control mechanisms 
at each phase transition called checkpoints that detect errors in the execution of a cell 
cycle event, leading to an arrest until the damage is repaired. These checkpoints are 
positioned before key cell cycle events like DNA replication and sister chromatids 
separation (Figure 1.3) and are critical for the maintenance of genomic fidelity [8]. An 
attenuation of their function contributes to genomic instability that may benefit the 
development of cancer cells [9-11]. The major cell cycle checkpoints can be grouped in 
two classes according to their function in DNA damage, during the interphase, or in 
mitosis progression. DNA damage checkpoints have evolved as a network of cellular 
signaling pathways to ensure accuracy of DNA replication and, in turn, prevent 
progression into mitosis with damaged DNA. These cell cycle checkpoints arrest or 
delay cell cycle progression either in: the G1 phase, before DNA replication; in S-phase, 
during DNA replication; or in G2 phase, before mitosis [12, 13, 11]. Cells respond to 
DNA damage by inducing repair mechanisms or, in the presence of excessive and 
irreparable damage, by promoting cell death. For instance, if DNA damage occurs at 
G1, the G1 checkpoint induces the rapid stabilization and accumulation of the tumor 
suppressor p53 and cells with damaged DNA are restricted from entering S-phase until 
the damage is removed [14]. The Ataxia Telangiectasia Mutated (ATM) kinase is 
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activated by DNA double strand breaks (DSBs), acting as a transducer of DNA damage 
signals, and triggers the G1 checkpoint by phosphorylating and activating the 
Checkpoint Kinase 2 (Chk2) [15]. In turn, Chk2 inhibits Cdc25A, a phosphatase that 
removes inhibitory phosphorylation of the cyclin A-Cdk2 and cyclin E-Cdk2 
complexes, preventing cells from proceeding into S-phase [16]. ATM also induces 
phosphorylation and stabilization of p53, reducing its affinity for the negative regulator, 
the ubiquitin ligase Mdm2 [17, 18]. Stabilized p53 induces the transcription of the CKI 
p21 that binds and inhibits cyclin A-Cdk2 and cyclin E-Cdk2 complexes [19]. In case 
the damage cannot be repaired, this mechanism is capable of triggering apoptosis or 
senescence. The intra-S checkpoint delays or slows down DNA replication during S-
phase in order to minimize replication errors. The damage is sensed by the ATM and 
Rad3-related (ATR) kinase which by activating Checkpoint Kinase 1 (Chk1) induces 
Cdc25A proteosomal degradation, blocking further progression through S-phase [20, 
21]. ATR and Chk1 also trigger the G2/M checkpoint, which prevents cells with 
damaged DNA from entering mitosis, therefore minimizing chromosome 
missegregation [22]. The checkpoint operating during mitosis is termed spindle 
assembly checkpoint (SAC) and controls the successful bipolar attachment of all 
chromosomes with spindle microtubules and the consequent alignment at metaphase 
plate before cell transition to anaphase [23] (described in detail in section 4).  
 
Figure 1.3. Localization of the cell cycle checkpoints. Yellow lines represent the DNA 
damage-activated checkpoints (G1/S, intra-S and G2/M), positioned to detect DNA lesions 
before, during and after DNA replication; and the red line the mitotic checkpoint (SAC), which 
ensures that all chromosomes are aligned and correctly attached to the spindle microtubules 
before segregate. R represents the restriction point. 
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2. MITOSIS 
2.1. General description  
Mitosis represents one of the most important and fascinating events of the cell cycle, 
since the genomic material, duplicated in interphase are equally distributed by the new 
formed daughter cells, ensuring the accuracy of genome transmission.  
Based on structural changes, mitosis can be divided into five continuous stages: 
prophase, prometaphase, metaphase, anaphase and telophase (Figure 1.4 and 1.5). 
 At the beginning of prophase, the filaments of chromosomal DNA start to 
condense, originating recognizable chromosomes and making visible the two sister 
chromatids held together by a constricted region known as centromere. Simultaneously, 
centrosomes separate and start to migrate towards opposite sides of cell to initiate the 
bipolar microtubules array for the mitotic spindle assembly. The end of prophase and 
the onset of prometaphase is marked by the nuclear envelope breakdown (NEBD), 
allowing a dynamic interaction between chromosomes and spindle microtubules. 
Spindle microtubules attach to sister chromatids at the kinetochore, a specialized protein 
complex assembled on centromeric DNA. At this moment, the microtubules from 
opposite spindle poles, defined by centrosomes, start to attach to kinetochores of 
dispersed chromosomes in a classical process called “search and capture”. The 
metaphase is achieved when all captured chromosomes have established bipolar 
attachments with microtubules from opposite spindle poles, becoming bi-oriented, and 
reaches the alignment at the equatorial region of the spindle in a process known as 
congression. The metaphase to anaphase transition is the most dramatic event of 
mitosis. At anaphase A, the cohesion between the sister chromatids are swiftly lost and 
the separated chromatids are pulled towards opposite poles of the spindle, leading to 
their segregation. At anaphase B, the mitotic spindle elongates and the two poles move 
farther apart from of each other, completing the segregation. During the telophase, the 
spindle is disassembled, leaving a single centrosome associated with one set of 
chromosomes. The nuclear envelope reorganizes and repackages the already 
decondensing chromosomes, and other nuclear components, in two daughter nuclei. In 
addition, a contractile furrow starts to form between the nuclei and splits the cell in two 
due to actin and myosin action, characterizing the cytokinesis step.  
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Figure 1.4. Schematic representation of the mitotic stages and cytokinesis. In prophase the 
chromosomal DNA (blue and green lines) starts to condense, to generate well-defined 
chromosomes, and the centrosomes (orange) initiate the migration towards opposite sides of the 
cell to assemble the future bipolar spindle. The envelope nuclear breakdown (white line 
surrounding the nucleus in yellow) sets the beginning of prometaphase, and microtubules 
(black) from opposite spindle poles can now interact and capture chromosomes, thought their 
kinetochores (black points positioned on each chromosome arm). At metaphase, all 
chromosomes have established a bipolar attachment with microtubules and are aligned at the 
equatorial plane of the cell. During anaphase, the cohesion between sister chromatids is 
dissolved and they separate into opposite spindle poles. At telophase, the spindle is 
disassembled, the nuclear envelope reorganizes around each group of decondensing 
chromosomes. At the same time, the division of cytoplasm (cytokinesis) gives rise to 
independent daughter cells.   
 
 
 
Figure 1.5. Representative immunofluorescence images from culture cells showing the 
different mitotic phases. Cells were stained with an anti-α-tubulin antibody to visualize spindle 
microtubules (green) and the DNA was stained with DAPI (blue). Bar = 5 µm. 
 
2.2. Mitotic apparatus  
Early in mitosis, the mitotic spindle starts to assemble to allow chromosomes 
alignment at the spindle equator in metaphase, and to separate equally the sister 
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chromatids to daughter cells in anaphase. The spindle itself is a macromolecular 
machine composed of an array of dynamic microtubules, nucleated at centrosomes, and 
associated motor and non-motor proteins responsible for their assembly and 
maintenance and coordination of diverse mitotic events.  
2.2.1. Centrosomes 
The centrosome of animal cells is a large organelle consisting of a pair of centrioles, 
positioned orthogonally to each other, and surrounded by amorphous pericentriolar 
material (PCM) [24]. Each centriole is a short cylindrical array of nine microtubule 
triplets, associated with centrosome integrity and with recruitment of centrosomal 
proteins. The PCM is a fibrous scaffold lattice mainly composed by a specialized 
tubulin called -tubulin, which assembles into a multisubunit -tubulin ring complex (-
TuRC) to serve as a nucleation template for microtubule formation [25, 26] (Figure 
1.6).  
 
 
Figure 1.6. Simplified scheme of the centrosome and the centriole ultra-structure. (A) A 
centrosome is composed of a pair of centrioles (in gray, M - mother and D - daughter) 
embedded in a cloud of amorphous pericentriolar material (in yellow, PCM). Each centriole is a 
cylindrical structure composed of nine microtubule arrays, and each array consists of three 
microtubules. The main component of PCM is a specialized tubulin called -tubulin, which 
assembles into a multisubunit -tubulin ring complex (in blue, -TuRC) to serve as a nucleation 
template for microtubule formation (in green). (Adapted from [27]) (B) Electron micrograph of 
animal centriole. A longitudinal and a cross-section, illustrating the ninefold radial symmetry of 
microtubules, are shown (Adapted from [28]).  
 
For this reason, centrosomes are referred as the major microtubule-organizing center 
(MTOC), in higher eukaryotes, nucleating polarized microtubule arrays with their plus-
ends extending outward, to originate the mitotic spindle, a typical bipolar microtubule-
based structure [29, 30]. Microtubules can also be directly nucleated from chromatin 
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[31] and kinetochores [32]. In addition to their role in microtubules nucleation and 
spindle architecture, the centrosome has emerged as an important site of cell cycle 
regulation and plays a major role in diverse cellular functions, orchestrating G1/S 
transition and DNA damage, the entry into mitosis, anaphase onset and cytokinesis [33, 
26, 34]. Especially at mitosis, the centrosomes have the critical role to mediate the 
strictly balanced bipolar separation of chromosomes.  
Certain proteins are permanently associated with the centrosome core structure such 
as γ-tubulin, the γ-TuRC and centrin, remaining after treatment with microtubule 
depolymerizing agents such as nocodazole or colchicine, while others are temporarily 
associated, to perform centrosome-specific functions, such as 
the Nuclear Mitotic Apparatus protein (NuMA) which become the most significant 
centrosome-associated protein after NEBD [35]. NuMA is a multifunctional protein 
playing a significant role in the organization of the mitotic apparatus, and translocates 
from the nucleus to spindle poles at the onset of mitosis to form a crescent-shaped 
complex around centrosomes tethering microtubules into the accurate bipolar 
organization. This translocation occurs in a dynein-mediated mechanism, a molecular 
motor associated with microtubules [36, 37]. Interestingly, some kinases, such as the 
mitogen activated protein kinase (MAPK), and phosphatases seems to utilize 
centrosomes only as a docking or platform station [38]. A proteomic-based approach 
has identified several centrosomes proteins from human purified centrosomes grouped 
into structural proteins, regulatory molecules and heat shock proteins [39].  
In interphase, at G1, a single centrosome is positioned into the cytoplasm and 
closely associated with the nucleus. At S-phase, concomitantly with DNA synthesis, the 
centrosome duplicates in an accurate and semi-conservative process divided into four 
main stages: disengagement of the pair of centrioles, centriole duplication, centrosome 
elongation and sister centrosome separation (reviewed in [40, 41]). Centrosome 
separation is related to the spatial separation of centrosome material around the nucleus 
which is driven by plus- and minus-end directed microtubule motor proteins. Polo-like 
kinases (Plks) have been clearly implicated in several events of centrosomes cycle 
(reviewed in [42]).  
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2.2.2. Microtubules 
Microtubules (MTs) are hollow cylindrical polymers of α- and β-tubulin 
heterodimer subunits. Typically, microtubules are arranged in a head-to-tail 
configuration into 13 laterally associated protofilaments to form a 25 nm diameter 
structure [43]. In each protofilament all tubulin dimers are oriented in the same way, 
with β-tubulin exposed at one end (plus-end) and α-tubulin at the other end (minus-end), 
making microtubules natural polar structures (Figure 1.7) [44]. This polarity is central 
to the ability of motor proteins to move cargo to specific locations in vivo [45].  
 
 
Figure 1.7. Microtubule structure. Illustration of a 25 nm wide polymer composed of α- 
(orange circles) and β-tubulin (blue circles) subunits. In each protofilament all tubulin dimers 
are oriented in the same way with α-tubulin exposed at minus-end and β-tubulin at plus-end, 
creating polar structures (Adapted from [46]).  
 
Microtubules behavior is highly dynamic, since they are capable of polymerizing 
(growing) and depolymerizing (shortening) over many cycles, resulting in a versatility 
of cellular functions, including cell division, polarization and migration. The stochastic 
switch of microtubules between growing and shortening states is termed dynamic 
instability and results from the ability of β-tubulin to bind and hydrolyze guanosine 
triphosphate (GTP) to guanosine diphosphate (GDP). Although each α- and β-tubulin 
monomer binds to one guanine nucleotide, the nucleotide in α‐tubulin is non-
exchangeable (N‐site nucleotide) and non-hydrolysable, while the one in β‐tubulin is 
exchangeable in the unassembled dimer (E‐site nucleotide), becoming hydrolyzed to 
GDP and non-exchangeable within the microtubule lattice (Figure 1.8) [47]. GTP to 
GDP hydrolysis occurs very fast, during or soon after subunit addition, and the GDP-
bound β‐tubulin makes microtubules less stable and prone to depolymerization. 
However, the hydrolysis occurs with a delay after a tubulin dimer has been incorporated 
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into the microtubule end and it is accepted that the newly formed microtubule tip 
contains a cap of GTP-tubulin (GTP-cap), which has stabilizing properties, ensuring the 
stability of whole microtubule. In the presence of the GTP-cap, the microtubule 
continues growing while their lost leads to rapid microtubule shrinkage. The transition 
from polymerization to depolymerization, with rapid loss of GTP-tubulin subunits and 
oligomers from the microtubules end, is referred to as a catastrophe, and the reverse 
transition is referred to as a rescue (Figure 1.8) [48, 49]. In a steady state, when 
microtubules length is constant, there is continuous incorporation of tubulin subunits 
into microtubules plus-end and release of subunits at the minus-end, in a unidirectional 
flux, known as treadmilling [50, 51].  
 
Figure 1.8. Microtubules behavior. The cycle of tubulin assembly (polymerization) and 
disassembly (depolymerization) is powered by hydrolysis of the GTP bound to β-tubulin, which 
enables microtubules to switch between catastrophes and rescues. GTP-bound tubulin dimers 
are incorporated into growing (polymerizing) microtubules. GTP hydrolysis occurs, with a 
delay, after a GTP-tubulin dimer incorporates into the sheet-like structure of growing 
microtubule tips. Growing microtubule ends thus maintain a stabilizing GTP cap, the loss of 
which leads to a catastrophe and rapid depolymerization, resulting in shrinkage of the 
microtubule (Adapted from [49]). 
Microtubules of the mitotic spindle are arranged into a symmetric and fusiform 
structure at metaphase, with the slow-growing minus-ends oriented toward the poles 
and the faster-growing plus-ends pointed to the cell cortex [52]. According to the 
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orientation of the plus-ends, spindle microtubules are divided into three classes: astral, 
interpolar and kinetochore microtubules (Figure 1.9). Astral microtubules arise from 
centrosomes and radiate out into the cytoplasm with the plus-ends contacting with the 
cell cortex and are thought to contribute to spindle pole separation and positioning 
within the cell. Interpolar microtubules emanates from centrosomes towards the cell 
center and interdigitate at spindle midzone, connecting the two poles and conferring 
spindle stability [53, 54]. Kinetochore microtubules have a function to connect the 
spindle poles to chromosomes, at kinetochores, in an initial lateral attachment that is 
then converted into a mature end-on attachment for chromosomes bi-orientation, 
creating a distinct bundle known as kinetochore-fiber (K-fiber) [55]. Within the three 
classes of microtubules, the K-fibers are the more stable and the less dynamic, resistant 
to cold treatment [56] .  
 
Figure 1.9. Mitotic spindle structure. Illustration of spindle showing its symmetric and 
fusiform shape, in which microtubules slow-growing minus-ends (-) are oriented toward the 
poles and the faster-growing plus-ends (+) oriented to the cell cortex. Three different classes of 
microtubules are shown: astral microtubules (a), interpolar microtubules (b) and kinetochores 
microtubules (c) creating the k-fiber.  
 
2.2.3. Microtubule-associated proteins (MAPs) 
The dynamic instability of microtubules and their connections with cellular 
structures are controlled by numerous factors, which can be broadly grouped into 
microtubule-associated proteins (MAPs). MAPs are defined as proteins that specifically 
bind to microtubules, at least transiently, either in vitro or in vivo. The targets are 
soluble tubulin subunits, microtubule lattice and/or microtubule ends, and can be 
divided in two major classes: non-motor and motor MAPs [49]. Among these, a 
specialized MAPs, known as microtubule plus-end-tracking proteins (+TIPs), are 
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distinguished by their ability to concentrate at growing microtubule ends [57], affecting 
the polymerization rate. For example, the end-binding protein 1 (EB1) increases the 
microtubules polymerization by inducing a structural change near the plus-end and by 
recruiting additional +TIPs [58, 59]. Microtubule polymerases such as member of 
XMAP215/Dis1 and CLIP-associated proteins (CLASP) recruit tubulin dimer subunits 
to the plus-end, increasing the rate of tubulin addition to growing tips [60]. In addition, 
CLASPs have been shown to suppress microtubules catastrophe [61] and cytoplasmic 
linker protein-170 (CLIP-170) has been shown to promote microtubule rescue [62]. 
Non-motor microtubule associated proteins are involved in the control of cell cycle 
progression, mediation of motor function and regulation of microtubule nucleation, 
organization and dynamics. It could be found at different structures including 
microtubule lattice, microtubule ends, kinetochores, centrosomes, spindle poles, central 
spindle, and midbody [63].  
In contrast to non-motor proteins, the microtubules-based motors proteins couple the 
chemical energy of ATP hydrolysis to mechanical force production and movement [64]. 
These cargo-transporting motors include members of the kinesin superfamily and 
dyneins. Most kinesin family members transport cargoes towards the microtubules plus-
end (plus-end directed motors) whereas dyneins transports cargo towards the minus-end 
(minus-end directed motors) [65].  
Kinesins (kinesin-1 to kinesin-14) play an important role at different stages of cell 
division [66] and in the intracellular vesicles and organelle transport [67]. They have a 
well-conserved globular domain that contains both a catalytic core for the ATP 
hydrolysis and the binding sites for microtubules. Members of this family are essential 
for bipolar spindle formation in all eukaryotes, since in its absence or lack of function 
centrosomes do not separate and result in monopolar spindles.  
Kinesin-8 family members, accumulate at microtubule ends on the basis of their 
ATP hydrolysis-driven movement inducing catastrophe. Members of the kinesin-4 
family decrease overall turnover at the microtubule plus-end, stabilizing microtubules at 
a specific length in contexts such as the mitotic spindle and cell cortex. The mitotic 
centromere-associated kinesin (MCAK), a kinesin-13 family member, is able to diffuse 
one-dimensionally along microtubules and induce depolymerization at either the plus- 
or minus-end; its overexpression causes spindle defects [68]. The Kinesin-5, Eg5, is a 
plus-end directed motor consisting of two motor dimers oriented in an anti-parallel 
manner with a pair of motor domains (heads) on either end [69]. By cross-linking 
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microtubules, kinesin-5 plus-end directed motility is activated and induces antiparallel 
microtubule sliding and it is  also involved in centrosome separation at prophase to 
initiate the bipolar spindle assembly [70, 71]. 
Basic microtubule-binding regions present in the kinesin tails can enhance motor 
processivity and the ability of motors to remain attached to microtubule ends, as has 
been shown for the kinesin-8 family members kinesin-related protein 3 (KIP3) and 
KIF18A and the kinetochore kinesin-7 member centromere protein E (CENP-E).  
Although at least 14 classes of kinesins have been identified, the dyneins fall into 
only two major classes, axonemal and cytoplasmic. Axonemal dynein is involved in the 
regulation of microtubule sliding in the axonemes of cilia and flagella while 
cytoplasmic dynein is implicated in a versatility of cellular functions including 
intracellular transport, cell polarization and directed cell movement, and in mitosis [72].  
Two forms of cytoplasmic dynein have been identified: cytoplasmic dynein 1 and 
cytoplasmic dynein 2, according to their distributions and functions within the cell. 
While cytoplasmic dynein 1 is found in all microtubule-containing cells and is 
associated with several cellular compartments such as Golgi apparatus, lysosomes, 
endosomes and RNA-containing complexes and kinetochores; cytoplasmic dynein 2 is 
found almost exclusively within and around the base of cilia and flagella.  
Structurally, dynein forms a massive multisubunit complex (>500 KDa) comprised 
of a homodimer of two identical heavy chains (DHC) and several additional subunits, 
including intermediate (DIC), light intermediate (DLIC) and light chains (DLC), which 
are usually associated with the cargo-binding. The DHC forms two prominent 
structures, an N-terminal domain consisting in the base of the molecule, to which most 
of the accessory subunits bind, and a motor domain [72]. The motor domain contains 
six discernible AAA ATPase units, that form into a ring-like structure, identifying the 
DHC as a divergent member of the AAA+ family of ATPases [73] that bind to 
microtubules and hydrolyze ATP for force production (Figure 1.10).  
During mitosis, cytoplasmic dynein 1 (hereinafter dynein) localizes at three distinct 
mitotic loci: cell cortex and spindle poles reflecting their role in spindle 
formation/integrity and spindle rotation/positioning and at kinetochores where dynein 
has involved in MT-attachment [74-77], chromosome movement [78-81] and regulation 
of the SAC response [82-84]. Accordingly, dynein accumulates at kinetochores prior to 
MT attachment [77] and as chromosomes achieve bipolar attachment and approach the 
metaphase plate becomes less prominent being visible along spindle fibers and at 
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spindle poles [83, 84], consistent with dynein involvement in SAC silencing. After 
chromosome congression dynein is undetectable at kinetochores [84, 74].  
Most of the activities described above are carried out by dynein working in 
conjunction with dynactin, a multi-subunit protein complex working as dynein cofactor, 
and several adaptor proteins that link dynein-dynactin to specific cargos [85]. ZW10, 
LIS-1, nudE/nudEL, nudC, and Spindly have been identified as dynein partners required 
either for dynein functions and localization at kinetochores (reviewed in [86]).  
 
 
 
Figure 1.10. Cytoplasmic structural organization of the dynein. Dynein is a complex of two 
heavy chains (DHC), two intermediate chains (DIC), two light intermediate chains (DLIC), and 
three light chains (DLC). The motor domain comprises six AAA+ ATPase modules (1-6) that 
form a ring, and a stalk that contains the microtubule domain. The N-terminal tail domain 
interacts with the smaller non-catalytic subunits, and is responsible for dimerization and cargo 
interaction. The arrow indicates the direction of movement along microtubules (Adapted from 
[87]).  
 
3. THE KINETOCHORE 
3.1. Kinetochore structure  
The kinetochore is at the heart of microtubules attachment to chromosomes and the 
first insights into their structure were provided by classical electron microscopy studies 
[88]. The observation of the vertebrate chromosomes ultrastructure revealed that 
kinetochores have a trilaminar proteinaceous morphology (Figure 1.11) [89-92]. The 
innermost layer, known as the inner kinetochore plate, is a disk of densely packed 
material, continuous with the centromeric heterochromatin [93]. This region is thought 
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to be responsible for the assembly and size determination of a robust kinetochore. The 
outer kinetochore plate is an electron-dense DNA-free structure that constitutes the 
primary site of attachment for spindle microtubules. With a questionable existence, a 
third lighter middle layer separates and connects the inner and outer regions of the 
kinetochore [91]. At the outer plate surface, in the absence or presence of a few attached 
microtubules, is visible an expanded filamentous meshwork called fibrous corona [94, 
95], containing a dynamic network of mainly transient proteins implicated in 
microtubule capture, dynamics and SAC response. 
The size and complexity of kinetochores differ considerably among different 
species, as well as, the number of attached microtubules. Indeed, S. cerevisiae 
kinetochore binds just one microtubule, S. pombe bind up to four, D. melanogaster on 
average bind eleven and vertebrate kinetochores typically bind fifteen to twenty-five 
microtubules [96, 97].  
 
Figure 1.11. Vertebrate kinetochore ultrastructure. (A) A schematic of a mitotic 
chromosome with paired sister chromatids; the chromatid on the right is attached to 
microtubules and the chromatid on the left is unattached. The inner kinetochore, the outer 
kinetochore, the inner centromere and the fibrous corona, which is detectable on the unattached 
kinetochore, are highlighted. (B) Electron micrograph of a human kinetochore (image courtesy 
of Y. Dong and B. McEwen, State University of New York at Albany, USA). The micrograph 
represents a single slice from a tomographic volume of a high-pressure frozen mitotic cell and 
has been labelled as in (A) to highlight the key structural features of the kinetochore. Scale bar, 
100 nm (Adapted from [98]). 
 
3.2. Molecular composition of kinetochore 
To identify functional components of the kinetochore, a combination of genetics, 
RNA interference (RNAi)-based screens and biochemistry was used in model 
organisms. The studies conducted in budding yeast were particularly successful given 
their short centromeric DNA sequence and although most kinetochore proteins show 
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limited homology between species, vertebrate counterparts of many of the proteins have 
been identified in model organisms.  
The organization and molecular composition of the human kinetochore appear to be 
conserved among eukaryotes, and there are more than one hundred kinetochore 
proteins, localized at specific domains, identified until now. The assembly of 
kinetochore components occurs in a stepwise manner from the heterochromatin to the 
outer kinetochore plate, although a less linear hierarchy occurs at the outer kinetochore 
and fibrous corona. Here, the assembly of components is mainly transient and is 
influenced by the microtubule attachment status and local signaling pathways (Figure 
1.12). 
 
Figure 1.12. Overview of protein complexes that build the kinetochore in animal cells. The 
kinetochore is built on the centromere as a trilaminar protein-rich structure: the inner 
kinetochore, the outer kinetochore and the fibrous corona. Proteins that compose each 
kinetochore layer are grouped by function (APC/C, anaphase promoting complex/cyclosome; 
Bub1BubR1-Bub3, budding uninhibited by benzimidazole; Cdc20, cell division cycle 20; 
CENP, centromere protein; CLASP, CLIP-associating protein; CLIP170, cytoplasmic linker 
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protein-170; CPC, chromosome passenger complex; EB1, end-binding protein-1; INCENP, 
inner centromere protein; kMTs, kinetochore microtubules; LIS1, lissencephaly-1; Mad1-Mad2, 
mitotic-arrest deficient; MCAK, mitotic centromere-associated kinesin; MPS1, multipolar 
spindle-1; MT, microtubules; NPC, nuclear pore complex; PLK1, polo-like kinase-1; RanBP2, 
Ran-binding protein 2; RanGAP, Ran-GTPase-activating protein; RZZ, Rod (rough deal); SAC, 
spindle assembly checkpoint; Ska1–3, spindle and kinetochore-associated proteins; Zw10, zeste 
white 10-Zwilch complex; Zwint, Zw10 interactor (Adapted from [99]). 
 
The main component of centromeric heterochromatin is the chromosomal passenger 
complex (CPC), composed of Aurora B, INCENP, Borealin and Survivin, which is one 
of the most widely studied and highly conserved hetero-tetrameric complexes.  
A fundamental determinant of the inner kinetochore identity is the centromere 
protein (CENP)-A, a histone H3 homologue and one of the core subunits of 
nucleosomes. In humans, CENP-A associates with several additional inner kinetochore 
proteins collectively known as constitutive centromere associated network (CCAN). 
CCAN allows the assembly of the outer kinetochore domain, the microtubule binding 
and in deposition of new CENP-A [100-102]. Given their function, depletion of 
components of the CCAN often leads to cell-cycle arrest, kinetochore-assembly defects, 
severe chromosome missegregation and loss of kinetochore function (reviewed in [98]). 
The outer kinetochore is the microtubule-binding interface, and its core is the KMN 
network. KMN is composed of Knl-1 protein (Blinkin ⁄ Spc105 in human and budding 
yeast, respectively) and the two sub-complexes Mis12 (composed of four proteins 
Mis12⁄Nnf1⁄Nsl1⁄Dsn1) and Ndc80 (containing the four proteins Ndc80 (Hec1 in 
mammals)/ Nuf2⁄Spc24⁄Spc25) ) [98]. In metazoans, the Ndc80 complex associates with 
kinetochores prior to nuclear envelope breakdown and forms a rod-like structure with 
two globular heads at each end separated by a long coiled-coil region. The globular 
regions of Ndc80 and Nuf2, localizes at the outer kinetochore domain and bind directly 
to microtubules while the globular regions of Spc24 and Spc25 are oriented towards the 
inner kinetochore plate. The crystal structure of the globular domain of the Ndc80 
subunit has revealed that it is folded into a calponin-homology (CH) domain, also 
exhibited by the microtubule binding region of the plus-end-associated protein EB1 
suggesting an ancient evolutionary origin for this fold.  
Ndc80 complex localization at vertebrate kinetochores is influenced by both the 
Mis12 complex and the CCAN [101, 103]. The Ncd80 affinity to microtubules is weak, 
but when in association with Mis12 complex and Knl1protein the microtubule-binding 
affinity is synergistically increased [104]. The association of Ndc80 complexes with 
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spindle microtubules is critical for chromosome segregation and their depletion or 
inactivation causes the most severe chromosome segregation defect.  
Localized at the kinetochore fibrous corona are the proteins involved in SAC 
signaling pathway, like Bub1, BubR1, Bub3, Mad1, Mad2 and Mps1; the SAC targets 
Cdc20 and APC/C; components involved in kinetochore-microtubules attachment 
and/or SAC silencing like RZZ complex (Rod, Zw10, Zwilch), Spindly, dynein, 
dynactin, Lis1, CENP-E, CENP-F and Ska complex (Ska1, Ska2, Ska3); and 
microtubule-plus-end-tracking proteins (+TIPs) like CLASPs, CLIP-170, ch-TOG, EB1 
and APC. The role of the majority of outer kinetochore proteins are discussed in 
following topics. Together, all these kinetochore proteins create an environment that 
allows efficient chromosome alignment at the metaphase plate and promote proper 
chromosome segregation.  
 
4. KINETOCHORE-MICROTUBULE INTERACTIONS  
4.1. Kinetochore-microtubule binding, chromosome capture and 
bi-orientation 
Proper kinetochore capture by spindle microtubules is achieved in a stepwise 
manner. After nuclear envelope breakdown at prometaphase, chromosomes are released 
into the cytosol and become accessible to the microtubules from the mitotic spindle. 
These, probe the cytoplasm, through episodes of lengthening and shortening of their 
plus ends, to search and capture chromosomes [105, 106]. This “search and capture” 
model remains the cornerstone of spindle assembly, 31 years later after being proposed. 
Nevertheless, over the last few years, functional and proteomic-based analysis of the 
kinetochore-microtubule interface has increased our understanding of the molecular 
mechanism of chromosome attachments to the spindle and shed light on kinetochore bi-
orientation [98, 107]. Different studies have demonstrated that the plus ends of 
microtubules bind to kinetochores through the KMN protein network. Removal of any 
of the KMN network components leads to the disruption of the binding scaffold for 
microtubules at the outer kinetochore plate [108, 103]. Initial capture results in the 
binding of one kinetochore to the lateral surface of the microtubules, followed by rapid 
poleward movements of attached chromosome along highly dynamic astral 
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microtubules (Figure 1.13). This movement is probably powered by the motor activity 
of the cytoplasmic dynein [78, 109, 77, 81, 79], recruited to kinetochore by the RZZ 
complex via Spindly [110-115]. The high density of microtubules near the spindle pole 
will contribute to the conversion of the lateral attachments to mature end-on attachments 
(Figure 1.13). RZZ complex and Spindly were reported to be required for this 
conversion [113]. Furthermore, the Ska complex was also shown to be involved in 
stable end-on kinetochore-microtubule (KT-MT) attachments in vertebrate cells [116-
118]. Due to the polar ejection forces, the now mono-attached chromosome is forced to 
move towards the spindle equator, a process known as chromosome congression, with 
the unattached sister-kinetochore facing the microtubules from the opposing pole, 
resulting in its end-on attachment [119]. Besides this simplified mechanism, in 
metazoan cells, mono-oriented chromosomes could be transported towards the spindle 
equator by gliding alongside microtubules attached to other already bi-oriented 
chromosomes, driven by the kinetochore-bound CENP-E, a plus end-directed 
microtubule motor of the kinesin-7 family [120] and by chromokinesins kinesin-10 
(Kid/NOD) and kinesin-4 (Kif4/Xklp1) that push the chromosome arms away from the 
centrosome [121-123]. Indeed, how a spatially selective activities mediated by the 
kinetochore motors, dynein and CENP-E, ensure chromosome congression were 
recently reported [80] and was associated with microtubule (de)tyrosination, one of the 
tubulin post-translational modification (PTM) (Figure 1.14) [124, 125]. Accordingly, 
dynein has a preference for tyrosinated astral microtubules and counteracts 
chromokinesin-mediated polar ejection forces. By bringing chromosomes to the vicinity 
of the spindle-pole-localized Aurora A kinase, dynein prevents premature stabilization 
of erroneous end-on attachments and contributes to the local activation of CENP-E. At 
the pole, CENP-E interacts with detyrosinated microtubules (modified α-tubulin lacking 
the C-terminal tyrosine), becoming dominant over dynein to move chromosomes 
towards the equator (Figure 1.14). This model is linked to the emerging concept that 
tubulin PTMs are a part of the so-called tubulin code [126, 127], that is read by the 
molecular motors and determines the preferences for particular tubulin PTMs [124].  
In addition, RanGTP-induced diffusible gradients [128, 129] and adaptive changes 
in chromosome architecture [130, 131] has been proposed as facilitators of kinetochore-
based chromosome motility during early mitosis. Nonetheless, these recent mechanisms 
have been organically incorporated into the search and capture model, which even so 
still sustains their basic principles and simplicity. 
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Invariably, chromosomes are successfully aligned at the metaphase plate once they 
become bi-oriented, a condition known as amphitelic attachment, with full microtubule 
occupancy.  
 
 
 
Figure 1.13. Chromosome biorientation during prometaphase. When the nuclear envelope 
breaks down, the kinetochore is captured by the lateral surface of microtubules emanating from 
a spindle pole (A), resulting in its transport toward that pole (arrow). The high density of 
microtubules near the pole contributes to the maturation of the lateral attachment to end-on 
attachment, with the  kinetochore tethered at the plus end of the microtubules (B). Polar ejection 
forces and/or gliding alongside microtubules attached  to other already bi-orientated 
chromosome (not represented in the figure) drive the mono-orientated chromosome toward the  
metaphase plate (C), resulting in its bi-orientation (D) [99].  
 
 
 
 
 
Figure 1.14. Schematic representation of the impact of tubulin tyrosination/detyrosination 
on the regulation of motor proteins responsible for chromosome movements in mitosis. 
Dynein/dynactin have a preference for tyrosinated astral microtubules and counteract 
chromokinesin-mediated polar-ejection forces. By bringing chromosomes to the vicinity of the 
spindle-pole-localized Aurora A kinase, dynein/dynactin prevent premature stabilization of 
erroneous end-on attachments and contributes to the local activation of CENP-E. At the pole, 
CENP-E interacts with detyrosinated microtubules, becoming dominant over dynein to move 
chromosomes towards the equator. Thus, the levels of microtubule (de)tyrosination provide the 
direction albias for CENP-E-mediated chromosome transport and regulate the dynein/CENP-E 
activity switch that facilitates chromosome congression (adapted from [124]). 
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4.2. Correction of kinetochore-microtubules attachment errors 
It is known that the amphitelic attachment, achieved when sister kinetochores are 
attached to opposite poles of the spindle, is the only geometry that ensures an accurate 
segregation of sister-chromatids to daughter cells, at anaphase. However, due to the 
stochastic nature of the widely accepted “search and capture” mechanism, and to the 
chromosome position within the cell and the geometry of their sister-kinetochores 
relative to microtubules at the onset of prometaphase, other connections can occur and 
compromise the proper segregation of chromosomes. There are three possibilities for 
kinetochore-microtubules mis-attachments: monotelic, syntelic, and merotelic (Figure 
1.15) [132, 133]. Monotelic kinetochore attachment occurs when one sister kinetochore 
is unattached while the other is attached to microtubules from just one pole. This is 
common in early mitosis and it is a normal condition at the very beginning of 
prometaphase. Syntelic attachment is observed, although rarely, when the two sister 
kinetochores are bound to microtubules from the same spindle pole. Both monotelic and 
syntelic attachments activate the SAC, due to reduced tension at sister-kinetochores, and 
are generally corrected and converted into amphitelic configurations. Merotelic 
attachments occur when one sister kinetochore binds to microtubules from both poles, 
frequently in early prometaphase. These attachments do not interfere with chromosome 
alignment during prometaphase and are not always detected by the SAC. Nevertheless, 
they rarely cause chromosome mis-segregation, as they are usually corrected before 
anaphase onset by an Aurora B-dependent mechanism [132-134]. 
 
 
 
Figure 1.15. Biorientation and kinetochore attachment errors. (A) In amphitelic attachment, 
sister kinetochores are correctly attached to the microtubules emanating from the opposite poles 
of the spindle, leading to chromosome bi-orientation. (B) In monotelic attachment, the 
chromosome is mono-oriented as one kinetochore is attached to the microtubules from one 
spindle pole, while its sister is unattached.  (C) In syntelic attachment, the chromosome is 
mono-oriented but, in this case, both sister kinetochores are attached the microtubules from the 
same spindle pole. (D) In merotelic attachment, one sister kinetochore is attached to 
microtubules from both spindle poles, the chromosome is improperly bi-oriented and, if left 
uncorrected, can produces an anaphase lagging chromosome (Adapted from [99]). 
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Proper tension across the sister kinetochores contributes to the detection and 
correction of merotelic and syntelic attachment errors. Sister kinetochores in amphitelic 
attachments are under tension, which results from the pulling forces of the spindle 
microtubules in opposite directions. Pioneering micromanipulation experiments from 
Nicklas and co-workers suggested that the mechanical tension at kinetochores increases 
the occupancy of microtubule attachment sites, which contributes to stabilizing 
kinetochore to microtubules attachments [135, 136]. It is widely accepted that tension is 
the signal that distinguishes different attachment states of sister kinetochores and that 
the Aurora B kinase, the mammalian homologue of the budding yeast Ipl1 kinase, acts 
as a tension sensor to correct mis-attachments by destabilizing them [134, 137]. Aurora 
B localizes to the inner centromere and regulates the interactions between the 
kinetochores and microtubules through phosphorylation of the Ndc80 complex and the 
member of the kinesin-13 family of microtubule depolymerases, MCAK [138]. A 
spatial separation model was proposed that might explain how tension mediates 
correction of mis-attachments by Aurora B kinase [139]. The low tension at the 
syntelically attached kinetochores and the unbalanced tension resulting from merotelic 
orientation would locate the kinetochores close to a peak of Aurora B kinase activity in 
the inner centromere, which release microtubules as a consequence of Ndc80 and 
MCAK phosphorylation. Indeed, phosphorylation of the Ndc80 complex weakens its 
affinity for microtubules while phosphorylated MCAK catalyses depolymerization at 
the ends of microtubules [104, 140]. The selective destabilization of incorrect 
chromosome attachments provides a new chance to bi-orient. Bi-orientation increases 
the distance between the kinetochores and the inner centromere, due to the forces 
exerted by spindle microtubules in opposite directions. As a consequence, Aurora B 
becomes spatially separated from its substrates and the attachments are stabilized. In 
this spatial separation model, a constitutively active phosphatase, such as PP1 (protein 
phosphatase 1) in budding yeast and PP1 and PP2A in vertebrates, would 
dephosphorylate Aurora B substrates allowing for rapid re-attachment [137]. It was also 
reported that Mps1 kinase phosphorylates Borealin/DasraB on residues that are crucial 
for Aurora B activity and chromosome alignment. Other models are possible for the 
mechanisms by which Aurora B regulates kinetochore-microtubule attachments, 
stressing the need to clarify the molecular nature of the processes through which 
improper attachments are detected and corrected [134, 137]. It was recently reported 
that disturbing the microtubules-binding Dam1 and Ska1 complexes, other additional 
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Aurora B substrates, destabilizes kinetochore-microtubules attachments even in tension 
absence [141].  
The polo-like kinase 1 (Plk1), localized at kinetochores during prometaphase [142, 
143], has also been implicated in the correction of attachment errors, stimulating the 
kinetochore activity of both kinetochore-microtubules stabilizers and destabilizers. Plk1 
activity is required for the initial formation of stable kinetochore-microtubules 
attachments, probably by phosphorylating the KT-MT stabilizing protein BubR1 [144, 
145]. Paradoxically, Plk1 phosphorylates and stimulates the microtubule depolymerase 
activity of kinesin family member 2B (KIF2B), required to destabilize KT-MT 
attachments and efficiently correct errors [146, 147].  
Unexpectedly, it has been proposed that Aurora A kinase contribute to error 
correction, by opposing the stabilizing effect of the elevated polar ejection forces close 
to the spindle poles. Through inhibitory phosphorylation of the kinetochore subtract 
Ndc80/Hec1, Aurora A increases the incidence of kinetochore-microtubules mis-
attachments, in a balanced activity with polar ejection forces, giving the chance for a 
corrected attachment similar to its counterpart Aurora B on centromeres [148]. Dynein 
also contributes to prevent error formation by counteracting the role of chromokinesins 
in the stabilization of end-on kinetochore-microtubule attachments [149, 150], while 
promoting Aurora-A-mediated kinetochore-microtubule destabilization, in a balanced 
process of forces [151].  
 
5. THE SPINDLE ASSEMBLY CHECKPOINT  
The spindle assembly checkpoint (SAC) is a constitutive surveillance mechanism in 
eukaryotic dividing cells that is extremely sensitive to defects in kinetochore 
attachment. It prevents chromosome misssegregation by delaying the metaphase to 
anaphase transition until all chromosomes are correctly connected to the spindle 
microtubules, bi-oriented and aligned at the metaphase plate [23]. The SAC consists of 
a signalling cascade that represents the primary cell-cycle control mechanism in mitosis 
and is activated immediately after mitosis entrance, every cell cycle. Accurate activity 
of this checkpoint mechanism is crucial for equal segregation of the genetic material 
into the two daughter cells and thus, for the effective reduction of the error rate 
occurring during cell division. Failure in SAC function has been suggested as a possible 
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cause of aneuploidy in several tumor types [152, 153]. Moreover, SAC contributes to 
the temporal organization of the cell cycle, since the cell only progresses to the next 
phase when its requirements are satisfied. The SAC molecular pathway involves the 
detection of the attachment error and the generation of the signal that inhibits mitosis 
progression, error correction, and SAC silencing. 
5.1. Molecular components and checkpoint activation 
The proteins of the SAC molecular pathway can be divided in to two groups: i) 
proteins that form the “bona fide” SAC components and ii) proteins of the attachment, 
APC/C regulatory, correction, and SAC silencing machineries, with which true SAC 
proteins must interact to monitor attachments and cell cycle progression [98]. The 
distinction between the two groups of proteins was elegantly expressed in an opinion 
article [154].  
The bona fide SAC proteins are comprised of Mad1, Mad2, BubR1, Bub1, Bub3, 
Mps1, which have been initially identified in budding yeast [23, 98]. Homologues for 
these proteins have also been identified in higher organisms, including mammals. These 
proteins were shown to share a high degree of both sequence and functional homology 
with their yeast counterparts. Functional disruption studies through dominant-negative 
mutants, antibody injection or RNA interference (RNAi) completely compromised the 
spindle checkpoint activity, causing chromosome misssegregation, aneuploidy and 
escape from mitotic arrest in the presence of microtubule poisons such as nocodazole 
and taxol [155]. 
Whenever unattached kinetochores are present, the Mad2, BubR1, and Bub3 
proteins localize there to generate, in association with Cdc20, the Mitotic Checkpoint 
Complex (MCC) [156], a “wait anaphase signal” that diffuses through the cytosol 
(Figure 1.16) [157, 158]. This keeps APC/C inhibited, an E3 ubiquitin ligase that 
regulates many cell cycle processes, preventing it from ubiquitinating Securin (Pds1 in 
budding yeast) and Cyclin B from targeting them for destruction by the 26S 
proteasome. By preventing Securin and Cyclin B degradation, sister-chromatid cohesion 
and the mitotic state are maintained, respectively. A “Mad2-template” model was 
proposed as the mechanism by which the cytosolic inhibitory signal is propagated away 
from the kinetochore [159]. According to this model, Mad2 can adopt either an open 
(O-Mad2) or closed (C-Mad2) conformation [159-161]. A constitutively C-Mad2 bound 
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to Mad1 serves as template or receptor at unattached kinetochore for cytosolic O-Mad2 
to switch this latter to C-Mad2 bound to Cdc20 form. The C-Mad2/Cdc20 complex 
leaves the kinetochore and acts as a structural equivalent of Mad1/Mad2 to convert 
more O-Mad2 into Cdc20 bound C-Mad2 in the cytosol, resulting in signal 
amplification (Figure 1.16) [159, 162]. This model starts with an early nuclear envelope 
breakdown when the level of the MCC complex is not yet sufficient to prevent 
anaphase. Recently, some elegant studies focused on SAC understanding shed light into 
this mechanism and suggested novel theories, especially concerning MCC-APC/C 
activity. It was described that C-Mad2 induces a conformational modification in Cdc20, 
enhancing its binding with N-terminus of BubR1, already bound to Bub3 which, in turn, 
inhibits the APC/C [163]. Moreover, Bub3 has emerged as a promoter and an enhancer 
of two different interactions between BubR1 and Cdc20 to sustain the anaphase 
inhibitor signal [164]. 
 
Figure 1.16. Molecular view of spindle assembly checkpoint (SAC) pathway. (A) 
Immunofluorescence image of a prometaphase cell, stained for microtubules (green), 
kinetochores (red) and for DNA (blue), showing the presence of unaligned chromosomes. 
Under these conditions, at early mitosis, when chromosomes are not aligned or improperly 
attached to microtubules, the SAC is turned on and the Mad1/c-Mad2 complex, localized at 
unattached kinetochore, recruits and converts cytosolic o-Mad2 into c-Mad2, which together 
with Bub3, BubR1 and Cdc20 forms the mitotic checkpoint complex (MCC), leading to 
anaphase promoting complex/cyclosome (APC/C) inhibition. Thus, the mitotic substract cyclin 
B remains associated with Cdk1 as does securin with separase, resulting in mitotic arrest. (B) 
Immunofluorescence image of a metaphase cell, stained as in (A), showing all chromosomes 
aligned at the metaphase plate. At this stage, SAC is turned off and MCC is disassembled, 
allowing APC/C activation by Cdc20 and subsequent ubiquitylation (U) of cyclin B and securin. 
As a result, separase can cleave cohesins to promote sister chromatid separation, while Cdk1 
becomes inactive which promotes exit from mitosis (Adapted from [165]). 
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Once the last chromosome becomes bi-oriented, the “wait anaphase” is no longer 
produced, consistent with SAC silencing, and Cdc20 is released to trigger APC/C 
activation, which in turn ubiquitinates Securin and Cyclin B, targeting them to 
proteasome degradation. Degradation of Securin, an inhibitor of the protease separase, 
leads to cohesin proteolysis and sister chromatid separation, whereas Cyclin B 
degradation leads to the inactivation of cyclin-dependent kinase 1 (Cdk1), which drives 
mitotic exit. 
Protein phosphorylation and dephosphorylation have probably a major role in the 
transduction and the amplification of SAC signals. In this respect, however, the exact 
role of the kinase activity of the checkpoint proteins Bub1, BubR1, and (to a lesser 
extent) Mps1 in SAC signaling has long been controversial. Contradictory results were 
reported regarding the requirement of these checkpoint kinases in the SAC, probably 
due to the variability between the different assays used to assess the SAC response or 
inefficient depletion of the endogenous proteins [166, 167]. Bub1 was reported to 
phosphorylate Cdc20, inhibiting its ability to activate the APC/C [168], suggesting a 
model in which Bub1 kinase contributes to amplify or strengthen the SAC signal in the 
presence of few unattached kinetochores [169]. Other studies have shown that the Bub1 
kinase activity is not sufficient to complete SAC function [170]. Less certain is the 
contribution of the BubR1 kinase activity to the SAC. It was reported that BubR1 kinase 
activity is activated by binding to CENP-E tail and inactivated upon CENP-E binding to 
microtubules [171]. Conflicting studies had reported mixed results as to whether BubR1 
kinase activity is required for efficient chromosome capture and congression [172-174]. 
There is no doubt regarding the necessity of Mps1 kinase activity for SAC activity as its 
inhibition overrides the SAC [175, 176]. Mps1-mediated direct phosphorylation of Knl1 
is required for Bub1 and Bub3 kinetochore localization [177, 178].  
Mps1 kinase activity was also shown to be involved in the error correction during 
chromosome bi-orientation [179]. Moreover, Mps1 phosphorylates Borealin that in turn 
directs the activity of Aurora B [180], in agreement with its role in regulating 
chromosome attachment and alignment. Phosphorylation of Mad1 has been reported to 
be Mps1-dependent [181], but the role of the Mad1 phosphorylation in the SAC remains 
to be determined.  
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5.2. Mechanisms of checkpoint silencing  
SAC silencing implies preventing the generation of the “wait anaphase” signal upon 
stable chromosome attachment. This presumes the existence of a regulatory link 
between chromosome bi-orientation and silencing mechanisms. Several models for 
SAC silencing mechanism were proposed [182, 183].  
The first model suggests that MCC production is halted by dynein-dependent 
stripping of SAC components from the attached kinetochore [82]. Upon kinetochore-
microtubule attachment, the minus-end directed motor dynein actively transports, along 
spindle microtubules, SAC proteins such as Mad2 and BubR1 away from the attached 
kinetochore, towards spindle poles (Figure 1.17). Consistently with this mechanism, 
cells arrest in mitosis with high kinetochore-associated Mad2 levels following depletion 
of the dynein light intermediate chain 1 (LIC1) or after microinjection of 70.1 anti-
dynein antibodies [184, 82].  
 
 
 
Figure 1.17. SAC protein recruitment to and removal from kinetochores. (A) SAC proteins 
Mps1, Mad1, Mad2 and the Bubs (Bub1, Bub3 and BubR1) localize to the unattached 
kinetochore by interacting with members of the KMN complex (consisting of the Knl1, Mis12 
and Ndc80 complexes). (B) Upon microtubule binding, several mechanisms, namely dynein-
mediated protein stripping, and Mps1 removal by microtubules, contribute to removal of the 
SAC proteins (Adapted from [185]). 
 
By recruiting dynein to kinetochores Spindly, a 605 aa protein consisting of two 
coiled coil domains, plays a critical role in checkpoint silencing [186, 114, 187]. 
Spindly kinetochore localization depends on the RZZ complex, since ZW10 knockdown 
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leads to their abrogation [114]. Recently, it was reported that Spindly undergoes 
farnesylation at C-terminal cysteine residue, a post-translational lipid modification, to 
interact with RZZ and, hence, to target kinetochores [188, 189]. Spindly inhibition 
causes chromosome alignment defects, loss of dynein-dynactin kinetochore localization 
and a severe prometaphase delay, consistent with permanent SAC activation [114, 190, 
186]. Curiously, in Spindly-depleted cells, where kinetochore dynein is absent, Mad1 
and Mad2 were found to dissociate from kinetochores following microtubule 
attachments, and the SAC is silenced without poleward transport. This observation 
suggests an existence of kinetochore dynein-independent mechanism, probably 
dependent on the KMN network that has the ability to couple both silencing and 
attachment mechanisms [186]. 
Another silencing mechanism is the inhibition exerted by the p31
comet
 protein on 
Mad2, preventing it from inhibiting the APC/C
Cdc20 
in mammalian cells [191, 192]. By 
binding the dimerization interface of Mad2, the p31
comet
 protein prevents Mad2 
activation and promotes the dissociation of the Mad2/Cdc20 complex [192]. Indeed, 
HeLa cells that recover from a SAC-dependent nocodazole-induced block are delayed 
in mitosis under conditions of low p31
comet
 expression. Accordingly, overexpression of 
p31
comet
 abrogates the SAC-dependent mitotic arrest in HeLa cells treated with 
microtubule poisons [192]. Additionally, phosphorylation of Mad2 was reported to 
inhibit its interaction with APC/C
Cdc20
 or Mad1, suggesting its implication in SAC 
silencing [193]. Although the regulatory mechanism whereby Mad2 becomes 
phosphorylated and silences the SAC upon kinetochore attachment is still unknown, it is 
possible that the phosphorylated form of Mad2 facilitates its binding by p31
comet 
and/or 
makes it competent to be transported by dynein during kinetochore stripping.  
An alternative silencing mechanism, namely in countering MCC production, was 
related to the protein phosphatases PP1 and PP2A [194, 195, 178, 196]. Both have been 
proposed to dephosphorylate the Mps1-targeted repeat motifs in Knl1 leading to 
kinetochore SAC signaling inhibition [195, 178]. Although PP1 binds the KMN 
directly, via motifs in Knl1, PP2A-B56 connects to Knl1 indirectly by binding to 
BubR1, which in turn interacts with the Bub1/Bub3 dimer [197-200].   
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6. ROLE OF THE SPINDLE ASSEMBLY CHECKPOINT IN 
TUMORIGENESIS 
The discovery of SAC and its relevance to genetic stability (Figure 1.18), together 
with the fact that many cancer cells exhibit weakened SAC activity, had initially 
prompted many scientists to search for mutations in SAC genes in several tumors, in 
order to establish a relationship between SAC and tumorigenesis and, eventually, to 
anticipate the prevention, diagnosis and cancer treatment [153].  
 
 
 
Figure 1.18. Different cell fates according to SAC activity status. Cells with a functional 
SAC (left) detect unattached or mis-attached kinetochores and an arrest in mitosis is sustained 
until correct attachment is achieved, resulting in accurate chromosome distribution between 
daughter cells. In cells with a weakened SAC (middle), a sustained arrest in mitosis could not be 
ensured in the persistence of errors in kinetochore attachment and, missegregation occurs 
resulting in aneuploid daughter cells which could potentiate tumorigenesis. Cells with complete 
loss of SAC activity (right) exit mitosis prematurely, and die as a result of massive 
aneuploidization (Adapted from [201]). 
 
Although the first identification of mutations in the SAC genes BUB1 and BUB1B 
in human colorectal cancer cell lines was encouraging [202], genetic lesions on SAC 
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components revealed to be rather rare in a large number of aneuploid cancers with 
weakened SAC activity, suggesting that epigenetic alterations are responsible for the 
SAC impairment [203]. Indeed, many studies reported altered expression of SAC 
components in various tumors. Moreover, mice with heterozygous SAC genes, hence 
with low levels of SAC proteins, have a weakened SAC activity, exhibit a high 
frequency of aneuploid cells and develop tumors [204-206]. Although mutations or 
altered expression levels of SAC genes were reported in many aneuploid cancers, it 
remains to be elucidated whether these alterations are directly responsible for SAC 
weakening. It is likely that the decreased levels of some SAC components, known to 
have a role in chromosome congression, may contribute to aneuploidy in cancer cells. 
For instance, Bub1-, BubR1- or Bub3-depleted cells were reported to exhibit 
chromosome congression defects [207-210]. While the presence of a compromised SAC 
and its contribution to aneuploidy in many tumors had gained a widespread acceptance, 
a number of studies reported that the SAC is fully functional in most aneuploid cancer 
cells [211, 212]. Aneuploid cell lines were shown to arrest in response to microtubule 
damage for longer than non-transformed cells and, interestingly, they only rarely enter 
anaphase in the presence of unaligned chromosomes [212]. A study analyzing the 
consequences of gradual increases in chromosome segregation errors in the viability of 
tumor cells and normal human fibroblasts, found that partial inhibition of SAC proteins 
BubR1 and Mps1,both involved in checkpoint activation and chromosome alignment, 
sensitizes the tumor cell lines to low doses of taxol due to increased severity of 
chromosome segregation errors, therefore suggesting that a weak spindle checkpoint 
and an increase in chromosome segregation errors might selectively kill tumor cells 
[213]. One possible explanation to this controversy is that the SAC status varies 
between cancer types depending on the putative underlying molecular alterations. For 
instance, different expression profiles of SAC genes were reported in different cancer 
lines, with the same genes showing increased expression in some cancers and decreased 
expression in others. Moreover, efficient SAC activity is based on the equilibrium 
between its components and their expression levels; therefore, the SAC status in a given 
tumor would be influenced by the extent to which this equilibrium is affected by the 
overall alterations in the expression profile of all SAC genes in that tumor. Taken 
together, it appears that the SAC activity in aneuploid cancer cells is sufficient to 
prevent premature anaphase under normal growth conditions. However, its ability to 
sustain an artificially prolonged arrest, such as the one imposed by microtubule poisons, 
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would depend on the nature of the molecular alterations in the SAC components or in 
the components of other mechanisms that allow premature satisfaction of the SAC, such 
as those responsible for microtubule dynamics or for correcting chromosome 
attachment errors. 
Independently of the controversy around the SAC status in cancer cells and its role 
in the occurrence of chromosome instability and tumorigenesis, there is no doubt that 
complete SAC inactivation is lethal to cells due to massive chromosome 
misssegregation [214, 215]. As the SAC is only required during mitosis, its targeting 
obviously represents a promising therapeutic strategy to selectively kill dividing cells, 
which could circumvent the resistance to or the side effects caused by the anti-cancer 
agents currently in use, such as those that target microtubules. In this respect, SAC 
components with no functional roles outside of mitosis constitute the suitable targets 
[216].  
 
7. TARGETING MITOSIS IN CANCER THERAPY 
7.1. Classical Antimitotic drugs  
Antimitotic drugs block mitosis progression and have been extensively used in 
cancer chemotherapy as they restrict cancer cells growth and spread. Classical 
antimitotic drugs targets microtubule dynamics, and for this reason are referred as 
microtubules-targeting agents (MTAs) and have carrying a proven history of clinical 
efficacy [217].  
MTAs are typically divided in two major classes: microtubule-stabilizing and 
microtubule-destabilizing agents [218]. The former class consists of taxanes (eg. 
paclitaxel and docetaxel) that are currently used in clinical treatment for a wide range of 
cancers namely advanced breast, non-small cell lung, androgen-independent prostate, 
and ovarian cancers [219]; and the second class concerns to Vinca alkaloids (eg. 
vinblastine, vincristine and vinorelbine) that have shown antitumor activity in Hodgkin 
and non-Hodgkin lymphoma, Kaposi sarcoma, acute leukemias, neuroblastoma, 
rhabdomyosarcoma, Wilms tumor, and testicular, breast, and non-small cell lung 
cancers [217]. Although taxanes and Vinca alkaloids are amongst the most popular 
MTAs, a more recent class of microtubules-stabilizing agents are the epothilones (A and 
B) which bind at the taxane-binding site on microtubules [220]. The ixabepilone, a 
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semi-synthetic analog of epothilone B, was FDA-approved, in 2007, for clinical use in 
the treatment of metastatic breast cancer [221].  
 Both of these agents disturb the dynamic of microtubules and causes abnormal 
spindle formation, by interfering with assembly and disassembly of tubulin subunits 
[222, 223]. The taxanes inhibit microtubules depolymerization, by binding to β-tubulin 
subunits, stabilizing them while the Vinca alkaloids prevent microtubules assembly, 
destabilizing the whole filament. Cells exposed to MTAs arrest in mitosis due to 
chronic activation of the SAC [224]. Following a prolonged mitotic arrest cells respond 
to mitotic inhibition by different ways: die in mitosis via apoptosis, divide unequally 
producing aneuploid daughter cells or exit mitosis without dividing, a process known as 
slippage. After slippage cells can enter into an abnormal G1 state, followed by cell 
death, arrest in a tetraploid G1 state (interphase arrest), or continue to proliferate (cell 
cycle progression) (Figure 1.19) [212, 225].  
 
 
 
Figure 1.19. Cell fate in response to anti-mitotic drug treatment. When cells are exposed to 
an anti-mitotic agent, they arrest in mitosis due to chronic activation of the spindle assembly 
checkpoint. They then undergo one of several fates. Cells might die directly in mitosis, or divide 
unequally to produce aneuploid daughter cells. Alternatively, cells might exit mitosis without 
undergoing division (slippage). In this case, cells might then die in interphase, arrest in 
interphase indefinitely or enter additional cell cycles in the absence of division (Adapted from 
[225]). 
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Thus, the fate of cells exposed to antimitotic agents is, in part, determined by the length 
of the mitotic arrest and their ability to activate apoptosis. It was proposed that cell fate 
is determined by two competing networks that run in parallel upon exposure to MTAs, 
one that involves accumulation of cell death signal, and another that promotes gradual 
cyclin B degradation [226]. Therefore, the network that reaches first its threshold will 
determine the fate of the mitosis-arrested cell. For instance, if cyclin B decreases below 
the threshold level (that sustains the mitotic state) first, then the cell will exit mitosis 
(slippage). Slippage is linked to resistance to anti-mitotic agents due to impaired SAC 
activity in many cancers. In SAC defective cancers, cyclin B degradation threshold 
would be readily reached which favours slippage and aneuploid cells are produced. 
 Actually, to predict how a given tumor will respond to antimitotic therapy remains 
a great challenge and no tools are yet available. Indeed, using a high-throughput 
automated time-lapse light microscopy approach it was shown that cancer cells display 
profound intra- and interline variation following prolonged exposure to antimitotic 
drugs, resulting in multiple cell fates within a cell population [212].  
 Throughout the years, MTAs have proven their efficacy in cancer treatment. 
However, several limitations such as adverse side effects and drug resistance remain to 
restrict their clinical potential [227]. The most frequent adverse side effects are 
associated with neuro and hematological toxicity since, unfortunately, MTAs do not 
distinguish between malignant and normal cells. Neurotoxicity can be explained by the 
high content of microtubules in axons, which are vital for the transport in neurons [228] 
and the hematological toxicity, or myelosuppression, can result from the impairment of 
normal rapidly dividing cells, namely the bone marrow cells [229, 230]. To the other 
hand, drug resistance can emerge due to mutations at drug binding sites, changes in 
microtubule dynamics and in expression of tubulin isotopes, modifications in 
microtubule-regulatory proteins and efflux activity of the P-glycoprotein and the 
multidrug-resistance protein MRP1 that involves the transport of drugs out of the cell, 
thus dropping the intracellular drug concentration. Accordingly, several screens have 
been performed to identify markers of resistance or sensitivity to paclitaxel. A diverse 
array of candidates has been identified, such as proteasome subunits, cyclin G1, and 
solute carriers transporters [231-238], although no validated biomarker that predicts 
which patients will benefit from paclitaxel therapy was discovered.  
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7.2. Second generation of Antimitotic drugs  
 Due to the abovementioned disadvantages that limit MTAs efficacy, a novel 
generation of antimitotic drugs is being developed, in a mitosis-selective approach, that 
inhibit mitosis without affecting microtubules dynamics in non-dividing cells [239].  
 Several mitotic-related components have been proposed as drug target candidates, 
and the front-runners include the plus end-directed motor protein Eg5 (kinesin-5) and 
Aurora and Polo-like kinases. 
 Eg5, involved in centrosome separation at prophase, initiates the bipolar spindle 
assembly [70, 71]. Inhibition of their motor activity results in assembly of a monopolar 
spindle, leading to impairment on chromosome congression and chronic SAC 
activation, followed by cell death [240, 241]. Notably, Eg5 inhibition showed to 
effectively kill paclitaxel-resistant cell lines [242], making this protein a suitable anti-
cancer target. Indeed, a diversity of selective Eg5 inhibitors has been developed and 
some of them have entered clinical trials. Despite the initial expectative and although 
limited cytotoxicities have been found in patients treated with Eg5 inhibitors, only 
partial responses have been reported so far [243], suggesting that these agents should be 
used in combination with other cytotoxic drugs. Moreover, mutations in Eg5 have been 
reported as inducers of resistance to Eg5 inhibitors [244-246]. Also, increased 
expression of Kif15 allows cancer cells to overcome a mitotic delay induced by Eg5 
inhibition [247].   
 Aurora kinases play a key role in the control of mitosis. Defects in these kinases 
activity are related with chromosomal instability and aneuploidy, and they are 
frequently deregulated in human cancers. Aurora A is found overexpressed in breast, 
ovary, lung, bladder, stomach, pancreas, head-and-neck, and colon cancers whereas 
Aurora B is overexpressed in breast cancer, NSCLC, glioblastoma, and prostate cancer 
[248-250]. A role for Aurora C in tumorigenesis has not been established until now. 
Due to their recognition as potential targets for cancer treatment, around 30 Aurora 
kinase inhibitors have reached different stages of pre-clinical and clinical development 
[251]. Despite the demonstrated antitumor activity in several cancer cell lines and 
xenografts models in clinic the results are still disappointing [252, 253].  
 Amongst of Polo-like kinases family, Plk1 has the most studied kinase and plays a 
central role in mitosis being required for their initiation, maintenance, and completion 
[254]. Overexpression of Plk1 has been found in a diversity of human cancers, such as  
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glioma [255], thyroid carcinoma [256], head and neck squamous cell carcinoma [257], 
melanoma [258], colorectal [259], esophageal [260], ovarian [261], breast [262], and 
prostate cancers [263] and it was associated with poor prognosis [264-266]. Plk1 
suppression by RNAi, antibodies or kinases inhibitors has shown an efficient inhibition 
of cancer cells proliferation and an induction of apoptosis [267, 268], suggesting that 
Plk1 could be an attractive target for cancer therapy. Moreover, from the discovery of 
Plk1 is highly expressed in primary tumor tissues [269], its role as an oncogene gain 
additional relevance [270, 271]. Several studies point Plk1 targeting as a novel approach 
for overcoming drug resistance in cancer chemotherapy and to sensitize tumor cells to 
radiation. For example, it was reported that Plk1 silencing could enhance the sensitivity 
to cisplatin in human TP53-mutated epidermal squamous carcinoma cells by 
upregulating p73a [272] or potentiate the neoplastic effect of paclitaxel, causing 
synergistic effects in breast cancer cell lines and in human breast cancer xenografts 
[273]. In addition, Plk1 inhibition showed to suppresses cell growth and enhances 
radiation sensitivity in medulloblastoma cells [274]. The BI2536, a small molecule 
inhibitor of Plk1, it was also reported as could enhance the inhibition of imatinib and 
nilotinib on chronic myeloid leukemia cell growth [275]. Unfortunately, so far, the 
small molecule inhibitors of Plk1 have not achieved a satisfactory therapeutic effect in 
clinical trials [276], probably due to dose-limiting toxicities. In accordance, there is a 
study revealing that reduced efficacy of the Plk1 inhibitor BI2536 on progressive 
hepatocellular carcinoma was due to low intratumoral drug levels [277].  
 The kinesin motor protein CENP-E has been added to the list of potential 
antimitotic targets. Apparently, CENP-E functions are restricted to mitosis namely in 
chromosome congression, as described above, and in SAC response by modulating 
BubR1 function [278, 279] a critical MCC component. In agreement, CENP-E 
inhibition leads to mitotic delay with several misaligned chromosomes and has been 
shown to elicit anti-tumor effects in mouse models of spontaneous tumor formation and 
in mice bearing xenografts of human tumor cells [280, 281]. Overexpression of CENP-
E was found in human melanoma and cervical cancer [282, 283]. Notably, an increase 
in CENP-E levels was linked to epothilone B resistance in A549 lung cancer cells, 
suggesting CENP-E protein expression could potentially act as a predictive biomarker 
to identify patients more likely to benefit from treatment with microtubule-stabilizing 
drugs [284]. Small-molecules inhibitors of CENP-E are under evaluation and some of 
them has reached phase I of clinical trials [243, 285].  
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 Mps1 is a dual-specificity protein kinase that binds to kinetochores. Mps1 is 
required to sustain SAC functions and promotes correct kinetochore-microtubule 
attachment [286]. Due to its function in mitosis, Mps1 is an appealing target for anti-
cancer therapies. High levels of Mps1 are found in many types of human malignancies 
including glioblastoma, anaplastic thyroid carcinoma, breast and lung cancers [287-
291]. Overexpressed Mps1 correlates with a shorter period of recurrence and survival 
time suggesting that Mps1 might also be an independent biomarker indicative of cancer 
prognosis [288]. Inhibition of Mps1 leads to SAC abrogation, thereby leading to 
shortened mitosis, chromosome misssegregation, aneuploidy or polyploidy and cell 
death [180] Mps1 reduced levels have showed to increase tumor cells sensitivity to 
paclitaxel, resulting from severe chromosome missegregation, leading to cell death 
[213]. Although several chemical inhibitors of human Mps1 kinase activity led to 
promising results, none has fulfilled clinical premise [292]. The first phase I clinical 
trials of oral Mps1 inhibitors (BAY1161909, BAY1217389) in combination with 
paclitaxel are still underway (ClinicalTrials.govID: NCT02138812, NCT02366949).  
 Overall, most of this new generation of antimitotic drugs that reach clinical trials, 
has been showing the lack of anti-microtubules-related side effects but the effectiveness 
to kill tumor cells stayed behind. These unexpected results could be, in part, related with 
the hidden mechanism underlying MTAs-mediated cytotoxicity. Nonetheless, 
antimitotic drugs are still subject of intense research that aims to improve maximal 
clinical benefit with reduced toxicity through new strategy of drug design, formulation 
and delivery or taking advantages of combinatorial drugs regimens. Another important 
issue is the improvement of strategies to more effectively target heterogenic tumor cell 
populations and the identification of which tumor/patients are most likely to respond to 
anti-cancer drugs, highlighting the role of the emerging era of pharmacogenomics.  
7.3. MCC components as potential anticancer targets  
 Anti-mitotic activity can be achieved either by inhibiting mitotic exit or by forced 
mitotic exit, depending on the targeted SAC component. The rational of this approach is 
that: i) inhibiting mitotic exit should maximize the time that tumor cells spend in 
mitosis, ultimately leading to their death; and, alternatively, ii) forcing tumor cells to 
exit mitosis prematurely should inevitably result in their death as a consequence of 
massive chromosome misssegregation. Both approaches were tested in human cancer 
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cells, with varying degrees of success. It should be noted that there are two functionally 
different groups of SAC components, that elicit two different types of response upon 
inhibition: i) the core SAC components (Aurora B, Mps1, Bub1, BubR1, Bub3, Mad2, 
and Mad1) which are involved in the generation of the diffusible inhibitory signal, and 
whose inhibition results in forced mitotic exit; and ii) the SAC components (Plk1, Hec1, 
Mis12, Knl1, Rod/Zwilch/Zw10, Ska1-3, CENP-E Spindly and dynein) which are 
involved in kinetochore-microtubule attachment and/or chromosome congression but 
are not required for SAC signal generation, and whose inhibition elicits a mitotic arrest. 
In principle, most SAC components are potential targets [216].   
 Focusing on MCC components, to date, only one inhibitor is available in preclinical 
studies.  
 Mad2 is a key component of the MCC, with central role in SAC signal 
amplification in response to unattached kinetochores. Overexpression of Mad2 was 
found in breast, renal, lung, salivary, esophageal, pancreatic, gastric, colorectal, 
hepatocellular, bladder, cervical and oral cancer and in retinoblastoma and 
osteosarcoma [291, 293-299]. RNAi targeting of Mad2 caused massive chromosome 
missegregation and apoptosis in colorectal cancer cells, and reduced growth of 
xenograft tumors [300, 215]. In contrast, in gastric cancer, Mad2 inhibition showed an 
increase of proliferation, apoptosis inhibition and multidrug resistance by regulating the 
activation of phosphorylated survivin [301]. Downregulation of Mad2 has been 
associated with worse prognosis and as a driver of resistance to conventional 
chemotherapeutics drugs, such as paclitaxel or cisplatin [302-306]. Interestingly, an 
overcome of cisplatin resistance in non-small cell lung cancer with Mad2 silencing 
siRNA delivered systemically using EGFR-targeted chitosan nanoparticles was recently 
described [307]. Through fluorescence polarization-based screen, the first small 
molecule inhibitor of Mad2 (M2I-1), was proposed as targeting the binding of Mad2 to 
Cdc20. Cellular studies revealed that M2I-1 weakens the SAC response, indicating that 
the compound might be active in cells [308]. 
BubR1 is a serine/threonine protein kinase that binds to kinetochores, and is 
involved in SAC signaling in response to a lack of tension on kinetochores. BubR1-
depleted cells are unable to maintain stable KT-MT attachments, consistent with their 
role to regulate the switching from lateral to end-on attachment [207, 208]. BubR1 was 
reported as overexpressed in several human cancers, including gastric adenocarcinoma, 
hepatocellular, urothelial bladder, esophageal, cervix, ovarian, thyroid, renal, lung, 
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prostate, colorectal and oral squamous cell carcinomas and pediatric glioblastoma [145, 
309-311, 296, 312-318, 295]. Overexpression of BubR1 was reported as associated with 
disease progression and poor survival in human lung adenocarcinoma patients. 
Moreover, BubR1 knockdown inhibited metastasis and prolonged overall survival, 
suggesting that therapeutic strategies targeting BubR1 may prove efficacious as single 
agents [319]. RNAi-mediated knockdown of BubR1 showed to restores cancer cell 
sensitivity to paclitaxel [145, 213]. A natural diterpenoid, Pharicin A, was reported to 
inhibit BubR1autophosphorylation, leading to impaired spindle checkpoint functions 
and inhibition of proliferation of leukemia and solid tumor-derived cells. Also, Pharicin 
A was showed to induce mitotic arrest in paclitaxel-resistant Jurkat and U2OS cells 
[320].  
In human cells, Bub3 is shown to be required for the establishment of accurate KT-
MT attachments, since RNAi-mediated Bub3 repression leads to persistent chromosome 
misalignment phenotype [208, 207, 321]. Moreover, Bub3-depleted cells or BUB3 null 
embryos exit prematurely from mitosis as a result of SAC activation failure [208], 
leading to anaphases with lagging chromosomes [208] and micronuclei formation [322]. 
Indeed, a role of Bub3 as a tumor suppressor was reported in Drosophila melanogaster 
tumorigenic model [323]. These findings suggested that Bub3 repression is associated 
with chromosomal instability (CIN) and aneuploidy [205], a hallmark of most solid 
tumors. Variations in Bub3 expression were reported in human tumors being 
upregulated in breast [324, 325], gastric [318], cervical [283] and salivary gland [326] 
cancers and downregulated in pediatric glioblastoma [309]. However, the 
clinicopathological significance of Bub3 deregulation is still missing. Suppressing Bub3 
in HeLa cervical carcinoma cells seems to produces paclitaxel resistance [327].  
Cdc20 is the main target of SAC activity, whose inhibition leads to mitotic arrest 
and an extended apoptotic cell death. Its overexpression was found in breast, 
hepatocellular, head and neck, pancreatic, bladder, cervical and gastric cancers [283, 
328-332]. An inhibition of cancer cells growth, due to mitotic arrest, and an 
improvement of cytotoxic activity of both paclitaxel and irradiation were reported after 
Cdc20 knockdown [333] [334] as well as an significant inhibition of hepatocellular 
carcinoma growth in the orthotopic liver tumor model [335]. In histological samples 
from Oral Squamous Cell Carcinoma (OSCC), Cdc20 overexpression was linked to a 
poor prognosis, suggesting Cdc20 as a novel independent prognostic factor, as well as a 
molecular marker to categorize high-risk OSCC subgroups [332].  
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Overall, the abovementioned reports reinforce that targeting the MCC components, 
may be promising target for antimitotic activity. Also, combinatorial regimen between 
SAC components and conventional antimitotic drugs could be an attractive therapeutic 
avenue of exploration of new cancer therapies.  
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MOTIVATION AND AIMS 
 
The spindle assembly checkpoint (SAC) is the major safeguard mechanism for 
protecting cells against chromosome missegregation at anaphase by monitoring the 
status of kinetochore-microtubule (KT-MT) attachments [99]. SAC signaling pathway 
is activated by unattached or misattached kinetochores, and it is silenced after these 
kinetochores form stable end-on microtubule attachments [99]. Bub and Mad proteins 
are key players for effective SAC response. Nonetheless, the role of SAC proteins was 
expanded with the discovery that BubR1, Bub1, and Bub3 are themselves implicated in 
the regulation of KT-MT attachment [207], besides their role in SAC signaling. In 
higher eukaryotes, KT-MT attachments are mainly mediated by the minus-end directed 
motor dynein [78, 109, 79, 81], and the plus-end directed kinesin motor CENP-E [120, 
151]. The link between SAC signaling and KT-MT binding machinery is still not 
completely understood. Dynein was also reported as involved in SAC silencing, namely 
in the stripping of SAC proteins from the attached kinetochores towards spindle poles 
[82, 336]. An open issue is to clarify which components are poleward transported by 
dynein, to switch off the SAC signal, since the reported results remains controversial. 
Hence, the first aim of this thesis was focused on SAC function and regulation 
(Chapter 3), with two specific objectives:  
 
(i) To establish a relationship between the SAC protein Bub3 and the microtubule 
motor dynein in regulating kinetochore-microtubule attachment and 
chromosome congression; 
(ii) To elucidate the role of dynein-mediated transport of SAC components off 
kinetochores to promote SAC silencing.  
Targeting mitosis in cancer cells leads to mitotic arrest, due to chronic SAC 
activation, and frequently to cell death [225]. This explains the proven success of the 
anti-microtubule drugs, taxanes and Vinca alkaloids, in the clinical treatment of several 
human cancers [217]. Despite this and given their limitations, conventional antimitotic 
drugs are still subject of intense research that aims to enhance their efficacy while 
minimizing their toxicity. Although it seems hard to achieve, efforts have recently 
focused on the use of molecularly targeted agents, either alone or in combination with 
standard therapies such as taxanes, in order to improve survival and quality of life 
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outcomes. Moreover, effective clinical use of the novel targets and/or combined 
therapies will require the development of predictive biomarkers and patient stratification 
which, in turn, will require an in-depth understanding of the molecular mechanisms 
behind how these drugs kill cancer cells. 
Accordingly, the second aim of this thesis was directed to therapeutic implications 
of spindle assembly checkpoint targeting (Chapter 4), with two specific objectives:  
 
(i) To explore the potential of Spindly, a kinetochore regulator of dynein, as a target 
for cancer therapy, either alone or in a combination therapy 
ii) To explore the potential of Spindly as diagnostic/prognostic biomarker of cancer. 
 
These two aims allow to establish a bridge between the basic and applied research 
which is important for future progress namely in SAC function, regulation and 
therapeutic implications, at a translational view.   
  
  
 
 
 
 
 
 
 
CHAPTER 3 
 
 
 
SHEDDING LIGHT ON SPINDLE ASSEMBLY CHECKPOINT 
REGULATION AND FUNCTION  
 
 
According to the objectives highlighted in the previous section, this chapter is divided 
into two parts:  
3.1. Co-silencing of human Bub3 and dynein highlights an antagonistic 
relationship in regulating kinetochore-microtubule attachments; 
3.2. Dynein-dependent transport of spindle assembly checkpoint proteins off 
kinetochores toward spindle poles. 
  
 
 
 
 
 
 
 
3.1. Co-silencing of human Bub3 and dynein highlights 
an antagonistic relationship in regulating kinetochore-
microtubule attachments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The information presented in this section was based in the following published paper: 
 
Patrícia M.A. Silva,  Álvaro A. Tavares and Hassan Bousbaa. Co-silencing of human 
Bub3 and dynein highlights an antagonistic relationship in regulating kinetochore-
microtubule attachments. FEBS Letters. 2015;589(23):3588-94. 
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1. Abstract 
We previously reported that the spindle assembly checkpoint protein Bub3 is 
involved in regulating kinetochore-microtubule (KT-MT) attachments. Also, Bub3 was 
reported to interact with the microtubule motor protein dynein. Here we examined how 
this interaction contributes to KT-MT attachments. Depletion of Bub3 or dynein 
induced misaligned chromosomes, consistent with their role in KT-MT attachments. 
Unexpectedly, co-silencing of both proteins partially suppressed the misalignment 
phenotype and restored chromosome congression. Consistent with these observations, 
KT-MT attachments in co-depleted cells were stable, able to drive chromosome 
congression, and produce inter- and intra-kinetochore stretch, indicating they are 
functional. We suggest that a mutual antagonism exists between Bub3 and dynein to 
ensure optimal KT-MT attachments. 
 
 
Keywords: Bub3, dynein, Spindly, kinetochore-microtubule interactions, chromosome 
congression, antagonistic interaction. 
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2. Introduction 
Faithful chromosome segregation in mitosis relies on appropriate kinetochore-
microtubule (KT-MT) attachments, under the surveillance of the spindle assembly 
checkpoint (SAC). The SAC prevents anaphase onset until all chromosomes accomplish 
proper bipolar attachments and come under tension. Core components of the SAC 
proteins include, among others, the evolutionary conserved Mad2, Bub3, and BubR1, 
which form the mitotic checkpoint complex (MCC) with Cdc20 whenever unattached or 
improperly attached kinetochores are present. As a consequence, Cdc20 is unable to 
activate the anaphase promoting complex/cyclosome (APC/C) and anaphase is blocked 
[99, 23]. Besides this surveillance role, SAC components were also involved in the 
regulation of KT-MT attachments [207]. For instance, we previously reported that Bub3 
is required for the establishment of stable end-on KT-MT attachments. Yet, the 
relationship between Bub3 and other proteins involved in the same process of KT-MT 
attachments remains unknown. A good candidate for this relationship is the cytoplasmic 
dynein. Dynein was reported to interact with Bub3 [337, 338]. Although there is still no 
clear demonstration of a direct role of dynein in the formation of stable KT-MT 
attachments, in many reports, displacement of kinetochore dynein was reported to delay 
chromosome congression and the formation of load-bearing attachments. For instance, 
inhibition of dynein results in unstable KT-MT attachments and interferes with 
metaphase chromosome alignment [339, 340]. Here, we studied the functional 
relationship between Bub3 and dynein in regulating KT-MT attachments.  
 
3. Materials and Methods  
3.1. Cell culture and siRNA transfection  
HeLa cells, HeLa cells stably expressing EGFP-Bub3 [341], and HeLa cells stably 
expressing EGFP-CENP-A (a gift from Dr. Lars Jansen, IGC, Lisboa, Portugal) were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Biochrom, São Mamede de 
Infesta, Portugal), supplemented with 10% fetal bovine serum (FBS, Biochrom), and 
maintained at 37°C, in a 5% CO2 humidified atmosphere. For HeLa cell lines stably 
expressing EGFP-Bub3 and EGFP-CENP-A, the medium was supplemented with 400 
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µg/ml of a selective agent G418 and 1 µg/ml Blasticidin (Sigma-Aldrich Co., Saint 
Louis, MO, USA) respectively.  
For transfection with siRNAs, cells were seeded in 22 mm poly-L-lysine-coated 
coverslips in 6-well plates containing DMEM and, 24 hours later, transfected using 
INTERFERin siRNA Transfection Reagent (PolyPlus, New York, USA) according to 
the manufacturer’s instructions. The culture medium was replaced 6 hours after 
transfection with fresh DMEM. Validated siRNA duplexes against Dynein Heavy Chain 
(DHC) and Bub3 (Santa Cruz Biotechnology, Dallas, USA) were used at a final 
concentration of 13.3 nM and 6.7 nM, respectively. A validated siRNA sequence 
against Spindly [342] was synthetized by Sigma-Aldrich and was used at a final 
concentration of 100 nM. Microscopic analysis was performed 48 or 72 hours post-
transfection.  
3.2. Cell extracts and Western Blotting 
For total cell extracts, cells were harvested by centrifugation and resuspended in 
lysis buffer (50 mM Tris pH 7.5; 150 mM NaCl; 1 mM EDTA; 1% Triton-100) 
containing a protease inhibitor cocktail (Sigma-Aldrich). Protein quantification was 
performed using a BCA
TM 
Protein Assay Kit (Pierce Biotechnology), according to the 
manufacturer’s instructions.  A total of 15 µg of protein lysate was resuspended in SDS-
sample buffer (375 mM Tris pH 6.8; 12% SDS; 60% Glycerol; 0.12% Bromophenol 
Blue; 600 nM DTT), boiled for 3 minutes at 100°C and proteins were separated on a 
7.5% SDS-PAGE gel. After electrophoresis, proteins were transferred to a nitrocellulose 
membrane (Amersham) by semidry transfer system (Hoefer). Membrane was blocked 
with 5% nonfat dried milk in TBST (50 mM Tris pH 7.5; 150 mM NaCl, 0.05% Tween-
20) for 1 hour at room temperature (RT) with mild agitation. Primary antibodies were 
diluted, in 1% nonfat dried milk, as follows: mouse anti-Bub3 (1:1000, 611731 clone 
31, BD Biosciences); mouse anti-DIC (1:200, D5167 clone 70.1, Sigma-Aldrich); rabbit 
anti-Spindly (1:3000, gift from Dr. R. Gassmann, IBMC, Portugal), rabbit anti-α-tubulin 
(1:1500, ab15246, Abcam) and mouse anti-α-tubulin (1:5000, T568 Clone B-5-1-2, 
Sigma-Aldrich). After washing in TBST, membrane was probed, for 1 hour at RT, with 
horseradish peroxidase (HRP)-conjugated secondary antibodies, diluted at 1:1500 (anti-
mouse, Vector) or at 1:1000 (anti-rabbit, Sigma). Proteins were visualized using the 
Enhanced Chemiluminescence (ECL) method and the relative signal intensity of the 
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bands was determined as normalized against α-tubulin intensity levels using ImageJ 
1.4v software (http://rsb.info.nih.gov/ij/).  
3.3. Immunofluorescence  
Cells were fixed in fresh 2% paraformaldehyde (Sigma-Aldrich) in phosphate-
buffered saline (PBS) for 12 minutes, rinsed three times 5 minutes in PBS and 
permeabilized with 0.5% Triton X-100 in PBS for 7 minutes. Alternatively, cells were 
fixed in -20ºC cold methanol for 10 minutes and rehydrated twice in PBS. Non-specific 
binding sites were blocked with 10% FBS in PBST (PBS plus 0.05% Tween-20) for 30 
minutes at RT. Then cells were incubated for 1 hour with primary antibodies diluted in 
PBST containing 5% FBS as follows: human anti-CREST (1:4500, gift from Dr. E. 
Bronze-da-Rocha, IBMC, Porto, Portugal); mouse anti-Hec1 (1:600, ab3616, Abcam); 
rabbit anti-Spindly (1:3000, gift from Dr. R. Gassmann, IBMC, Portugal); rabbit anti-α-
Tubulin (1:100, Abcam); mouse anti--Tubulin (1:1500, T6557, Clone GTU-88, Sigma-
Aldrich) mouse anti-α-Tubulin (1:2500, Sigma-Aldrich). After washing in PBST, cells 
were incubated with secondary antibodies for 1 hour. All secondary antibodies were 
used at 1:1500 (Molecular Probes), with the exception of Alexa Fluor 647-conjugated 
secondary antibody which was used at 1:2000 (Molecular Probes). DNA was stained 
with 2 µg/ml 4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) diluted in 
Vectashield mounting medium (Vector, H-1000). 
3.4. Functional assays for kinetochore-microtubule attachments 
To assess cold-stable microtubules, cells in culture medium were incubated at 4°C 
for 5 minutes and processed immediately for immunofluorescence with anti-α-tubulin 
and anti-Hec1 antibodies. Inter-kinetochore distance was measured between Hec1 spots 
on kinetochore pairs of bi-oriented chromosomes. Kinetochore stretching (intra-
kinetochore distance) was obtained by subtracting the distance between CENP-A spots 
(inner kinetochore marker) from the distance of Hec1 spots (outer kinetochore marker), 
using GFP-CENP-A expressing HeLa cell line. More than 50 kinetochore pairs from 10 
cells were analyzed. To evaluate the ability of KT-MT attachments to drive 
chromosome congression, cells were first incubated with 1 µM nocodazole (Sigma-
Aldrich) for 1 hour to depolymerize microtubules, in the presence of 10 µM of the 
proteasome inhibitor MG-132 (Sigma-Aldrich) in order to arrest cells at metaphase-
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anaphase boundary. Then cells were released into medium in the presence of MG-132 
for 1 hour before immunostaining [208]. Nocodazole washout gives cells the 
opportunity to nucleate a new set of microtubules and MG-132 give chromosomes time 
to achieve successful bipolar KT-MT attachments and to align at the equator to 
(re)organize a metaphase plate. More than 750 mitotic cells were counted for each 
condition. 
3.5. Image acquisition and processing 
Phase-contrast images were acquired with a 10x objective, on a Nikon TE 2000U 
microscope, using a DXM1200F digital camera and with Nikon ACT-1 software 
(Melville, NY). Fluorescence images were acquired with Plan Apochromatic 63x/NA 
1.4 objective on an Axio Observer Z.1 SD microscope, coupled to an AxioCam MR3 
digital camera (Carl Zeiss, Germany). Z-stacks were acquired at 0.4-μm intervals and 
images were processed using ImageJ software after deconvolution with AxioVision 
Release 4.8.2 SPC software. Insets are representative of each condition with 2-4 stacks 
projection.  
Quantification of kinetochore fluorescence signals was performed as previously 
described except that values were normalized to Hec1 fluorescence intensities [208]. 
Each value was derived from at least 300 kinetochores in ten representative cells. For 
quantification of cold-stable microtubules, unattached and attached kinetochores were 
counted in 5 representative cells as previously described except that Hec1 staining was 
used to identify kinetochores in image Z-stacks [208]. More than 90 kinetochores were 
counted per cell. 
3.6. Statistical analysis 
Data are presented as the means ± standard deviation (SD) of at least three 
independent experiments. Statistical analysis was performed using an unpaired Student 
t-test in GraphPad Prism version 6 (GraphPad software Inc., CA, USA). The level of 
significance was set at probabilities of *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001. 
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4. RESULTS AND DISCUSSION 
4.1. Bub3 and dynein are not mutually interdependent for kinetochore 
localization 
To study the relationship between Bub3 and dynein in KT-MT attachment, we 
performed single and double depletions using validated siRNAs (Figure 3.1A and B). 
An important question that needed to be clarified first was whether depletion of one 
protein affects kinetochore localization of the other. This possibility was excluded as 
Bub3 properly localized to kinetochores in dynein-depleted cells, as did dynein in 
Bub3-depleted cells (Figure 3.1B). Thus, the chromosome misalignment phenotype 
known to result from depletion of one protein is not a consequence of depletion of the 
other.  
 
Figure 3.1. Bub3 and dynein depletion are not interdependent for kinetochore localization. 
(A) Immunoblots showing efﬁcient siRNA-mediated individual (siBub3 and siDHC) and co-
depletion of Bub3 and dynein (siBub3/siDHC). Note that the levels of one protein are not 
affected by depletion of the other. (B) Immunoﬂuorescence images showing that (top panel) 
depletion of Bub3 (siBub3) did not affect kinetochore localization of dynein (DIC), and (middle 
panel) depletion of dynein (siDHC) did not affect kinetochore localization of Bub3 (EGFP-
Bub3); (bottom panel) shows depletion of both proteins (siBub3siDHC). Cells were treated with 
1µM nocodazole prior immunoﬂuorescence to create conditions where Bub3 and dynein are 
maximally enriched at kinetochores. Bar, 5µm. 
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4.2. Dynein depletion partially suppresses chromosome misalignment 
phenotype associated with Bub3 depletion  
We then proceeded to the analysis of chromosome congression in the absence of 
both Bub3 and dynein in order to determine if a relationship exists between the two 
proteins. For that, we determined the ability of chromosomes to align at spindle 
midzone and to form a defined metaphase plate in Bub3/dynein co-depleted cells. Cells 
were treated with the anaphase inhibitor MG-132 prior to immunostaining in order to 
give chromosomes enough time to reach the metaphase plate [208, 207, 215]. Most 
mitotic cells in control were blocked in metaphase (91.0±0.7%) and had all 
chromosomes aligned (Figure 3.2A and B). In contrast, the majority of mitotic Bub3-
depleted cells (62.0±1.5%) that reached metaphase exhibited misaligned chromosomes 
(Figure 3.2A and B), consistent with defective KT-MT attachments we previously 
reported [208]. In dynein-depleted cells, we observed three distinct mitotic figures: 
metaphases with misaligned chromosomes (36.2±7.2%), full metaphases (26.2±3.1%), 
and mitotic cells with no defined organization that we scored as disorganized 
metaphases (37.6±2.4%) (Figure 3.2A and B). While the presence of metaphases with 
misaligned chromosomes reflects the dynein role in initial attachments and probably in 
their conversion into end-on attachment [74, 75, 340], the disorganized figures 
displayed abnormal mitotic spindle morphology with no focused spindle poles, probably 
reflecting dynein role in spindle organization and centrosomes separation [109, 78]. 
Nevertheless, the metaphases with misaligned chromosomes and full metaphases 
showed bipolar spindles with focused poles as judged by the centrosome marker γ-
tubulin (Figure 3.2C). Quantification of metaphases in MG-132-treated Bub3/dynein 
co-depleted cells showed a significant increase in full metaphases, from 38.4±1.5% in 
Bub3- and 26.2±3.1% in dynein-depleted to 47.4±8.1% after depletion of both proteins 
(Figure 3.2A and B). This increase was accompanied with a concomitant decrease in 
metaphase with misaligned chromosomes, with a drop from 61.7±1.5% in Bub3 and 
36.2±4.6% in dynein single knockdown to 22.4±1.8% in the absence of both proteins. 
The percentage of disorganized metaphases did not seem to be affected by the co-
depletion. 
Then, we sought to clarify whether the contribution of dynein to the rescue of 
chromosome alignment observed in Bub3/dynein co-depletion was specific to its 
kinetochore pool, or it is due to the multiple roles of its cytosolic pool in mitotic spindle 
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organization. To selectively deplete dynein from kinetochore, we used validated 
siRNAs against Spindly, a protein required for dynein recruitment to kinetochores 
[343]. As expected, dynein was absent from kinetochore after Spindly depletion (Figure 
3.S1A and B). We also certified that Bub3 and Spindly were not interdependent for 
kinetochore localization (Figure 3.S1C and D). In MG-132-treated Bub3/Spindly co-
depleted cells, the severity of chromosome misalignment was clearly attenuated, 
compared to Spindly depletion, with a net increase in well-defined metaphase plates 
having few to no misaligned chromosomes (Figure 3.2D and E).  
Collectively, these observations indicate that co-depletion of Bub3 and dynein 
suppresses, at least partially, the misalignment phenotype generated by depletion of 
each protein individually, which probably underlies an antagonistic interaction. Of note, 
as a dynein-recruitment independent role in chromosome alignment has been proposed 
for Spindly [186], we do not exclude the possibility that Bub3/Spindly co-depletion is 
also rescuing alignment defects that are not necessarily dependent on dynein. 
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Figure 3.2. Bub3 and dynein co-depletion rescues chromosome alignment. (A) 
Immunofluorescence images showing misalignment phenotype after individual (siBub3 and 
siDHC) and co-depletion of Bub3 and dynein (siBub3/siDHC) showing many misaligned 
chromosomes in a cell depleted of Bub3 (siBub3) or dynein (siDHC). Co-depletion 
(siBub3/siDHC) suppressed the misalignment phenotype. Microtubules (green) were stained 
with anti-α-tubulin antibody, kinetochores (red) with anti-Hec1 antibody, and DNA (blue) with 
DAPI. PM = prometaphase; M = metaphase; Mis = misaligned; Dis = disorganized. (B) 
Quantification of data shown in (A). (C) Immunofluorescence images of control and siDHC-
treated cells, stained for α-tubulin to visualize spindle microtubules (green) and for γ-tubulin to 
localize spindle pole position (red). In siDHC cells, metaphase plates with misaligned 
chromosomes (middle) exhibited a defined bipolar spindle similar to control (left), while 
disorganized metaphases (right) displayed abnormal spindle morphology and thus were 
excluded from this study. (D) Immunofluorescence images showing many misaligned 
chromosomes in a cell depleted of Bub3 (siBub3) or Spindly (siSpindly). Co-depletion 
(siBub3/siSpindly) greatly improved chromosome alignment. Cells were processed as in (A).  
(E) Quantification of data shown in (D). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001. Bar, 5 µm. 
 
4.3. Kinetochore-microtubule attachments in Bub3/dynein co-depleted cells 
are stable and functional enough to restore the alignment 
Successful chromosome congression relies on stable and functional KT-MT 
attachments. We asked whether the apparent rescue of chromosome alignment upon 
Bub3/dynein depletion was due to a rescue of stable and functional KT-MT 
attachments. For that, we performed functional assays to test the robustness of KT-MT 
attachments and their ability to generate tension and to drive chromosome movement 
and alignment in co-depleted cells. 
The robustness of kinetochore-attached microtubules (or K-fibers) was tested after a 
brief exposure of cells to low temperature. Low temperature induces disassembly of 
unstable, but not stable, K-fibers [56]. After cold treatment, metaphases in Bub3- or 
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dynein-depleted cells exhibited few cold-resistant K-fibers and many unattached 
kinetochores, as judged by Hec1/tubulin immunostaining (Figure 3.3A). Instead, 
unattached kinetochores were rather rare or absent in metaphases of co-depleted cells, 
almost indistinguishably from control metaphases, indicating that robust KT-MT 
connections were restored.  
Robustness of KT-MT attachments in co-depleted cells was further assessed for 
their ability to generate tension across sister-kinetochores due to poleward forces 
exerted by microtubules on kinetochores. Tension between kinetochores can be 
appreciated by measuring inter- and intra-kinetochore distances [344]. Inter-kinetochore 
distance reflects centromere stretching and intra-kinetochore distance reflects stretching 
at the kinetochore itself [345, 346]. Inter-kinetochore distance was found to be smaller 
in siBub3 cells (1.39 ± 0.09 μm) and in siDHC cells (1.56 ± 0.10 μm), compared to 
control cells (2.08 ± 0.37 μm), in agreement with previous data (Figure 3.3B) [340, 79, 
207]. In co-depleted cells, inter-kinetochore distance slightly increased to reach 1.66 ± 
0.19 μm. Although it did not reach control values, this slight increase underlies an 
improvement in KT-MT attachments. Interestingly, a clear improvement of intra-
kinetochore distance (kinetochore stretching) was found in co-depleted cells (68.33 ± 
0.02 nm), compared to Bub3-depleted cells (45.00 ± 0.07 nm) (Figure 3.3C). Here, 
intra-kinetochore stretching was restored to levels indistinguishable from control (68.50 
± 0.05 nm). Intra-kinetochore stretch can occur at low levels of inter-kinetochore stretch 
and reflects the attachment of dynamic microtubules, ultimately leading to satisfaction 
of the SAC [345]. Taken together, these observations strongly indicate that Bub3 and 
dynein co-depletion restores robust and dynamic KT-MT attachments that are able to 
generate tension.    
Finally, we were concerned whether the restored KT-MT attachments in co-depleted 
cells were functional and, thus, able to drive chromosome congression. For that, we 
assessed their ability to drive chromosome movement and alignment after a nocodazole 
treatment/washout assay in the presence of MG-132. After 45 minutes of recovery, up 
to 80% of mitotic control cells have formed full metaphases, while only 12% in Bub3- 
and 20% in dynein-depleted mitotic cells exhibited full alignment (Figure 3.3D). 
However, upon co-depletion, up to 40% of mitotic cells reaching full metaphases, 
indicating that Bub3/dynein co-depletion restores functional KT-MT attachments that 
are able to drive chromosome congression. 
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Figure 3.3. Bub3 and dynein co-depletion rescues stable and functional Kinetochore-
microtubule attachments. (A) (Top) Quantification of cold-stable microtubules (as percentage 
of attached kinetochores per cell) after individual (siBub3 and siDHC) and co-depletion of Bub3 
and dynein (siBub3/siDHC). (Bottom) Representative immunofluorescence images of (A) 
showing several unattached kinetochores (free Hec1 red spots) in cells depleted of Bub3 
(siBub3) or dynein (siDHC), whereas most kinetochores were attached (Hec1 red spots with 
attached green fibers) in siBub3/siDHC cells, similarly to control. (B) Distance between Hec1 
spots of aligned sister kinetochore pairs, showing a slight increase in inter-kinetochore distance 
in siBub3/siDHC cells, comparatively to individual depletions. Lower images and insets are 
representative of each condition. (C) Kinetochore stretching (intra-kinetochore distance), of bi-
oriented kinetochores, showing an increase in intra-kinetochore distance in siBub3/siDHC, 
comparatively to individual depletions. Kinetochore stretching (c) was measured by subtracting 
the distance between inner kinetochore CENP-A spots (b) from that between outer kinetochore 
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Hec1 spots (a) and divided by two, as illustrated in the lower image. (D) Cells were treated with 
nocodazole to depolymerize microtubules in the presence of MG132, released into fresh culture 
medium containing MG132 for 45 minutes, and stained for α-tubulin (green) and Hec1 (red). 
The ability of cells to form a metaphase plate was significantly improved in siBub3/siDHC 
cells, comparatively to siBub3 cells. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.  
Bar in A-C, 5 µm; bar in D, 1 µm. 
 
4.4. How to explain this unexpected antagonistic interaction between Bub3 
and dynein and what would be its functional significance? 
At first glance, the question may seem difficult to answer. Indeed, given the role of 
Bub3, and most probably also of dynein, in promoting end-on attachments, one should 
expect a rather worst chromosome misalignment phenotype in the absence of both 
proteins. Nevertheless, in light of previous reports, involvement of dynein in intriguing 
antagonistic relationships is not too surprising. For instance, depletion of dynein 
restored bipolar spindles in cells depleted of the drosophila homolog of human CLASP, 
a protein required to incorporate tubulin subunits into microtubule plus-ends, suggesting 
an unexpected antagonistic role of the two proteins in kinetochore-microtubule plus-end 
dynamics [347]. Similarly, depletion of the drosophila motor protein CENP-E partially 
suppressed the unstable KT-MT attachments associated with the depletion of the SAC 
protein BubR1 [348]. As both proteins are implicated in stable KT-MT attachments, the 
restoration of stable attachments upon their co-depletion revealed, again, an intriguing 
antagonistic interaction. Interestingly, alleviation of chromosome alignment defects has 
been also surprisingly seen upon co‐depletion of Spindly and Rod/ZW10/Zwilch (RZZ) 
complex by allowing constitutive binding of Ndc80 complex to microtubules [187]. 
One possible explanation for the antagonistic interaction is that Bub3 and dynein are 
functioning in parallel pathways to promote KT-MT attachments and that the two 
pathways might, either directly or indirectly, mutually restrain the activity of each other. 
Particularly consistent with this possibility is the partial suppression of the 
misalignment phenotype associated with Bub3 depletion when dynein was also 
removed.  The restoration of full metaphase after the double knockdown could result 
from a restoration of balance between residual Bub3/dynein or from other regulators of 
KT-MT interactions. 
As to the functional significance of this antagonistic interaction, first we believe that 
this crosstalk is the result of direct interactions between Bub3 and dynein as both 
proteins were reported to interact in human [338]. The crosstalk between Bub3 and 
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dynein activities may serve to fine-tune KT-MT interactions, probably to achieve 
optimal end-on attachments. It may also serve to link the state of KT attachment to the 
SAC signaling machinery in order to ensure that efficient KT-MT attachments are 
established before anaphase resumes. Additionally, the crosstalk would allow dynein to 
probe when SAC proteins need to be transported away from kinetochores to promote 
SAC silencing. In this respect, Bub3 itself is a dynein cargo during the step of SAC 
silencing according to our previous report [341]. Future work will be needed to 
understand the mechanistic aspect of this crosstalk. 
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6. Supplementary figures  
 
 
 
Figure 3.S1. Displacement of kinetochore dynein as mediated by spindly depletion. (A) 
Immunoblots showing efficient siRNA-mediated depletion of Spindly (siSpindly, top blot), and 
efficient co-depletion of Bub3 and Spindly (siBub3/siSpindly, bottom blot). (B) 
Immunofluorescence images showing efficient delocalization of dynein (DIC) from 
kinetochores after depletion of Spindly (siSpindly). CREST serum was used as kinetochore 
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marker (green). (C) Immunofluorescence images showing that (top panel) depletion of Bub3 
(siBub3) did not affect kinetochore localization of Spindly, and (middle panel) depletion of 
Spindly (siSpindly) did not affect kinetochore localization of Bub3 (EGFP-Bub3); (bottom 
panel) shows depletion of both proteins. Cells in B, and C were treated with 1 μM nocodazole 
prior immunofluorescence to create conditions where Bub3, dynein and Spindly are maximally 
enriched at kinetochores. (D) Quantification of kinetochore staining intensity of Spindly in 
Bub3-depleted cells (top), and of EGFP-Bub3 in Spindly-depleted cells (bottom). Bar, 5 μm. 
  
 
 
 
 
 
 
3.2. Dynein-dependent transport of spindle assembly 
checkpoint proteins off kinetochores toward 
spindle poles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The information presented in this section was based in the following published paper: 
Patrícia M.A. Silva,  Rita M. Reis, Victor M. Bolanos-Garcia, Claudia Florindo, 
Álvaro A. Tavares and Hassan Bousbaa. Dynein-dependent transport of spindle 
assembly checkpoint proteins off kinetochores toward spindle poles. FEBS Letters. 
2014;588(17):3265-73.
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1. Abstract  
A predominant mechanism of spindle assembly checkpoint (SAC) silencing is 
dynein-mediated transport of certain kinetochore proteins along microtubules. There are 
still conflicting data as to which SAC proteins are dynein cargoes. Using two ATP 
reduction assays, we found that the core SAC proteins Mad1, Mad2, Bub1, BubR1, and 
Bub3 redistributed from attached kinetochores to spindle poles, in a dynein-dependent 
manner. This redistribution still occurred in metaphase-arrested cells, at a time when the 
SAC should be satisfied and silenced. Unexpectedly, we found that a pool of Hec1 and 
Mis12 also relocalizes to spindle poles, suggesting KMN components as additional 
dynein cargoes. The potential significance of these results for SAC silencing is 
discussed. 
 
 
Keywords: Mitotic checkpoint, checkpoint silencing, cytoplasmic dynein, Mad1, 
Mad2, Bub1, BubR1, Bub3, Hec1. 
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2. Introduction  
Accurate chromosome segregation relies on the activity of the spindle assembly 
checkpoint (SAC) [23], a surveillance mechanism that monitors the status of 
kinetochore-microtubule attachment and prevents anaphase onset until all chromosomes 
are bipolarly attached to the mitotic spindle and aligned at the metaphase plate [349]. 
Inhibition of anaphase onset is achieved by the SAC through downregulation of the 
APC/C (anaphase promoting complex/cyclosome). The latter is an E3 ubiquitin ligase 
required for targeting cyclin B1 and securin for degradation by the 26S proteasome, 
thereby delaying cell in mitosis and preventing precocious sister-chromatid separation. 
APC/C inhibition is predominantly achieved by the MCC, the mitotic checkpoint 
complex that forms between the SAC proteins Mad2, BubR1 and Bub3, and the 
cofactor and activator of APC/C, Cdc20 [157]. It is widely believed that unattached or 
improperly attached kinetochores provide the catalytic platform for the formation of the 
anaphase inhibitor MCC [350, 23].  
SAC components also include the evolutionary conserved proteins Mad1, and the 
kinases Bub1, Mps1, and Aurora B. These proteins localize to kinetochores and 
participate in the recruitment, activation, or formation of the MCC. Kinetochore levels 
of these proteins fall upon microtubule attachment [349]. Once all kinetochore-
microtubule attachments are efficiently established, SAC must be extinguished in order 
to allow for mitotic progression, a process known as SAC silencing. Extinguishing SAC 
requires that assembly of new MCC is prevented and existing inhibitory complexes are 
disassembled in order to release Cdc20 and, thus, alleviate APC/C inhibition [351, 352] 
[353]. A predominant mechanistic model of SAC silencing postulates the removal of 
proteins that are required for SAC activation from attached kinetochores via stripping 
(also known as streaming) [353]. Stripping is mediated by the minus-end directed 
microtubule motor dynein, which transports certain SAC proteins off kinetochores 
towards spindle poles along kinetochore-microtubules. Using an ATP depletion assay 
that maintained dynein activity but prevented release of its cargo from spindle poles, 
Howell et al. were the first to report that Mad2 and BubR1 (as well as CENP-E, dynein 
itself and 3F3/2 antigens) are transported to spindle poles, and that inhibition of dynein 
prevented Mad2 removal from attached kinetochores [82]. Subsequent studies also 
based on ATP depletion have catalogued several kinetochore components for their 
ability to be transported by dynein [336]. While it is consensual that Mad1, Mad2, and 
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spindly (which is required for dynein kinetochore binding) are dynein cargoes, there is 
conflicting data concerning the poleward transport of Bub1 and BubR1 [336, 82]. 
Furthermore, whether all SAC components are transported to spindle poles upon 
checkpoint silencing is not known yet.  
In an attempt to clarify these issues, we used two ATP depletion assays to assess the 
poleward transport of SAC proteins, focusing the analysis on those that are relevant to 
the generation of the anaphase inhibitory signal. Through this approach, we confirm the 
dynein-dependent transport to spindle poles of Mad1 and Mad2; we clarify that Bub1 
and BubR1 are indeed dynein cargoes; and propose Bub3 as additional dynein cargo. 
We also report that the poleward transport of these SAC proteins persists in metaphase 
arrested cells, a situation when the cells are in a SAC inactive state with all 
chromosomes bipolarly attached. Interestingly, we further propose dynein-dependent 
poleward transport of the KMN components Hec1 and Mis12. 
3. Materials and Methods  
3.1. Cell culture, drug treatment, and RNAi 
HeLa cells were cultured in DMEM (PAA Laboratories, E15-883), supplemented 
with 10% FBS (GIBCO, 10500-064) and 1% antibiotic/antimycotic (GIBCO, 12605-
028) and maintained at 37°C, in a 5% CO2 humidified atmosphere. EGFP-Bub3 stably-
expressing HeLa cell line was generated by inserting the hBub3 cDNA in frame into 
pIC113 vector [354]. Clones expressing near endogenous levels of EGFP-Bub3 were 
selected and maintained in culture under 400 µg/ml of G418 (Sigma-Aldrich, A1720-
1G). 
MG-132 (Sigma-Aldrich, 2211-5MG) was used at 10 M for 60 minutes; 
nocodazole (Sigma-Aldrich, M1404-2MG) was used at 1 µM for 60 minutes; 
nordihydroguaiaretic acid (Biomol, BML-EI101-0001) was used at 30 µM for 30 
minutes as described [336]. The ATP inhibition assay was performed as described  [82].  
Dynein knockdown was performed using validated siRNA oligoduplexes against 
Dynein Heavy Chain [355] (Santa Cruz Biotechnology, sc-43738). Spindly knockdown 
was performed using validated siRNAs sequence [186] that was synthetized by (Sigma-
Aldrich). Cells were transfected as previously described [208], except that 
INTERFERin siRNA Transfection Reagent (PolyPlus, 409-10) was used. For 
immunoblotting, cells were collected by centrifugation, lysed, and resuspended on SDS-
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sample buffer containing protease inhibitors (Sigma-Aldrich cocktail, P2850-1ML), and 
loaded onto a 7.5% SDS-PAGE and western blots were processed and analyzed as 
described [208].  
3.2. Immunofluorescence 
Cells were fixed for 12 min in freshly prepared 2% paraformaldehyde (Sigma-
Aldrich, 158127-500G) in phosphate-buffered saline (PBS), permeabilized with 0.5% 
Triton X-100 in PBS for 7 min, rinsed in PBS and blocked with 10% FBS in PBST 
(PBS plus 0.05% Tween-20) for 30 min. Cells were then incubated for 1 hour with 
primary antibodies diluted in PBST with 5% FBS. After three washes in PBST for 5 
minutes each, cells were incubated with fluorescently-labeled secondary antibodies for 
1 hour, and then washed three times 5 minutes in PBST. DNA was stained with 2µg/ml 
DAPI (Sigma-Aldrich, D9542-5MG) diluted in Vectashield mounting medium (Vector, 
H-1000).  
Images were acquired on a Spinning Disc AxioObserver Z.1 SD confocal 
microscope (Carl Zeiss, Germany), coupled to an AxioCam MR3, and with a Plan 
Apochromatic 63x/NA 1.4 objective. Z-stacks were acquired at 0.5 μm intervals, 
deconvolved using AxioVision Release 4.8.2 SPC software, and projected using ImageJ 
software (http://rsbweb.nih.gov/ij/). 
3.3. Antibodies 
Primary antibodies used were: mouse anti-Mad2L1 (1:200, Sigma-Aldrich, 
WH0004085M1-100UG); mouse anti-Bub1 (1:400, Abcam, ab54893); mouse anti-
BubR1 (1:1000, BD Biosciences, 612503); rabbit anti-Cdc20 (1:1000, Sigma, C5497); 
rabbit anti-Mad1 (1:100, gift from Dr. Kuan-The, NIH, USA); human anti-CREST 
(1:4500, gift from Dr. Bronze-da-Rocha, IBMC, Portugal); mouse anti-Hec1 (1:600, 
Abcam, ab3613); rabbit anti-α-Tubulin (1:100, Sigma, T5168); mouse anti-dynein 
intermediate chain (1:200, Sigma, D5167); mouse anti-Spindly (1:100, Sigma, 
WH0054908M1-100UG); rabbit anti-Spindly (1:3000, gift from Dr. R. Gassmann, 
IBMC, Portugal). Alexa Fluor 488- and 568-conjugated secondary antibodies were used 
at 1:1500, and 647-conjugated secondary antibody which was used at 1:2500 
(Molecular Probes). Horseradish peroxidase (HRP)-conjugated secondary antibodies 
was used at 1:1500 (Vector). 
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3.4. Live-cell imaging 
HeLa cells stably expressing EGFP-Bub3 were seeded on glass bottom dish 
(Bioptechs) and synchronized in S phase using a double thymidine (2.5 mM) block of 
24 hours, with a 12 hours interval between the blocks. Cells were filmed 8–10 hours 
after the final release as they entered mitosis, on a Delta Vision microscope, using a 
100x/NA 1.4 Plan Apo objective, and an EMCCD camera (Cascade2_1k) with gain 75. 
Time-lapse images were acquired every minute (7 stacks at 1 m intervals). 
4. Results 
We were particularly interested in understanding the behavior of bona fide SAC 
proteins in terms of their dynein-dependent removal from attached kinetochores during 
SAC silencing.  
We first examined Mad1 and Mad2 as it has been established that these proteins 
function as dynein cargoes. After treatment of HeLa cells with sodium azide/2-
deoxyglucose (AZ/DOG), we observed a strong accumulation of Mad2 at spindle poles 
in all prometaphase and metaphase cells analyzed, while Mad2 was undetectable at 
attached kinetochores (Figure 3.4A). Mad1 redistribution from kinetochores to spindle 
poles mirrored that of Mad2 (Figure 3.4B), in accordance with previous reports [336, 
186, 82]. Treatment with nordihydroguaiaretic acid (NDGA) showed similar results 
(data no shown).  
BubR1 has been shown previously to redistribute to spindle poles in an ATP 
reduction assay [82]. However, a subsequent study using NDGA treatment reported that 
BubR1 did not accumulate at spindle poles and therefore ruled out the role of BubR1 as 
dynein cargo [336]. In an attempt to clarify this crucial aspect of SAC signaling, we 
treated HeLa cells with AZ/DOG or with NDGA followed by staining of BubR1. In the 
NDGA assay, BubR1 was observed at kinetochores but not at spindle poles, behaving 
much like untreated cells (Figure 3.4C), thus suggesting that BubR1 is insensitive to 
NDGA in the experimental conditions here described. In the 30 minutes AZ/DOG 
assay, we were unable to detect BubR1 at kinetochores and at spindle poles (Figure 
3.S2A). However, in a recovery experiment, 10 minutes after AZ/DOG washout, BubR1 
readily reappeared on kinetochores (Figure 3.S2A). In order to clarify whether BubR1 
stability was affected by AZ/DOG, making it inaccessible to the antibodies, we reduced 
the AZ/DOG incubation time to 10 minutes. Under such conditions BubR1 was 
consistently observed at spindle poles with a clear loss from both unaligned and aligned 
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kinetochores (Figure 3.4D), suggesting that BubR1 was affected by ATP reduction at 
longer incubation periods. Although definition of how exactly BubR1 is affected by 
ATP reduction requires further investigation, our results suggest that BubR1 relocalizes 
to spindle poles upon kinetochore attachment and that conflicting results from previous 
studies is due to differences in the experimental protocols used by different authors. 
Such discrepancies extend to the study of Bub1, which has been reported to function as 
dynein cargo in AZ/DOG but not in NDGA assays [336, 356]. Our data shed light into 
this process as they consistently show that Bub1 leaves the kinetochores toward spindle 
poles after 30 minutes incubation with the inhibitors (Figure 3.4E) thus supporting the 
view that Bub1 functions as dynein cargo. Bub3 is a crucial kinetochore partner of Bub1 
and BubR1 that is required for efficient kinetochore-microtubule attachments [208].  
Bub3 forms part of the MCC; binds to the recently identified protein BuGZ [357, 
358] and is required for SAC activation and silencing. Given the multiple roles of Bub3 
in SAC signaling, we set out to investigate whether Bub3 is poleward transported by 
dynein upon kinetochore-microtubule attachment. For this, we used a HeLa cell line 
stably expressing EGFP-Bub3. Thirty minutes after treatment with AZ/DOG (Figure 
3.4F) or NDGA (data not shown), we observed EGFP-Bub3 at spindle poles, while a 
pool was retained at attached kinetochores in all prometaphases and metaphases 
analyzed (Figure 3.4F). The persisting EGFP-Bub3 pool at kinetochores was not due to 
insufficient inhibition as Mad2 was depleted from kinetochores within the same treated 
cells (Figure 3.4G). Importantly, extension of the incubation time with the inhibitors 
gave the same results (data not shown). Although the possibility that EGFP-Bub3 
competed with the endogenous version cannot be ruled out, our data support the idea of 
the normal retention of a Bub3 pool at aligned kinetochores until the onset of anaphase 
[359]. The possibility of our observations being the result of an incomplete enzymatic 
reaction is remote given the time scale of mitosis in HeLa cells and the fact the assays 
were performed for up to 45 minutes. Comparable incubation times for ATP reduction 
assays have been reported by others [186] thus allowing a fair and meaningful 
comparison of our experiments with such reports.  
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Figure 3.4. SAC proteins accumulate at spindle poles upon ATP reduction. (A) ATP 
reduction was performed by 30 minutes incubation either with isotonic salt solution with 
glucose (Saline G) or with sodium azide/2-deoxyglucose (AZ/DOG) [82]. Cells were stained 
with anti-Mad2, CREST as kinetochore marker, and anti-tubulin to localize spindle pole 
position. (B) Cells were treated as in (A) except that they were stained for Mad1. (C) ATP 
reduction was performed by 30 minutes incubation with nordihydroguaiaretic acid (NDGA) and 
cells were stained for BubR1, CREST, and tubulin. (D) Cells were treated as in (A) except that 
they were incubated for 10 minutes only with AZ/DOG and stained for BubR1. (E) Cells were 
treated as in (A) except that they were stained for Bub1. (F) Cells were treated as in (A) except 
that a HeLa line stably expressing EGFP-Bub3 was used to visualize Bub3 spindle pole 
relocalization, with a persistent pool at kinetochores. (G) A cell treated as in (A) showing that 
the persistence of the EGFP-Bub3 kinetochore pool is not due to insufficient inhibition as Mad2 
was completely removed from kinetochores in the same cell. PM = Prometaphase; M = 
Metaphase; Bars, 5 µm. 
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Interestingly, we observed that upon AZ/DOG or NDGA treatment, Mad1, Mad2, 
BubR1, Bub1, and Bub3 accumulate at spindle poles from prometaphase through 
anaphase (Figure 3.4), suggesting that their poleward transport may occur even in cells 
with the checkpoint satisfied. This was particularly clear in the case of Mad2 in 
metaphase when this protein was absent from attached kinetochores [360]. To assess if 
this could be the case of other SAC proteins, we treated cells with the proteasome 
inhibitor MG-132 to arrest cells in metaphase before performing the ATP reduction 
assay. In these conditions, all SAC proteins were still able to accumulate at spindle 
poles (Figure 3.5A). We took advantage of the HeLa cell line stably expressing EGFP-
Bub3 to perform live-cell imaging experiments in order to monitor spindle pole 
relocalization of Bub3 upon ATP reduction. In control cells, the behavior of EGFP-
Bub3 is consistent with the cellular distribution pattern described for endogenous Bub3 
throughout mitosis (Figure 3.5B and movie 3.1) [208]. We noted, however, that mitotic 
progression stopped almost instantaneously upon addition of AZ/DOG, indicating that it 
is affected by ATP reduction.  This aspect was not appreciated before in the previous 
works that used ATP reduction assays, which precludes any comparison with such 
reports. We therefore monitored mitotic progression by time-lapse microscopy, and 
once cells reached the desired mitotic phase AZ/DOG was added to the medium and 
cells immediately filmed. Under these conditions, EGFP-Bub3 was observed to 
immediately accumulate to spindle poles with a pool retained at kinetochores (Figure 
3.5B), confirming the results described above Moreover, while no accumulation of 
EGFP-Bub3 at spindle poles was apparent in MG-132 metaphase-arrested cells during 
the 30 min of filming, addition of AZ/DOG to these MG-132-pretreated cells resulted in 
immediate EGFP-Bub3 relocalization to the poles (Figure 3.5B and movie 3.2). 
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Figure. 3.5. Poleward transport of SAC proteins still occurs at metaphase. (A) HeLa cells 
were pre-treated with MG-132 for 1 hour, subjected to ATP reduction assay, and stained for 
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Mad2, Mad1, BubR1, or Bub1. For Bub3, the EGFP-Bub3 expressing HeLa line was used. 
CREST was used to localize kinetochore position, and anti-tubulin to localize spindle pole 
position. (B) Selected 1 µm Z-stacks collected every minute in time-lapse experiments using 
HeLa cells stably expressing EGFP-Bub3. Control saline G cells (top) show intense EGFP-
Bub3 staining on prometaphase (PM) kinetochores and reduced staining on metaphase (M) and 
anaphase (AN) kinetochores. EGFP-Bub3 relocalizes to spindle poles (yellow arrowheads) 
almost instantaneously upon AZ/DOG treatment in prometaphase (middle) and metaphase 
(bottom). The red arrows indicate EGFP-Bub3 foci streaming towards the pole. (C) HeLa cells 
stably expressing EGFP-Bub3 were treated with MG132 and filmed for 30 minutes, then 
AZ/DOG was added and the cells were further filmed for 60 minutes. EGFP-Bub3 relocalized 
to spindle poles (yellow arrowheads) at the start of filming. Time is shown in hours:minutes. 
Bar, 5 µm. 
 
We then inhibited dynein in order to establish if poleward transport of the 
aforementioned SAC proteins was dependent on this motor protein. Inhibition of dynein 
was achieved either by direct RNAi depletion or by preventing its kinetochore 
localization through RNAi depletion of Spindly, a protein indispensable for the 
kinetochore localization of dynein (Figure 3.S2B). Our results show that dynein 
inhibition abolished spindle pole relocalization of Mad1, Mad2, BubR1, Bub1, and 
Bub3 following AZ/DOG treatment (Figure 3.6). Also, we found that dynein-inhibited 
cells, without or with AZ/DOG treatment, did not retain SAC proteins on kinetochores 
of aligned chromosomes. Instead, these proteins accumulated only on misaligned 
kinetochores (Figure 3.6). The same results were obtained in cells co-depleted of 
dynein and spindly in order to maximize dynein depletion from kinetochores, therefore 
ruling out the possibility that residual dynein delocalised SAC proteins from 
kinetochores (Figure 3.6). These results support the idea of the existence of a dynein-
independent mechanism of protein stripping from attached kinetochores during SAC 
silencing [187, 114, 186]. Moreover, we noted that Cdc20 was not subjected to 
poleward transport (data not shown) which is in good agreement with similar, previous 
observations [336]. 
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Figure 3.6. Poleward transport of SAC proteins is suppressed upon dynein depletion. Cells 
were depleted of dynein (siDHC), spindly (siSpindly), or both (siDHC/siSpindly), subjected to 
ATP reduction assay, and stained for (A) Mad2, (B) BubR1 and (C) Bub3 (analyzed using the 
EGFP-Bub3 expressing cell line). Note that in all cases, SAC proteins accumulate on unaligned 
but not on aligned kinetochores. Mad1 behaves identically to Mad2 (not shown); and Bub1 
behaves identically to Bub3 (not shown). Bars, 5 µm. 
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An unexpected result from our analyses concerned the protein Hec1, a subunit of the outer 
kinetochore KMN network that constitutes the core site for microtubule attachment. In the 
present study we first intended to use Hec1 as kinetochore marker instead of CREST. 
Interestingly, we noted that 30 minutes after AZ/DOG treatment, Hec1 accumulated at spindle 
poles and a pool remained at attached kinetochores, in a manner that mirrored Bub3 localization 
(Figure 3.7A). The localization of Hec1 to spindle poles was prevented upon dynein inhibition 
(Figure 3.7A), thus suggesting that Hec1 function as an additional dynein cargo [114, 336]. 
Similar results were obtained for the other component of the KMN network, Mis12, except that 
its spindle pole localization was not observed at prometaphase but only when a metaphase plate 
became evident (Figure 3.7B). 
 
 
Figure 3.7. KMN components are dynein-dependent cargoes. (A) EGFP-Bub3 expressing 
HeLa cells were subjected to ATP reduction assay and stained for Hec1. (Left) Upon the assay, 
Hec1 redistributes to spindle poles with a pool left on kinetochores, mirroring the behavior of 
Bub3.  (Right) Dynein depleted cells (siDHC) were subjected to ATP reduction assay and 
CHAPTER 3 
83 
stained for Hec1 and CREST. Note the absence of Hec1 at spindle poles in cells depleted of 
dynein. (B) HeLa cells were transiently transfected with pBABEblast YFP-Mis12 construct and 
subjected to ATP reduction assay. (Left) Upon the assay, Mis12 redistributed to spindle poles 
with a pool left on kinetochores. (Right) YFP-Mis12 expressing cells were depleted of dynein 
(siDHC) and subjected to ATP reduction; CREST was used as kinetochore marker. Note the 
absence of Mis12 at spindle poles in cells depleted of dynein PM = Prometaphase; M = 
Metaphase; Bars, 5 µm. 
 
5. Discussion 
Unattached kinetochores activate and accumulate critical SAC components such as 
Mad1, Mad2, Bub1, BubR1, and Bub3. Binding of Mad2 to Mad1 to the kinetochore 
induces significant conformational changes that promote Mad2 binding to Cdc20, which 
in turn makes Cdc20 unable to activate the APC/C [159]. Additionally, the Mad2-
Cdc20 complex associates with Bub3 and BubR1 to form the MCC, the protein 
assembly that acts as a pseudosubstrate to inhibit the APC/C [361, 362, 163]. Bub1 is 
required to recruit all the above SAC components to the kinetochore and contributes to 
APC/C inhibition through Cdc20 phosphorylation [353, 168].   
We used two previously described ATP reduction assays [336, 82] which prevent 
release of dynein and its cargoes from spindle poles, in order to identify core SAC 
proteins that are transported off kinetochores toward spindle poles. We found that 
Mad1, Mad2, Bub1, BubR1, and Bub3 accumulated at spindle poles following 
treatment with the inhibitors. This poleward transport was dynein-dependent as it was 
abolished upon dynein inhibition. The result confirmed that Mad1 and Mad2 function as 
dynein cargoes, a feature shown in earlier reports [336, 186, 82]. We argue that the 
discrepancy between previous studies concerning BubR1 and Bub1 function as dynein 
cargoes is due to differences in the experimental approaches, a concern that has been 
expressed by others [336, 82]. We found that BubR1 was the only SAC protein which 
was insensitive to NDGA but not to AZ/DOG as co-staining of NDGA-treated cells 
showed BubR1 only at kinetochores while Bub3 was relocalized to spindle poles 
(Figure 3.S2A). We have also determined that Bub3 is a new dynein cargo that is 
poleward transported upon kinetochore attachment, suggesting a role in SAC silencing. 
Such role seems consistent with Bub3 direct involvement in the MCC complex whose 
assembly must be prevented to relieve inhibition exerted on the APC/C thus allowing 
mitotic progression. Interestingly, the SAC proteins were not retained at aligned 
kinetochores upon dynein depletion, supporting the existence of a dynein-independent 
mechanism for SAC silencing as previously suggested [187, 114, 186]. Also, it should 
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be noted that spindle pole accumulation of SAC proteins reported in the present study 
depends on the specific treatment we used to inhibit dynein cargo release at the poles; 
such poleward transport needs, however, to be confirmed under physiological 
conditions upon chromosome attachment.  
We found that ATP depletion assays performed on cells arrested at metaphase after 
pretreatment with MG-132 still resulted in a poleward transport of all the SAC proteins 
reported in this study, in a manner that mirrored that of ATP depletion assays without 
prior MG-132 treatment. This poleward relocalization was dynein-dependent as it was 
abolished by dynein inhibition. These finding suggests that metaphase cells with 
complete chromosome alignment are still competent to generate a SAC signal. This is 
consistent with the recently reported ability to reestablish SAC activity after initial 
silencing, [363] and with the persistence of SAC activity observed in MG-132-treated 
mitotic cells and in proteasome deficient cells [364, 365]. As MG-132-treated cells can 
be arrested in metaphase with kinetochores that develop normal tension, [366] it was 
assumed that the kinetochores in these cells would be depleted of Mad2, a condition that 
should inactivate the SAC [336]. Although the absence of Mad2 poleward stripping in 
metaphase-arrested cells, in a previously reported ATP reduction assay, seems to 
support this assumption, [336, 82] Zeng et al. showed that cells treated with the 
proteasome inhibitor MG-132 were unable to sustain a prolonged metaphase arrest after 
depletion of Mad2, suggesting that MG132-mediated metaphase arrest may depend on 
continued inhibition of APC/C by the SAC [367]. The latter notion would explain why 
SAC components could be detected at spindle poles of metaphase-arrested cells in our 
ATP depletion assays. Intriguingly, it is unclear how SAC proteins appeared at spindle 
poles in a stage when their levels are lowered since all kinetochores are attached and 
under tension, particularly in the case of Mad2, which leaves the kinetochore upon 
attachment [360].  
Interestingly, and contrary to what has been reported, [114, 336] we observed that a 
pool of Hec1, a subunit of the outer kinetochore KMN network that constitutes the core 
site for microtubule attachment, [104] accumulated at spindle pole in a dynein-
dependent manner. Hec1 is one of four proteins of the outer kinetochore Ndc80 
complex that together with the KNL-1 protein and the Mis-12 complex form the 
conserved KMN (KNL-1/Mis-12/Ndc80) network that constitutes the core microtubule 
binding site at the kinetochore [104]. The observed dynein-dependent relocalization of 
Hec1 to spindle poles is consistent with early studies where Hec1 was reported to 
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localize at the centrosome [368, 369]. As Mis-12 exhibited similar behaviors, it is 
tempting to speculate that KMN streaming from kinetochores would partially 
disassemble the docking platform that recruits SAC proteins, therefore contributing to 
SAC silencing by preventing further assembly of anaphase inhibitors. At the same time, 
a significant pool of KMN components must be retained at kinetochores in order to 
ensure the efficient attachment and chromosome transport at anaphase onset. This is 
consistent with the decrease in Hec1 kinetochore levels following an ATP reduction 
assay, [108] and with the recently reported disassembly of all KMN components at the 
onset of anaphase [370]. We have previously shown that Bub3 is required for efficient 
kinetochore-microtubule attachment [207, 208]. Accordingly, the pool of Bub3 retained 
at the kinetochores, as observed in the present study, might serve to sustain attachment 
during metaphase and anaphase. 
In summary, this report presents evidence of additional SAC components to be 
subjected to dynein-mediated transport to the spindle pole. We also show that poleward 
transport still occurs in metaphase-arrested cells consistent with the reported SAC 
reactivation ability at metaphase [371], and that a pool of Hec1 and Mis12, may 
function as additional dynein cargoes, thus providing new insights into the contribution 
of the KMN network to SAC silencing.  
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7. Supplementary figures  
 
 
Figure 3.S2. (A) BubR1 is insensitive to sodium azide/2-deoxyglucose assay.  (Left) Cells were 
treated for 30 minutes with sodium azide/2-deoxyglucose (AZ/DOG) and stained for CREST 
and BubR1. Alternatively, treated cells were allowed to recover for 10 minutes after AZ/DOG 
washout (Recovery) before immunostaining. (Right) A NDGA-treated cell showing BubR1 only 
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at kinetochores while Bub3 was relocalized to spindle poles. Bar, 5 µm.  (B) Efficiency of 
RNAi-mediated depletion of dynein and spindly. (Top left) Representative western blots 
showing depletion of dynein (siDHC) as assessed by an anti-dynein intermediate chain [184] 
antibody, spindly (siSpindly), or both (siDHC/siSpindly). Tubulin was used as loading control. 
(Top right) siDHC-treated cells were incubated with nocodazole (to create conditions where 
dynein is maximally enriched at kinetochores) prior to immunostaining for dynein to confirm 
efficient depletion. (Bottom left) Spindly RNAi cells were treated with nocodazole and 
immunostained to confirm efficient spindly depletion. (Bottom right) Spindly RNAi cells were 
treated with nocodazole and stained with anti-DIC to confirm that dynein was efficiently 
prevented from localizing to kinetochores. 
 
  
 
 
 
 
 
 
 
CHAPTER 4 
 
 
 
EXPLORING THE POTENTIAL THERAPEUTIC 
IMPLICATIONS OF SPINDLE ASSEMBLY CHECKPOINT FOR 
CANCER THERAPY 
 
 
According to the objectives highlighted in Chapter 2, this chapter is divided into two 
parts:  
4.1. Suppression of Spindly Delays Mitotic Exit and Exacerbates Cell Death 
Response of Cancer Cells Treated with Low Doses of Paclitaxel; 
4.2. Spindly Expression, Prognostic Significance and Therapeutic Implications in 
Oral Squamous Cell Carcinoma. 
  
 
 
 
 
 
 
 
4.1. Suppression of Spindly Delays Mitotic Exit and 
Exacerbates Cell Death Response of Cancer Cells 
Treated with Low Doses of Paclitaxel 
 
 
 
 
 
 
 
 
 
 
 
 
 
The information presented in this section was based in the following published paper: 
Patrícia M.A. Silva, Nilza Ribeiro, Raquel Lima, Cláudia Andrade, Vânia Diogo, 
Joana Teixeira, Cláudia Florindo, Álvaro A.  Tavares, Helena Vasconcelos and Hassan 
Bousbaa. Suppression of Spindly Delays Mitotic Exit and Exacerbates Cell Death 
Response of Cancer Cells Treated with Low Doses of Paclitaxel. Cancer Letters. 
2017;394:33-42.
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1. Abstract 
Microtubule-targeting agents (MTAs) are used extensively for the treatment of 
diverse types of cancer. They block cancer cells in mitosis through the activation of the 
spindle assembly checkpoint (SAC), the surveillance mechanism that ensures accurate 
chromosome segregation at the onset of anaphase. However, the cytotoxic activity of 
MTAs is limited by premature mitotic exit (mitotic slippage) due to SAC silencing. 
Here we have explored the dual role of the protein Spindly in chromosome attachments 
and SAC silencing to analyze the consequences of its depletion on the viability of tumor 
cells treated with clinically relevant doses of paclitaxel. As expected, siRNA-mediated 
Spindly suppression induced chromosome misalignment and accumulation of cells in 
mitosis. Remarkably, these cells were more sensitive to low-doses of paclitaxel. 
Sensitization was due to an increase in the length of mitotic arrest and high frequency of 
multinucleated cells, both correlated with an exacerbated post-mitotic cell death 
response as determined by cell fate profiling. Thus, by affecting both SAC silencing and 
chromosome attachment, Spindly targeting offers a double-edged sword that potentiates 
tumor cell killing by clinically relevant doses of paclitaxel, providing a rationale for 
combination chemotherapy against cancer. 
 
 
Keywords: Spindly; paclitaxel; cancer cells; spindle assembly checkpoint; apoptosis; 
cell cycle 
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2. Introduction 
Attachment between kinetochores and microtubules during prometaphase is 
monitored by the spindle assembly checkpoint (SAC) that halts the metaphase-to-
anaphase transition until all chromosomes are fully attached and properly bioriented at 
the metaphase plate [99, 372]. SAC is activated by the presence of unattached or 
misattached kinetochores. As a consequence, a diffusible mitotic checkpoint complex 
(MCC) is formed between the proteins Mad2, BubR1, Bub3, and Cdc20, which 
promotes the inhibition of the anaphase-promoting complex/cyclosome (APC/C) [157]. 
APC/C is an E3 ubiquitin ligase that targets securin and cyclin B1 for degradation, 
thereby promoting sister-chromatid separation and mitotic exit [373]. Once all 
chromosomes are correctly aligned at the metaphase plate, SAC is switched off in a 
process called SAC silencing, which in turn relieves the inhibition of APC/C required 
for the completion of mitosis [99]. Several mechanisms have been proposed to 
contribute to SAC silencing, including the dissociation of MCC [374, 375], and the 
stripping of SAC proteins from the kinetochore by a dynein motor [82, 299]. 
Microtubule-targeting agents (MTAs) such as paclitaxel remain amongst the most 
effective cancer chemotherapeutics used in the clinic [217]. By preventing mitotic 
spindle assembly, MTAs delay cells in mitosis through chronic activation of SAC [349]. 
The fate of cells held in mitosis by MTAs is influenced by the duration of the mitotic 
arrest, and varies greatly between cancer cells [376, 377]. Prolonged mitotic arrest can 
lead to cell death in mitosis (DiM) through the accumulation of an apoptotic signal from 
the intrinsic pathway [226]. However, some cells can prematurely degrade cyclin B, 
before the accumulation of the apoptotic signal, and, thus, exit mitosis back to 
interphase without chromosome segregation, through a process known as mitotic 
slippage. Depending on the robustness of a still unclear post-mitotic response, these 
cells may either undergo post-mitotic death (PMD), or enter a new cell cycle [212]. 
Therefore, having a control over the different cell fates should influence the 
effectiveness of MTAs in cancer therapy. For instance, delaying mitotic exit should 
allow more time for death signals to accumulate thereby shifting cancer cell fates to 
death. 
Spindly protein is a kinetochore-specific regulator of dynein and functions in 
chromosome alignment and SAC signaling [112]. Knockdown of Spindly was reported 
to cause unstable kinetochore-microtubule interactions, severe chromosome alignment 
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defects, and extensive prometaphase delay [343, 114]. Importantly, kinetochore dynein-
mediated removal of Spindly is critical for checkpoint silencing [186, 187]. 
Our goal was to shift the fate of cancer cells exposed to clinically relevant doses of 
paclitaxel towards death. To achieve this goal, we investigated Spindly´s dual role in 
chromosome alignment and in SAC silencing, exploring the possibility of targeting 
Spindly as a strategy to delay mitotic exit in paclitaxel-based treatment. We show, for 
the first time, that targeting cancer cells with a combination of Spindly downregulation 
and clinically relevant doses of paclitaxel significantly promotes tumor cells death. This 
significant cell death response is due to an increase in the length and frequency of 
mitotic arrest and to severe multinucleation of treated tumor cells. The results provide a 
rationale for a promising future combination chemotherapy. 
3. Materials and methods 
3.1. Cell lines and culture conditions 
HPAEpiC (human pulmonary alveolar epithelial cells), Calu-3 (human lung 
adenocarcinoma) and A549 (human adenocarcinoma alveolar basal epithelial) cells 
were grown in DMEM medium with 10% fetal bovine serum (FBS, Biochrom) and 1% 
non-essential amino acids (Sigma-Aldrich Co., Saint Louis, MO, USA). NCI-H460 
(human non-small cell lung cancer) cells were grown in RPMI-1640 culture medium 
(Lonza, Basel, Switzerland) with 5% FBS. Cells were maintained at 37°C in a 5% CO2 
humidified incubator and all experiments were performed when exponentially growing 
cells presented more than 95% viability. 
3.2. RNA isolation and quantitative real-time PCR 
Total RNA was extracted using the PureZOL
TM
 RNA Isolation Reagent (Bio-Rad 
Laboratories, Inc. Hercules, CA, USA), according to the manufacturer’s instructions 
and quantified through spectrophotometry (NanoDrop 2000, Thermo Scientific, 
Waltham, MA, USA). cDNA synthesis was performed using the iScript
TM
 cDNA 
Synthesis Kit (Bio-Rad), following supplier’s instructions and was amplified using iQTM 
SYBR Green Supermix Kit (Bio-Rad) on iQ Thermal Cycler (Bio-Rad), according to 
the following program: initial denaturing step at 95.0°C for 3 min; 40 cycles at 94.0°C 
for 20 sec; 60.0°C for 30 sec and 72.0°C for 30 sec. The melt curve included 
temperatures from 65.0 to 95.0°C, with increments of 0.5°C for 5 sec. Primers, used at 
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final concentration of 10 µM, were as follows: Spindly: forward 5´-CTC AAA GAG 
GCT GAA GAA GAG-3´ and reverse 5´-TGT TCA TAA CTC TCA GTC ATG G-3´; 
Actin: forward 5´- AAT CTG GCA CCA CAC CTT CTA -3´ and reverse 5´- ATA 
GCA CAG CCT GGA TAG CAA-3´. Experiments were performed in triplicate for each 
data point. Data were acquired with CFX ManagerTM Software (version 1.0, Bio-Rad) 
and the results were analyzed according ΔCT and normalized against actin expression 
levels, which was used as control template. A fold value of mRNA level ≥ or ≤ 1.5 
relatively to that of normal cells was considered as over- or underexpression, 
respectively. 
3.3. Gens analyzed in this study 
To avoid gene symbol homonymy and species confusion [378], we list here gene 
symbols and their NCBI ID numbers. Genes under study included Spindly (SPDL1; 
NCBI ID# 54908), Actin (ACTB; NCBI ID#60), α-Tubulin (TUBA1B; NCBI ID# 
10376), PARP-1 (PARP1; NCBI ID# 142) and Cyclin B1 (CCNB1; NCBI ID# 891).   
3.4. siRNAs transfection  
For siRNAs transfection, cells were seeded in 22 mm poly-l-lysine-coated 
coverslips in 6-well plates or in 6-well dishes containing complete culture medium and, 
24 hours later, transfected using INTERFERin siRNA Transfection Reagent (PolyPlus, 
New York, USA) according to the manufacturer’s instructions. The culture medium was 
replaced 24 hours post-transfection with fresh medium. A validated siRNA sequence 
against Spindly (synthetized by Sigma-Aldrich) or a validated negative control siRNA 
(AllStars Negative Control siRNA, Qiagen, Germantown MD, USA) was used at a final 
concentration of 100 nM [186, 321].  
3.5. Cell extracts and Western blotting 
Total cell protein extracts were prepared and Western blot analysis carried out as 
previously described [321]. The primary antibodies used were: rabbit anti-Spindly 
(1:3000, gift from Dr. R. Gassmann, IBMC/i3S, Portugal); rabbit anti-cyclin B1 (1:500, 
C8831, Sigma-Aldrich); mouse anti-PARP-1 (1:2000, H-250, sc-7150, Santa Cruz 
Biotechnology); rabbit anti-α-tubulin (1:2000, Abcam) and mouse anti-α-tubulin 
(1:5000, T568 Clone B-5-1-2, Sigma-Aldrich). Horseradish peroxidase (HRP)-
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conjugated secondary antibodies were diluted at 1:1500 (anti-mouse, Vector) or at 
1:1000 (anti-rabbit, Sigma-Aldrich). The protein signal intensity quantification was 
performed using ImageJ 1.4v software (http://rsb.info.nih.gov/ij/) and normalized 
against α-tubulin expression levels.  
3.6. Indirect immunofluorescence  
Cells grown on coverslips were fixed in fresh 2% (w/v) paraformaldehyde (Sigma-
Aldrich) in phosphate-buffered saline (PBS) for 12 min, rinsed three times in PBS, and 
permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in PBS for 7 min. 
Alternatively, to visualize spindle microtubules, cells were immediately fixed in -20°C 
cold methanol (Sigma-Aldrich) for 10 min and rehydrated twice for 5 min in PBS. 
Then, cells were blocked with 10% FBS in PBST (0.05% Tween-20 in PBS) for 30 min 
at room temperature, followed by 1 hour incubation with primary antibodies diluted in 
5% FBS in PBST. The following primary antibodies were used: human anti-CREST 
(1:4000, gift from E. Bronze-da-Rocha, University of Porto, Portugal); mouse anti-α-
tubulin (1:2500, T568 Clone B-5-1-2, Sigma-Aldrich) and rabbit anti-Spindly (1:3000, 
gift from Dr. R. Gassmann, IBMC/i3S, Portugal). After washing in PBST, cells were 
incubated for 1 hour with Alexa Fluor 488 and 568 conjugated secondary antibodies 
(Molecular Probes, Eugene, OR, USA), diluted at 1:1500. DNA was stained with 
2µg/ml 4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) diluted in Vectashield 
mounting medium (Vector, H-1000, Burlingame, CA, USA). 
3.7. Mitotic index determination 
Mitotic index, the percentage of mitotic cells over the total cell population, was 
determined by cell-rounding under phase-contrast microscopy in 48 hours control- or 
Spindly siRNA-treated cells. Alternatively, mitotic index was determined under 
fluorescence microscope after DNA staining with DAPI. Paclitaxel (Sigma-Aldrich) 
was used at concentrations ranging from 0-100 nM. This clinically relevant dose range 
of paclitaxel were adapted from previous studies on breast cancer cell lines [379] and on 
lung cancer cell lines [380]. Nocodazole (Sigma-Aldrich) was used as a positive control 
at 1 µM. For each condition, more than 2000 cells were counted from random 
microscope fields.  
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3.8. Cell viability assay 
Cell viability was determined with MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) assay (Sigma-Aldrich). A total of 5x10
4
 control- and 
Spindly siRNA-treated cells were seeded in 96-well plate, allowed to attach for 6 hours 
and treated with paclitaxel (0-100 nM). Forty-eight hours later, cells were placed in 
fresh FBS-free medium and 20 µl MTT reagent (5mg/ml in PBS) was added and 
incubated at 37 °C and 5% CO2 for 4 hours. The purple formazan crystals were 
solubilized with a detergent solution (89% (v/v) 2-Propanol, 10% (v/v) Triton X-100, 
1% (v/v) HCl 3.7%), for 2 hours. Optical density was measured at 570 nm in a 
microplate reader (Biotek Synergy 2, Winooski, VT, USA) and retrieved through the 
Gen5 software (version 1.07.5, Biotek, Winooski, VT, USA). Cell viability was 
calculated relative to control siRNA-treated cells. 
3.9. Colony forming assay 
A total of 500 cells from 24 hours control- or Spindly siRNA-transfected cell 
cultures were seeded in six-well plates, allowed to attach for 6 hours, and treated with 4 
nM of paclitaxel. Forty-eight hours later, paclitaxel was removed by washing cells twice 
with PBS, then fresh medium was added and cells were allowed to grow for 10 days. 
The recovered colonies were fixed for 5 min with 3.7% (w/v) paraformaldehyde in PBS, 
and stained for 20 min with 0.05% (w/v) violet crystal (Merck Millipore, Billerica, MA, 
USA) in distilled water. The number of colonies was counted on duplicate dishes from 
three independent experiments. The plating efficiency (PE) was calculated as the 
percentage of the number of grown colonies over the number of cells seeded in control. 
For each condition, the survival fraction was determined as the number of colonies over 
the number of cells seeded × 1/PE.  
3.10. Flow cytometry  
For cell cycle analysis, cells were harvested, washed twice in PBS and fixed in 70 % 
ice-cold ethanol at 4°C until analysis. Cells were then resuspended in 5 µg/ml 
propidium iodide and 100 µg/ml RNase in PBS for 30 min, and analyzed in the flow 
cytometer. Cell distribution in G0/G1, S, or G2/M phases was determined using the 
Watson pragmatic fitting algorithm of FlowJo software (version 10.1, Williamson Way, 
Ashland, USA), after excluding cell debris and aggregates. For apoptosis detection, 
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cells were harvested and further processed with the “Annexin V-FITC Apoptosis 
Detection Kit” (eBioscience, Vienna, Austria) according to manufacturer’s instructions. 
Data was analyzed with FlowJo software, version 10. All flow cytometry analysis was 
carried out using a BD Accuri™ C6 Flow cytometer (BD Biosciences, Qume Drive, 
San Jose, CA) and analysis at least 20.000 events per sample. 
3.11. TUNEL assay 
Terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay 
was performed using DeadEnd Fluorometric TUNEL System (Promega, Madison, WI, 
USA), according to the manufacturer’s instructions. DNA was stained with 2µg/ml 
DAPI in Vectashield mounting medium. The level of cells undergoing cell death was 
determined by scoring TUNEL-positive cells in a total of 500 cells under fluorescence 
microscope, from at least ten random microscopic fields, for each experimental 
condition.  
3.12. Live Cell imaging  
Live-cell imaging experiments were performed as previously described [381]. 
Briefly, NCI-H460 cells were seeded onto LabTek II chambered cover glass (Nunc, 
Penfield, NY, USA) containing 1 ml of culture medium, allowed to attach for 24 hours 
at 37 °C with 5% CO2. Then, cells were transfected with control (control siRNA) or 
Spindly (siSpindly) siRNAs, or treated with 10 nM of paclitaxel, in RPMI without 
phenol red supplemented with 5% FBS. Time-lapse imaging was performed soon after 
siRNA or 10 nM paclitaxel addition. For siSpindly and paclitaxel co-treatment, 
paclitaxel 10 nM was added 24 hours after siRNA-transfection. In this case, Time-lapse 
imaging was initiated immediately after addition of siRNA-Spindly transfection 
solution. Images were captured at 10 minutes intervals up to 72 hours under differential 
interference contrast (DIC) optics, with a 63x objective on an Axio Observer Z.1 SD 
inverted microscope, equipped with an incubation chamber with the temperature set to 
37 °C and an atmosphere of 5% CO2. Movies were generated from the time-lapse 
images using ImageJ software (version 1.44, Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, MD, USA). The number of cells arrested at mitosis, 
apoptotic, or bypassed cytokinesis was scored. Mitotic cells and cell death were easily 
scored based on changes in cell morphology by DIC imaging. Mitotic entry was 
characterized by cell rounding and cell death by cell retraction and blebbing of the 
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plasma membrane. Cell death was classified as death in mitosis (DiM) when mitotic 
cells died before cell division, or as post-mitotic death (PMD) when death occurred 
following cell division. 
3.13. Microscopy analysis and Image Processing  
Phase-contrast microscopy images were recorded with a 10x objective, on a Nikon 
TE 2000-U microscope (Amsterdam, Netherlands), using a DXM1200F digital camera 
(Amsterdam, Netherlands) and with Nikon ACT-1 software (version 2.62, Melville, 
NY, USA). Fluorescence images were acquired with Plan Apochromatic 63x/NA 1.4 
objective or with 40x objective on an Axio Observer Z.1 SD microscope (Carl Zeiss, 
Germany), coupled to an AxioCam MR3. Z-stacks were acquired with 0.4μm intervals 
and after image deconvolution with AxioVision Release SPC software (version 4.8.2, 
Carl Zeiss, Germany) they were processed using ImageJ (version 1.44, Rasband, W.S., 
ImageJ, U. S. National Institutes of Health, Bethesda, MD, USA). 
3.14. Statistical analysis 
Statistical analysis was performed using an Unpaired Student t-test or an ordinary 
two-way ANOVA with Tukey's multiple comparisons test, in GraphPad Prism version 6 
(GraphPad software Inc., CA, USA). Alpha value was 0.05 and the confidence interval 
95%. Data are presented as the means ± standard deviation (SD) of at least three 
independent experiments. The level of significance was set at probabilities of *
/#
p < 
0.05, **
/##
p < 0.01, ***
/###
p < 0.001 and ****
/####
p < 0.0001. 
 
4. Results 
4.1. Spindly is overexpressed in lung cancer cells 
To gain insight into the relevance of Spindly as potential antimitotic target for 
cancer therapy, we first examined its expression in lung cancer cell lines. Analysis of 
Spindly mRNA levels by qRT-PCR showed that this gene was overexpressed in the 
tested cancer cell lines compared with mRNA levels in the non-tumor cell line (Figure 
4.1A). There was a 2.9 ± 0.4, 4.6 ± 0.2, and 5.4 ± 0.2 fold increase in Spindly 
expression in NCI-H460, Calu-3, and A549 cell lines, respectively, compared with 
Human Pulmonary Alveolar Epithelial Cells (HPAEpiC). Western blot analysis showed 
CHAPTER 4 
102 
that Spindly was also upregulated at protein level (Figure 4.1B). Spindly 
overexpression was also found in glioblastoma, colorectal and oral cancer cell lines 
(Silva and Bousbaa, unpublished data). Analyzing published databases from the 
publicly available Oncomine database confirmed Spindly upregulation in lung cancer 
[382] and, interestingly, in many other cancers (www.oncomine.org). This result 
highlights the relevance of targeting Spindly for cancer therapy. 
 
 
Figure 4.1. Spindly is overexpressed in lung cancer cells. (A) Relative expression of Spindly 
mRNA as determined by RT-PCR in NCI-H460, Calu-3 and A549 cell lines, comparatively to 
non-tumor HPAEpiC (left); a representative 2% agarose gel image of PCR products is shown 
(right). Actin served as a loading control. (B) Representative Western blot showing differential 
expression at protein levels in the cell lines analyzed in (A). Tubulin served as a loading control. 
**p < 0.01 and ****p < 0.0001 normal vs cancer cell lines. 
 
4.2. Depletion of Spindly protein levels from lung cancer cells 
There are many studies exploring the possibilities of RNA interference (RNAi) to 
silence genes with therapeutic applications. RNAi can be achieved locally by delivering 
synthetic siRNAs, or using shRNAs delivered via viral particles, or following 
transfection of plasmid DNAs [383, 384]. We used validated siRNA duplexes [186, 
321] to deplete the expression of Spindly in NCI-H460 and A549 cancer cells. Efficient 
Spindly repression was ascertained by immunofluorescence for Spindly kinetochore 
CHAPTER 4 
103 
staining of prometaphase cells as confirmed by its colocalization with the kinetochore 
marker CREST (Figure 4.S1A). Spindly depletion value of 98.9% and 98.4% was 
achieved as determined by immunoblotting against total NCI-H460 and A549 cell 
extracts, respectively (Figure 4.S1B). Furthermore, and according to Spindly depletion 
phenotype reports, Spindly silencing resulted in a severe chromosome misalignment 
(Supplementary figure S1A) and an increased mitotic index (Supplementary figure 
S1C) [321, 114]. These results indicate that the previously validated Spindly siRNA is 
suitable for subsequent studies on NCI-H460 and A549 cancer cell lines, namely, to 
determine whether Spindly targeting can render paclitaxel-mediated therapy more 
effective. 
4.3. Depletion of Spindly extends the length of mitotic arrest induced by 
paclitaxel 
We reasoned that if SAC silencing is delayed by Spindly depletion, then the mitotic 
delay induced by paclitaxel would be extended, thereby providing more time for 
paclitaxel to exert its cytotoxic effect. The NCI-H460 cell line was selected to address 
this hypothesis due to its suitability for in vivo microscopy and for quantitative 
evaluation of morphological changes.  Cells were transfected with control or Spindly 
siRNAs, 24 h post-transfection cells were treated with paclitaxel and the length of 
mitotic arrest was determined by time-lapse imaging. Mitosis in control siRNA-treated 
cells spent an average of 34.3 ± 7.3 min (n=30) from nuclear envelope breakdown to 
anaphase onset. In contrast, we found that Spindly-depleted cells spent more time in 
mitosis (628.1 ± 403.7 min, n=31) before mitotic exit or cell death (see below). These 
results are in good agreement with previous report [114]. We have observed that 
paclitaxel-treated cells spent 115.0 ± 142.1 min in mitosis (n=32); and, interestingly, the 
duration of mitosis was extended to 332.6 ± 220.9 min when paclitaxel was added after 
Spindly depletion (n=35) (Figure 4.2A). Notably, this prolongation of mitosis was 
concomitant with an increase in the mitotic index in cells treated with the combination 
siSpindly plus paclitaxel (41.8%), when compared to the residual accumulation of 
mitotic cells in 10 nM paclitaxel-treated cells (13.1%). Massive accumulation in mitosis 
(68.0% of total cells) was only achieved with a minimum of 100 nM paclitaxel (Figure 
4.2B). Our results demonstrate that preventing SAC silencing through Spindly depletion 
increases the length and the frequency of the mitotic arrest of cells treated with low 
doses of paclitaxel.  
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Figure 4.2. Spindly inhibition increases the duration of the mitotic block and the mitotic 
index under low doses paclitaxel treatment. (A) Mitosis duration as determined by time-lapse 
microscopy, in the absence or presence of 10 nM paclitaxel (PTX 10 nM) both for control- or 
Spindly siRNA-transfected cells. Each spot represents one NCI-H460 cell.  (B) Mitotic index of 
control siRNA- or siSpindly-treated cells, in the absence or presence of paclitaxel.  Cells were 
treated with control or Spindly siRNA for 48 hours, or 24 if Spindly siRNA was used in 
combination with paclitaxel. Mitotic Index was established upon DNA staining. **p < 0.01, 
***p < 0.001 and ****p < 0.0001 individual or combination treatments vs control siRNA; 
####
p 
< 0.0001 combination treatment vs siSpindly. 
 
4.4. Spindly depletion exacerbates the cytotoxic activity of paclitaxel 
As Spindly depletion led to much longer mitotic arrest in paclitaxel-treated cells, we 
asked whether this would result in an exacerbated cytotoxicity. To address this question, 
NCI-H460 and A549 cells were transfected with Spindly siRNAs, 24 h post-transfection 
cells were treated with various concentrations of paclitaxel. An MTT assay was 
performed 72 h post-transfection. In control siRNA-treated cells, viability was only 
marginally compromised at low doses of paclitaxel (<10 nM), and >50 nM of paclitaxel 
was required in order to significantly affect cell viability (Figure 4.3A). However, 
viability was drastically reduced by low doses of paclitaxel when Spindly was also 
downregulated. The results indicate that sensitivity to paclitaxel is significantly 
increased when Spindly is suppressed. 
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The increased sensitivity to paclitaxel of Spindly-depleted cells was also assessed by 
using a long-term (10 days) clonogenic assay. Sublethal concentrations of paclitaxel (4 
nM) greatly compromised colony formation in Spindly-depleted cells, when compared 
to control siRNA-treated cells (Figure 4.3B). Our results led us to conclude that that 
suppressing Spindly sensitizes human tumor cells to cytotoxic effect induced by 
clinically relevant doses of paclitaxel. 
 
Figure 4.3. Spindly depletion enhances paclitaxel-mediated cytotoxicity. (A) NCI-H460 
(left) and A549 (right) cell viability, as determined by MTT assay. Twenty-four hours post-
transfection with control or Spindly siRNA, paclitaxel (PTX) was added at the indicated 
concentrations (0-100 nM) and cells were incubated for an extra 48 hours. (B) NCI-H460 (left) 
and A549 (right) cells were treated as in (A), washed and allowed to grow for 10 days. Cells 
were then stained with crystal violet.  Results are the mean ± SD from three independent 
experiments, expressed as % of survival fraction. Representative images of surviving colonies 
(top) are shown for each condition. ****p < 0.0001 individual or combination treatments vs 
control siRNA; 
###
p < 0.001 and 
####
p < 0.0001 combination treatment vs siSpindly. 
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4.5. Spindly suppression promotes death of low doses paclitaxel-treated 
cancer cells 
In an attempt to understand the reason of the increased sensitivity to paclitaxel due 
to Spindly abolition we performed live-cell imaging experiments. Again, the NCI-H460 
was selected in this study for the aforementioned reasons. We aimed to directly 
determine the survival fate of each NCI-H460 arrested cell by time-lapse imaging over 
72 h time course as described above. Control- and Spindly-depleted cells were 
incubated with a sublethal dose (10 nM) of paclitaxel and imaged over a 72 h time 
course. All unperturbed NCI-H460 cells underwent normal cell cycling and division 
(n=30) (Figure 4.4A and movie 4.1). Spindly depletion induced cell death in 93% of 
cells (n=31) (Figure 4.4A and movie 4.2), while only 8% of cells (n=32) died after 
treatment with 10 nM paclitaxel (Figure 4.4A and movie 4.3). The same amount of the 
antimitotic drug triggered near-maximal cell death (86% of cells, n=35) in Spindly-
suppressed NCI-H460 cells (Figure 4.4A and movie 4.4). 
Cell death fell into two categories according to the stage of cell cycle at which it 
occurred: cell death in mitosis (DiM) when cells died during mitosis; and post-mitotic 
death (PMD) when death occurred following cell division. We have adopted DiM and 
PMD for standardization concern with previous report [212]. Of 93% of Spindly-
depleted cells that died, 90% underwent DiM while 3% only underwent PMD after the 
first division (Figure 4.4B); cells that survived (7%) remained in interphase for the 
duration of the imaging. Most of the paclitaxel-treated cells survived and continued 
cycling (84%), 8% stayed in interphase without cycling and only 8% underwent PMD 
(Figure 4.4B). For cells in which we used the combination treatment, 86% died. Most 
of these dead cells (72%) underwent PMD (mainly following the first division), the 
remaining 14% underwent DiM. Importantly, all the survivors (14%) were arrested in 
interphase for the duration of the imaging (Figure 4.4B). 
The strong tendency to die after cell division upon the combination treatment was 
confirmed by a two-fold decrease in cyclin B levels and a strong PARP-1 cleavage 
activity, supporting mitotic exit, and cell death, respectively (Figure 4.4C and D). In 
conclusion, Spindly targeting significantly increases post-mitotic death in paclitaxel-
based treatment. 
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Figure 4.4. A combination of low dose paclitaxel and Spindly depletion promotes post-
mitotic death in tumor cells. (A) Representative time-lapse sequences of NCI-H460 treated 
with control or Spindly siRNAs, either alone or in combination with 10 nM of paclitaxel (see 
section 2.12 for live-cell imaging details). It can be observed a control siRNA-treated cell and a 
paclitaxel-treated cell (PTX 10 nM) spending ~30 minutes in mitosis before cytokinesis; a 
siSpindly-treated cell is shown undergoing membrane blebbing >13 h upon mitotic block; a 
siSpindly plus paclitaxel-treated cell (siSpindly + PTX 10 nM) underwent post-mitotic death 26 
h:10 min after mitotic exit (white arrows). Cell death occurred more than 11h after the mitotic 
block. Numbers indicate times in 00hours:00minutes. Movies are available as supplementary 
materials. (B) Quantification of cell fates for each condition in (A). (C) Cyclin B1 levels (top) 
and PARP-1 activity (bottom) as determined by immunoblotting against protein extracts from 
NCI-H460 treated as in (A). Protein extraction was performed at the indicated time. For the 
combination, cells were treated with siRNA for 24h, then with paclitaxel for further 48h before 
protein extraction. (D) Ratio of Cyclin B1/tubulin for quantification of Cyclin B1 levels shown 
in (C). Results are the mean ± SD from three independent experiments. For Western blots α-
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tubulin was used as a loading control. **p < 0.01 individual or combination treatments vs 
control siRNA; 
#
p < 0.05 combination treatment vs siSpindly. 
 
Paclitaxel kills cancer cells mainly through the induction of apoptosis [226, 385]. 
The majority of cells that died, either by DiM or PMD, presented membrane blebbing 
characteristic of apoptosis. In addition to the aforementioned PARP-1 activity, 
apoptosis was further confirmed by TUNEL assay. Spindly depletion plus 10 nM 
paclitaxel resulted in more TUNEL-positive cells (30.1 ± 3.2%) than Spindly siRNA or 
paclitaxel alone (20.3 ± 3.6 % and 1.6 ± 0.6, respectively) (Figure 4.5A and B). Using 
an Annexin-V FITC and propidium iodide co-staining, we re-confirmed the apoptotic 
response by flow cytometry (Figure 4.5C and D). Therefore, a combination of 
clinically relevant doses of paclitaxel with suppression of Spindly enhances the 
apoptotic response of tumor cells. 
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Figure 4.5. Tumor cells treated with low doses of paclitaxel exhibits increased apoptosis 
upon Spindly inhibition. NCI-H460 cells were treated with control or Spindly siRNAs, 
either alone (- PTX 10 nM) or in combination with 10 nM of paclitaxel (+ PTX 10 nM). (A) 
Cells stained with TUNEL to detect apoptotic cells (green). DNA (blue) was stained with DAPI. 
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Bar = 5 µm. (B) Quantification of data shown in (A). (C) Representative cytogram from flow 
cytometry analysis of apoptosis by Annexin V/PI co-staining to confirm results presented in (A) 
and (B). The quadrants Q were defined as Q1=live (Annexin V- and PI-negative), Q2=early 
stage of apoptosis (Annexin V-positive/PI-negative), Q3= late stage of apoptosis (Annexin V- 
and PI-positive) and Q4=necrosis (Annexin V-negative/PI-positive). (D) Quantification of 
Annexin V-positive cells from the data shown in (C). Results are the mean ± SD from three 
independent experiments. ****p < 0.0001 individual or combination treatments vs control 
siRNA; 
#
p < 0.05, 
##
p < 0.01 and 
###
p < 0.001 combination treatment vs siSpindly. 
 
4.6. Spindly depletion potentiates multipolar spindle and multinucleation 
phenotype of paclitaxel-based treatment leading to cell death 
In order to gain a mechanistic understanding of the increased frequency of cell death 
induced by paclitaxel in Spindly depletion background, we investigated the precise 
impact of the combination on cell cycle progression and mitosis execution. Cells were 
processed for immunofluorescence and stained with -tubulin antibody to visualize 
mitotic spindle microtubules, and stained with DAPI for DNA. The microscopy analysis 
revealed major alterations in both the morphology of mitotic spindle and interphasic 
nuclei. We found that 56.8 ± 7.5% and 49.7 ± 10.7% of spindles were multipolar in 
mitotic cells depleted of Spindly or treated with 10 nM paclitaxel, respectively. The 
remainder exhibited near-normal bipolar spindles (Figure 4.6A). Interestingly, 
treatment of Spindly-depleted cells with 10 nM paclitaxel exacerbated this phenotype as 
96.0 ± 5.1% of spindles were multipolar. Paclitaxel was only able to induce comparable 
frequency of multipolar spindles if used at higher concentrations (> 100 nM). Similar 
behavior was observed when the morphology of interphasic nuclei was analyzed. While 
only 20% of cells exposed to individual treatments were multinucleated, 76.5 ± 7.4% of 
cells were multinucleated in the combination treatment (Figure 4.6B).  We further 
confirmed this result using flow cytometry analysis to analyze the cell cycle profile 
(Figure 4.6C). Spindly knockdown plus 10 nM paclitaxel resulted in an increased cell 
population with >4N DNA content (>G2), compared to untreated cells or to cells 
exposed to individual treatments.  
Overall, the results indicate that under Spindly depletion background, severe 
chromosome missegregation within a multipolar spindle is induced in low-dose 
paclitaxel-treated cells, generating multinucleated cells probably as a result of failure in 
cytokinesis, and leading eventually to cell death. 
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Figure 4.6. Spindly inhibition enhances multipolar spindles and multinucleation induced 
by low doses paclitaxel. (A) Quantification (graph) of mitotic spindle morphology (upper 
images, DAPI and tubulin -staining) after treatment with control or Spindly siRNAs, either 
alone or in combination with 10 and 100 nM of paclitaxel (PTX). Bar = 5 µm. (B) 
Quantification (graph) of nuclear morphology (upper images, DAPI staining) in NCI-H460 
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treated as in (A). (C) Confirmation of data in (B) by flow cytometry analysis. Results are the 
mean ± SD from three independent experiments. 
 
5. Discussion 
Despite the broad clinical use of microtubule targeting agents (MTAs), the 
associated hematopoietic and neurologic toxicities as well as the intrinsic or acquired 
drug resistance remain a significant problem limiting their overall effectiveness. Here 
we present data that support a rationale for targeting Spindly to potentiate the 
effectiveness of paclitaxel at clinically relevant doses, thus providing a novel and 
possibly effective approach for therapeutic intervention in cancer.  
In the present study, depletion of Spindly created misaligned chromosomes and 
lengthened mitosis, consistent with previous reports [114, 343]. As predicted, we found 
that depletion of Spindly rendered cells remarkably more sensitive to low doses of 
paclitaxel. Sensitization to paclitaxel was due to an enhanced antimitotic activity 
resulting, primarily, from an increase in the duration of mitotic delay. This was 
correlated with the extent of multinucleation and cell death response. Cell death 
consisted predominantly of post-mitotic death (PMD) as revealed by cell fate profiling. 
Paclitaxel induces SAC-dependent mitotic delay at high doses by inhibiting 
microtubule dynamics but at low doses, clinically relevant concentrations, it induces 
aneuploidy without mitotic arrest [386, 379]. It is possible that at low doses of 
paclitaxel, cells exhibit the same kinetics of chromosome attachment to the mitotic 
spindle as control cells, and the SAC is inactivated [345]. In this regard, due to its dual 
role in chromosome attachment and SAC silencing, targeting Spindly would have two 
consequences on cell division that would potentiate the effect of low doses of paclitaxel. 
On one hand, suppression of Spindly induces misattached chromosomes which activate 
the SAC and, consequently, block cells in mitosis. On the other hand, Spindly 
suppression prevents SAC silencing and, hence, mitotic exit, resulting in a lengthening 
of mitotic arrest. Both consequences, mitotic block and sustained SAC activation, create 
maximal conditions for apoptotic signal accumulation, thereby sensitizing tumor cells to 
cell death by clinically relevant doses of paclitaxel. 
The fate of cells exposed to antimitotic agents is determined by the length of the 
mitotic arrest and their ability to activate apoptosis [376]. As long as SAC is activated, 
rapid cyclin B1 degradation is prevented and cells are trapped in mitosis, allowing 
accumulation of apoptotic signals. However, cyclin B1 levels decline by slow and 
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continuous degradation that ultimately leads to SAC slippage which, if it happens 
before accumulation of sufficient cell death signal, drives cells out of mitosis, with the 
possibility of giving rise to surviving progeny cells [387, 212] . Therefore mechanisms 
that activate SAC and delay its silencing, such as Spindly inhibition, may increase the 
length of mitotic arrest induced by MTAs, allowing apoptotic signals to accumulate and 
irreversibly marking cell for death, even after mitotic slippage. It was proposed that 
enhancing chromosome missegregation and aneuploidy could be a strategy to sensitize 
cancer cells to MTAs [213]. Indeed, gross chromosome missegregation is not 
compatible with cell viability [215]. The high frequency of aneuploidy and cell death 
response that resulted from Spindly depletion plus paclitaxel treatment in our study 
confirms the relevance of such strategy to cancer cell killing. In this regard, the 
misattachment phenotype associated with Spindly depletion might potentiate the 
aneuploidy induced by low doses of paclitaxel. We therefore propose that future drug 
candidates against Spindly be added to the list of the so-called second-generation 
antimitotic drugs that block mitotic progression by disrupting spindle assembly, like 
inhibitors against mitotic kinesins  (e.g. Eg5 and CENP-E), and mitotic kinases (e.g. 
Plk1) [239]. Spindly inhibitors would have the advantage of acting on mitotic exit and 
not only on spindle assembly like the Eg5, CENP-E, and Plk1 inhibitors. In fact, 
blocking mitotic exit was reported to be better cancer therapeutic target than perturbing 
spindle assembly [377]. Although our results indicate that Spindly targeting alone was 
sufficient for an efficient cell killing, based on the reported limited success of second-
generation antimitotics in clinical trials [388, 389], we believe that candidates for 
Spindly inhibitors would provide a better clinical benefit if combined with the most 
successful chemotherapy drugs in history such as paclitaxel. 
Intriguingly, Spindly depletion led to DiM while the combination with paclitaxel 
induced PMD. It is possible that the longer mitotic arrest provided by Spindly depletion 
favors DiM due to accumulation of pro-apoptotic signal to a level that dictates cell death 
while cells are still in mitosis. On the other hand, in the combination treatment, subtle 
perturbations in microtubule dynamics and kinetochore-microtubule attachments, 
induced by low doses of paclitaxel, might induce Spindly-independent SAC silencing, 
leading to mitotic exit. Indeed, although mitotic delay in the combination was increased, 
its duration was shorter when compared to Spindly-depleted cells. At the same time, 
these cells have already accumulated enough apoptotic signals to irreversibly undergo 
post-mitotic death. 
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As SAC inactivation drives precocious mitotic exit and cell death as a result of 
massive chromosome missegregation, its modulation has been tested for cancer therapy 
experiments in many reports [390]. The overall conclusion is that, to be effective in 
cancer therapy, a complete abrogation of SAC is needed, which is difficult to achieve in 
vivo [391, 215]. On another hand, incomplete inactivation of SAC activity confers 
strong resistance to SAC-dependent antimitotic drugs in various cancer cell lines [392, 
212]. Together with the aforementioned reasons, this highlights the advantages of 
targeting Spindly in triggering cancer cell death more effectively than modulating SAC 
directly.  
In conclusion, we have explored the dual role of Spindly in chromosome attachment 
and SAC silencing to increase the effectiveness of clinically relevant doses of 
paclitaxel. We show that the suppression of Spindly sensitizes human tumor cells to 
death by low doses of paclitaxel by increasing the length of mitotic arrest and the 
frequency of aneuploidy. We thus propose Spindly inhibition as valid and valuable 
strategy in rational combination cancer therapy with paclitaxel. As low doses of 
paclitaxel can be used, this strategy might provide therapeutic benefits by overcoming 
problems of resistance and side effects. Additionally, SAC-deficient cancer cells resist 
cell killing by antimitotics because they prematurely exit mitosis, before initiation of 
apoptosis [377]. Preventing SAC silencing in these cells, through Spindly inhibition, 
might help circumvent this resistance. 
6. Acknowledgements 
This work was funded by CESPU – Cooperativa de Ensino Superior Politécnico e 
Universitário under the project “SpindlyTarget-CESPU-2016”. Patrícia M.A. Silva is a 
PhD fellowship holder from FCT (SFRH/BD/90744/2012), and partially supported by 
national Portuguese funding through FCT - Fundação para a Ciência e a Tecnologia, 
project ref. UID/BIM/04773/2013 CBMR. 
CHAPTER 4 
115 
7. Supplementary figures  
 
Figure 4.S1. Spindly depletion resulted in a significant increase in mitotic arrested lung 
cancer cells. NCI-H460 and A549 cells were transfected with control (control siRNA) or 
Spindly (siSpindly) siRNAs for 48 hours. (A) The expected Spindly kinetochore staining was 
exhibited by control siRNA-treated cells but was absent from siSpindly-treated cells, indicating 
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efficient Spindly depletion. Cells were immunostained with CREST and anti-Spindly antibodies 
to localize kinetochores (in red) and Spindly (in green), respectively. DNA is shown in blue 
(DAPI). Bar = 5 µm. (B) Representative immunoblots from NCI-460 (top) and A549 (bottom) 
cell extracts showing efficient Spindly downregulation upon transfection with siRNAs. α-
tubulin was used as a loading control. (C) Representative phase contrast microscopy fields 
showing an accumulation of NCI-H460 and A549 mitotic cells (rounded-shape) upon 
transfection with Spindly siRNAs (siSpindly). Nocodazole was used as a positive control of 
antimitotic activity. Bar = 20 µm. (D) Determination of mitotic index (percentage of mitotic 
cells over the total of cell population) from the data shown in (C). Results are the mean ± SD 
from three independent experiments.  ****p < 0.0001 control siRNA vs siSpindly.  
  
 
 
 
 
 
 
 
4.2. Spindly Expression, Prognostic Significance and 
Therapeutic Implications in Oral Squamous Cell 
Carcinoma 
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Spindly Expression, Prognostic Significance and Therapeutic Implications in Oral 
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1. Abstract 
The spindle assembly checkpoint (SAC) ensures genomic stability by preventing 
chromosome segregation at metaphase to anaphase transition in the presence of 
unattached or improperly attached chromosomes to mitotic spindle. Anaphase onset 
requires SAC silencing, a process that involves the protein Spindly. The aim of this 
study was to analyze the expression pattern of Spindly, its clinicopathological 
significance in patients with oral squamous cell carcinoma (OSCC), and its potential as 
therapeutic target. Immunostaining of tissue microarrays from OSCC patients 
demonstrated > 75% patients had high levels of Spindly expression. Both univariate and 
multivariate analyses showed that high expression of Spindly was an independent 
prognostic indicator for cancer-specific survival. Importantly, Spindly overexpression 
was associated with increased cellular proliferation. Moreover, Spindly was found to be 
upregulated in OSCC cell lines comparatively to their normal counterpart. RNAi-
mediated knockdown of Spindly compromises cell viability of OSCC cells and, 
interestingly, enhances their chemosensitivity to cisplatin. Overall, the data suggest 
promising clinical potential of Spindly as marker of cancer proliferation and prognosis, 
and highlights the potential therapeutic benefit of combining Spindly inhibition with 
cisplatin. 
 
 
Keywords:  Spindly; gene expression; oral squamous cell carcinoma; cisplatin; 
combinatorial therapy 
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2. Introduction  
Oral squamous cell carcinoma (OSCC) is the most common oral cancer worldwide, 
with a still dismally low survival rate [393, 394]. Like in other cancers, genetic and 
epigenetic events govern the multistep process of OSCC progression [395]. Therefore, 
identifying the changes that occur at the molecular and biological levels during oral 
cancer development could provide a mean for understanding the disease mechanisms, as 
well as for earlier diagnosis and the delivery of more efficacious and safer therapies, 
thereby improving health management. 
Spindly is a regulator of dynein at kinetochores during mitosis and is also involved 
in chromosome alignment and spindle assembly checkpoint (SAC) signaling [112, 114]. 
The SAC monitors the attachment of chromosomes to spindle microtubules and 
prevents anaphase onset until all chromosomes have achieved bipolar attachments and 
are properly aligned at the metaphase plate [99]. The transition from metaphase to 
anaphase requires SAC silencing, a process that involves kinetochore dynein-mediated 
removal of the 605-aa protein Spindly [341, 187, 186]. Knockdown of Spindly induces 
chromosome alignment defects and extensive prometaphase delay, consistent with its 
role in chromosome attachment and SAC silencing [396, 114]. 
The expression of many SAC components has been reported to be altered in cancer, 
and some of these components have been identified as suitable targets for the clinical 
treatment of cancer [99, 397]. To the best of our knowledge there is, however, no 
information available about the impact of Spindly in oral or any other cancer 
pathogenesis and clinical outcome. Thus, this is the first study where the patterns of 
Spindly expression were analyzed in OSCC patient samples, as well as its potential 
correlations between clinicopathologic significance, and its potential use in 
chemotherapy. We found that Spindly was highly expressed in OSCC patients with a 
significant correlation with tumor proliferation, and that this high expression inversely 
correlated with overall survival. More importantly, knockdown of Spindly significantly 
increased sensitivity of OSCC cells to cisplatin treatment. The prognostic and 
therapeutic relevance of these results are discussed. 
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3. Materials and Methods 
3.1. Patients and tissue specimens 
Tissue samples from primary OSCC (ICD 10: C00-06), were retrospectively 
collected from 2000 to 2006, at the Hospital de Santo António (HSA) - Centro 
Hospitalar do Porto, Portugal. The study was approved by institutional ethical board of 
the hospital (Investigation, Formation and Teaching Department – DEFI; 024/CES/03) 
and performed in accordance with the Declaration of Helsinki. The clinical 
characteristics of the OSCC patients are described in detail in Table 4.S1. Clinical 
follow-up information was obtained from the patients’ records.  
3.2. Immunohistochemistry processing and evaluation  
Immunohistochemistry was performed on tissue microarray (TMA) sections as 
previously described [398], using the NovoLink Polymer Detection System 
(Novocastra, Leica Biosystems Newcastle Ltd.). The primary antibodies used were a 
rabbit anti-human Spindly diluted at 1:500 (HPA044700, Sigma-Aldrich), and a rabbit 
anti-human Ki-67 diluted at 1:100 (clone MIB1, Dako, Glostrup, Denmark). Positive 
(oral mucosa) and negative (omission of primary antibody) controls were included. 
Immunohistochemical expression of Spindly was evaluated by two authors blinded 
to clinicopathological characteristics, who recorded the intensity of staining [0 
(negative), 1 (weak), 2 (moderate) and 3 (strong)]. Discordant cases were reviewed to 
achieve a consensus. We used the concordant result score out of at least two of the three 
cores examined per case, and when this was not possible, the case was excluded. For 
data analysis, score 0/1 was considered as low expression and scores 2/3 as high 
expression for Spindly marker [399]. The proliferative status of the tumors was 
evaluated by the percentage of Ki-67 positive nuclear staining and classified as tumors 
with low (0–49% of stained cells) or high (50–100% of stained cells) cellular 
proliferation activity [299]. 
3.3. Cell culture 
Oral squamous cell carcinoma cell lines SCC-09 and SCC-25 were grown in 
DMEM-F12 culture medium (Biochrom, São Mamede de Infesta, Portugal) with 10% 
fetal bovine serum (FBS, Biochrom), and supplemented with 40 ng/ml hydrocortisone 
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(Sigma-Aldrich, St. Louis, MO, USA). Human oral keratinocytes (HOK) were grown in 
an oral keratinocyte medium (Innoprot, Derio, Biscaia, Spain) according to the 
manufacturer’s instructions. Cells were maintained at 37°C in a 5% CO2 humidified 
atmosphere.  
3.4. Real-time PCR 
For isolation of total RNA, cDNA synthesis and amplification we performed as 
previously described [299]. Primers, used at final concentration of 10 µM, were as 
follows: Spindly: forward 5´-CTC AAA GAG GCT GAA GAA GAG-3´ and reverse 
5´-TGT TCA TAA CTC TCA GTC ATG G-3´; Actin: forward 5´- AAT CTG GCA 
CCA CAC CTT CTA -3´ and reverse 5´- ATA GCA CAG CCT GGA TAG CAA-3´. 
The housekeeping gene Actin was used as an internal control to normalize the 
expression levels of Spindly. Three experiments were performed in triplicate. 
3.5. siRNA transfection 
Cells were seeded in 22 mm poly-l-lysine-coated coverslips in 6-well plates, 
allowed attaching for 24 hours, and transfected using INTERFERin siRNA Transfection 
Reagent (PolyPlus, New York, USA) according to the manufacturer’s instructions. The 
culture medium was replaced 24 hours post-transfection with fresh medium. A validated 
siRNA sequence [186, 321] against Spindly (synthetized by Sigma-Aldrich) and a 
validated negative control siRNA (AllStars Negative Control siRNA, Qiagen, 
Germantown MD, USA) were used at a final concentration of 100 nM.  
3.6. Cell extracts and western blotting 
Western blot analysis was as previously described [321]. Briefly, cells were 
collected by trypsinization and resuspended on lysis buffer supplemented with protease 
inhibitors cocktail (Sigma-Aldrich). A total of 20 µg of denatured proteins were 
separated onto a 7.5% polyacrylamide gel. The primary antibodies were as follows: 
rabbit anti-Spindly (1:3000, gift from Dr. R. Gassmann, IBMC/I3S, Portugal) and 
mouse anti-α-tubulin (1:2500, Sigma-Aldrich). (HRP)-conjugated secondary antibodies 
were diluted at 1:1500 (anti-mouse, Vector) or at 1:1000 (anti-rabbit, Sigma). The 
quantification of signal intensity was performed using ImageJ 1.4v software and 
normalized against α-tubulin expression levels. 
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3.7. Cell viability assay 
Cell viability was determined through (3-(4, 5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) MTT (Sigma-Aldrich) assay. A total of 0.06x10
6
 siRNA-
treated cells were seeded in 96-well plate, allowed to attach for 6 hours and treated with 
1-200 µM cisplatin. After 24 hours, cells were placed in fresh FBS-free medium and 20 
µl of MTT reagent (5mg/ml in PBS) was added and incubated at 37°C and 5% CO2 for 
4 hours. Then, a solubilization solution (89% (v/v) 2-Propanol, 10% (v/v) Triton X-100, 
1% (v/v) HCl 3.7%) was added for 2 hours. The optical density was measured at 570 
nm in a microplate reader (Biotek Synergy 2, Winooski, VT, USA) and retrieved 
through the Gen5 software (version 1.07.5, Biotek, Winooski, VT, USA). Cell viability 
was calculated relative to control siRNA-treated cells. 
3.8. Colony formation assay 
A total of 1000 siRNAs-transfected cells were seeded in six-well plates, allowed to 
attach for at least 6 hours, and treated with 1 and 2 µM of cisplatin. Twenty-four hours 
later, to remove cisplatin, cells were washed twice with PBS and then incubated in fresh 
medium for 10 days. The recovered colonies were fixed with 3.7% paraformaldehyde in 
PBS, for 5 min, and stained with 0.05% (w/v) Violet Crystal (Merck Millipore, 
Billerica, MA, USA) in distilled water, for 20 min. The number of colonies was counted 
on duplicate dishes from three independent experiments. The plating efficiency (PE) 
was calculated as the percentage of the number of colonies formed over the number of 
cells seeded, in control siRNA-treated cells. The survival fraction was determined as the 
number of colonies over the number of cells seeded × 1/PE, for each condition. 
3.9. Statistical analysis 
For immunohistochemistry evaluation, the associations between categorical 
variables were evaluated by Chi-square tests. Cancer-specific survival (CSS) was 
defined as the time interval (months) between primary treatment and death from oral 
cancer or last follow-up. Survival curves were plotted using Kaplan–Meier method, and 
their prognostic effect was tested using the Log-rank test. Variables with significant 
influence in the univariate analyses were entered into Cox proportional hazards model 
to investigate their independent effects. Differences were considered statistically 
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significant at p < 0.05. Statistical analysis was performed using IBM SPSS Statistics 
version 22.0 software (IBM Corporation, NY, USA). 
For cell culture assays, statistical analysis was performed using an Unpaired Student 
t-test or an Ordinary Two-way ANOVA with Tukey's multiple comparisons test, in 
GraphPad Prism version 6 (GraphPad software Inc., CA, USA). Data are presented as 
the means ± standard deviation (SD) of at least three independent experiments. The 
level of significance was set at probabilities of *p < 0.05, **p < 0.01, ***p < 0.001 and 
****p < 0.0001. 
 
4. Results  
4.1. Spindly is differentially expressed in OSCC tissues  
The localization and expression of Spindly in paraffin-embedded OSCC samples 
were examined by immunohistochemical analysis. Spindly staining was mainly 
cytoplasmic in epithelial cells (Figure 4.7). Spindly expression was detected in all of 
the 61 (100%) OSCC tissue microarrays (Table 4.1). High levels of Spindly expression 
were detected in 75.4% of the tumor samples; the remainder expressed only weak 
levels. In contrast, adjacent non-tumor epithelial cells showed no staining or only low 
and marginal staining (Figure 4.7). 
 
Figure 4.7. Immunohistochemical expression and localization pattern of Spindly ioral 
squamous cell carcinoma. Normal oral mucosa stained for Spindly at low (a) and high (a’) 
magnification; Squamous cell carcinoma with low expression of Spindly at low (b) and high 
(b´) magnification; and with high expression of Spindly at low (c) and high (c’) magnification. 
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Note the cytoplasmic spindly staining of epithelial cells, homogenously distributed by the tumor 
islands. Low magnification (x 100); high magnification (x 400). Scale bar = 20 µm 
 
Table 4.1. Clinicopathological characteristics of the OSCC patients and its association with 
Spindly expression. 
 
  Spindly expression 
P
a
   Low 
expression 
 High 
expression 
Characteristic  N (%) N (%) N (%)  
All cases 61 (100) 15 (24.6) 46 (75.4)  
Gender        
    Female  16 (26.2) 3 (18.8) 13 (81.2) 
NS (0.528) 
    Male 45 (73.8) 12 (26.7) 33 (73.3) 
Age          
    <62 years 26 (42.6) 7 (26.9) 19 (73.1) 
NS (0.715) 
    ≥62 years 35 (57.4) 8 (22.9) 27 (77.1) 
Consumption habits         
    No habits 16 (30.2) 5 (31.2) 11 (68.8) 
NS (0.531) 
    Alcohol 5 (9.4) 1 (20.0) 4 (80.0) 
    Tobacco 12 (22.6) 1 (8.3) 11 (91.7) 
    Alcohol + tobacco 20 (37.7) 4 (20.0) 16 (80.0) 
Tumor location         
    Lip 7 (11.5) 3 (42.9) 4 (57.1) 
NS (0.600) 
    Floor of the mouth 5 (8.2) 2 (40.0) 3 (60.0) 
    Tongue 26 (42.6) 5 (19.2) 21 (80.8) 
    Buccal mucosa  4 (6.6) 1 (25.0) 3 (75.0) 
    Retromolar trigone  6 (9.8) 0 (0.0) 6 (100.0) 
    Hard palate 7 (11.5) 2 (28.6) 5 (71.4) 
    Gingiva 6 (9.8) 2 (33.3) 4 (66.7) 
Tumor size         
    T1 17 (27.9) 6 (35.3) 11 (64.7) 
NS (0.414) 
    T2 27 (44.3) 7 (25.9) 20 (74.1) 
    T3 3 (4.9) 0 (0.0) 3 (100.0) 
    T4 14 (23.0) 2 (14.3) 12 (85.7) 
N status         
    N0 37 (60.7) 12 (32.4) 25 (67.6) 
NS (0.315) 
    N1 11 (18.0) 2 (18.2) 9 (81.8) 
    N2 11 (18.0) 1 (9.1) 10 (90.9) 
    N3 2 (3.3) 0 (0.0) 2 (100.0) 
 
Abbreviations: SG= surgery; RT=radiotherapy; CT=chemotherapy; NS=No statistical significance. 
a
Chi-
square test. 
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Table 4.1. (continued) 
  Spindly expression 
P
a
   Low 
expression 
 High 
expression 
Characteristic  N (%) N (%) N (%)  
Stage         
    I 12 (19.7) 5 (41.7) 7 (58.3) 
 NS (0.109)     II 21 (34.4) 7 (33.3) 14 (66.7) 
    III 12 (19.7) 2 (16.7) 10 (83.3) 
    IV 16 (26.2) 1 (6.2) 15 (93.8) 
Treatment modality         
    SG 33 (54.1) 12 (36.4) 21 (63.6) 
0.042     SG + RT 18 (29.5) 3 (16.7) 15 (83.3) 
    CT + other 10 (16.4) 0 (0.0) 10 (100.0) 
Tumor grade         
    G1 37 (60.7) 13 (35.1) 24 (64.9) 
NS (0.057)     G2 22 (36.1) 2 (9.1) 20 (90.9) 
    G3 2 (3.3) 0 (0.0) 2 (100.0) 
Margin status         
    Free of tumor 32 (59.3) 9 (28.1) 23 (71.9) 
NS (0.906)     Tumor proximity 13 (24.1) 4 (30.8) 9 (69.2) 
    With tumor 9 (16.7) 2 (22.2) 7 (77.8) 
Vascular invasion     
    Absent 57 (93.4) 15 (26.3) 42 (73.7) 
NS (0.237) 
    Present 4 (6.6) 0 (0.0) 4 (100.0)   
Perineural permeation         
    Absent 52 (85.2) 14 (26.9) 38 (82.6) 
NS (0.309) 
    Present 9 (14.8) 1 (11.1) 8 (88.9) 
Lymphatic invasion         
    Absent 48 (78.7) 12 (25.0) 36 (75.0) 
NS (0.886) 
    Present 13 (21.3) 3 (23.1) 10 (76.9) 
 
Abbreviations: SG= surgery; RT=radiotherapy; CT=chemotherapy; NS=No statistical significance. 
a
Chi-
square test. 
 
 
4.2. High levels of Spindly expression correlate with tumor proliferation and 
poor prognostics 
Statistical analysis was performed to identify association between Spindly 
expression levels and clinicopathological parameters of OSCC. Apart from treatment 
modality, no significant correlation was found between Spindly levels and the assessed 
clinicopathologic factors (Table 4.1). Moreover, we evaluated whether Spindly 
expression was associated with patient prognosis. The follow-up mean time for the 61 
patients was 43.8 ± 33.1 months with a range from 1 to 142 months. Kaplan-Meier 
curves with univariate analyses showed that the patients with the highest Spindly 
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expression levels had a much reduced survival time than those with the lowest 
expression levels (P < 0.048) (Table 4.2 and Figure 4.8).  
Table 4.2. Univariate analysis of cancer-specific survival (CSS) according to the 
clinicopathological characteristics and Spindly expression in OSCC. 
 
 
Characteristic N Dead CSS
a
 p
b
 
Gender         
    Female  16 8 50.0 NS 
(0.134)     Male 45 13 71.1 
Age          
    <62 years 26 12 53.8 NS 
(0.156)     ≥62 years 36 9 74.3 
Consumption habits         
    No habits 16 6 62.5 
NS 
(0.827) 
    Alcohol 5 1 80.0 
    Tobacco 12 4 66.7 
    Alcohol + tobacco 20 9 55.0 
Location         
    Lip 7 1 85.7 
NS 
(0.870) 
    Floor of the mouth 5 2 60.0 
    Tongue 26 8 69.2 
    Buccal mucosa  4 1 75.0 
    Retromolar trigone 6 3 50.0 
    Hard palate  7 3 57.1 
    Gingiva 6 3 50.0 
Tumor size         
    T1 17 1 94.1 
<0.001 
    T2 27 9 66.7 
    T3 3 1 66.7 
    T4 14 10 28.6 
N status         
    N0 37 6 83.8 
<0.001 
    N1 11 5 54.5 
    N2 11 9 18.2 
    N3 2 1 50.0 
Stage         
    I 12 0 100.0 
0.001 
    II 21 5 76.2 
    III 12 5 58.3 
    IV 16 11 31.2 
 
Abbreviations: SG= surgery; RT=radiotherapy; CT=chemotherapy; NS=No statistical significance. 
a
Percentage of cases without event at 3 years of follow-up. 
b
Log-rank test. 
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Table 4.2. (continued) 
Characteristic N Dead CSS
a
 p
b
 
Treatment modality         
    SG 33 4 87.9 
<0.001     SG + RT 18 10 44.4 
    CT + other 10 7 30.0 
Tumor grade         
    G1 37 9 75.7 
NS 
(0.206) 
    G2 22 11 50.0 
    G3 2 1 50.0 
Margin status
c
         
    Free of tumor 32 8 75.0 
NS 
(0.329) 
    Tumor proximity 13 5 61.5 
    With tumor 9 5 44.4 
Vascular invasion     
    Absent 
57 20 64.9 
NS 
(0.872) 
    Present 4 1 75.0  
Perineural permeation          
    Absent 
52 17 67.3 
NS 
(0.372) 
    Present 9 4 55.6   
Lymphatic invasion         
    Absent 48 17 64.6 NS 
(0.876)     Present 13 4 69.2 
Ki-67 expression     
    Low 
30 9 70.0 
NS 
(0.186) 
    High 20 10 50.0  
Spindly expression         
   Low expression  15 2 86.7 
0.048 
   High expression 46 19 58.7 
 
Abbreviations: SG= surgery; RT=radiotherapy; CT=chemotherapy; NS=No statistical significance. 
a
Percentage of cases without event at 3 years of follow-up. 
b
Log-rank test. 
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Figure 4.8. Figure Kaplan–Meier curves for overall patient´s survival according to Spindly 
expression. 
 
The cumulative 5-year survival rate was only 54.1% for the high Spindly group, while it 
was 91.7% for the low Spindly group. Tumor size, N status, tumor stage, and treatment 
modality were also statistically significant prognostic factors in univariate analysis (p < 
0.001). Inclusion of these characteristics, together with Spindly expression values, into 
multivariable Cox proportional hazards regression model, showed that Spindly 
expression level was an independent prognostic factors for OSCC (P < 0.041) (Table 
4.3).  
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Table 4.3. Multivariate analysis of cancer-specific survival (CSS). 
 
Variable HR (95% CI) P 
Stage 
I+II 
III 
IV 
 
1 
0.317 (0.016-6.110) 
0.191 (0.012-3.088) 
 
 
0.447 
0.244 
Tumor size 
T1 
T2 
T3 
T4 
 
1 
13.455 (1.368-132.378) 
12.262 (0.379-396.844) 
32.261 (3.123-333.211) 
 
 
0.026 
0.158 
0.004 
N status 
N0 
N1 
N2 
N3 
 
1 
5.008 (0.343-73.133) 
23.925 (2.362-242.286) 
3.138 (0.156-63.277) 
 
 
0.239 
0.007  
0.456 
Treatment modality 
SG 
SG + RT 
CT + other 
 
1 
3.873 (0.972-15.434) 
2.766 (0.585-13.087) 
 
 
0.199 
0.055 
Spindly expression       
Low expression 
High expression 
 
1 
6.427 (1.080-38.264) 
 
 
0.041 
 
Abbreviations: HR=hazard ratio; CI= confidence interval; NS=No statistical significance; SG= surgery; 
RT=radiotherapy; CT=chemotherapy. 
 
Interestingly, when we investigated the relationship between Spindly expression and 
OSCC proliferation using Ki-67 expression, we detected high Spindly level in 100% of 
high proliferative (n=20) and in 63.3% (n=19) of low proliferative tumors (n=30). This 
highlights a strong association between Spindly expression and increased cellular 
proliferation (p = 0.002). Our data indicates that Spindly expression is associated with 
increased tumor cell proliferation, as well as with a greatly increased risk pointing to 
Spindly as a marker of poor prognosis. 
4.3. Spindly is highly expressed in OSCC cell lines 
 In order to study if Spindly could be a potential target for cancer therapy in vitro, 
we first conducted a quantitative real-time PCR to investigate the expression of Spindly 
on OSCC cell lines at the mRNA level. The SCC-09 and SCC-25 oral cancer lines 
exhibited a higher expression of Spindly mRNA than their normal cell counterpart HOK 
(human oral keratinocytes) (Figure 4.9). Therefore, Spindly expression is upregulated 
in OSCC lines. 
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Figure 4.9. Spindly gene expression in oral cancer cell lines. Spindly mRNA levels were 
analyzed by quantitative real-time PCR in oral cancer cell lines SCC-09 e SCC-25 
comparatively to normal human oral keratinocytes (HOK). 
 
4.4. Spindly depletion enhances sensitivity of OSCC cells to cisplatin 
Cisplatin is amongst the most potent chemotherapeutic agents currently in use, 
exerting its cytotoxic action through the formation of intra-strand DNA crosslink 
adducts [400]. However, intrinsic or acquired resistance is a major limitation of 
cisplatin-based chemotherapy. The aforementioned overexpression of Spindly in OSCC 
tissues and cell lines prompted us to analyze whether Spindly knockdown enhances 
cytotoxicity of OSCC cells to cisplatin treatment. We first certified that efficient 
Spindly knockdown (> 90%) was achieved in the OSCC lines by use of previously 
validated siRNA oligonucleotides (Figure 4.10A) [186]. OSCC cells were transfected 
with Spindly siRNAs, 24 h post-transfection cells were treated with various 
concentrations of cisplatin for further 24 h, and then processed for MTT assay. As 
shown by the dose-response histograms in Figure 4.10B and C, in control siRNA-
treated cells, viability was only marginally compromised at doses <10 μM cisplatin, 
while exposure doses as high as > 50 μM cisplatin were required in order to 
significantly affect cell viability. However, viability was drastically reduced by doses 
<10 μM cisplatin when Spindly was also downregulated. The results indicate that 
sensitivity to cisplatin treatment is significantly increased when combined with Spindly 
depletion. To further confirm our observations, a long-term (10 days) clonogenic assay 
was performed to evaluate cancer cell killing efficiency of the combination therapy. 
Low concentrations of cisplatin (1 to 2 μM) greatly compromised colony formation in 
Spindly-depleted cells, when compared to individual treatments (Figure 4.10D and E), 
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consistent with data in MTT assay. The data indicates that Spindly knockdown 
sensitizes OSCC cells to cytotoxic effect induced by clinically relevant doses of 
cisplatin. 
 
 
Figure 4.10. Spindly depletion potentiates cisplatin-mediated cytotoxicity. (A) 
Representative immunoblots from SCC-09 and SCC-25 cell extracts showing efficient Spindly 
downregulation upon cell transfection with siRNAs. α-tubulin was used as a loading control. 
Cells were transfected with control (control siRNA) or Spindly (siSpindly) siRNAs for 48 
hours. (B and C) Twenty-four hours post-transfection with control (control siRNA) or Spindly 
siRNA (siSpindly), cisplatin was added at the indicated concentrations and cells were incubated 
for 24 hours. SCC-09 (B) and SCC-25 (C) cell viability was determined by MTT assay. (D and 
E) Cells were treated as in B and C, washed in PBS and remained for 10 days in culture. After 
crystal violet staining, the number of colonies was counted. Results are the mean ± SD from 
three independent experiments, expressed as % of survival fraction. Representative images of 
surviving colonies (Top) are shown for each condition. *p < 0.05, **p < 0.001 and ****p < 
0.0001 individual or combination treatments vs control siRNA. 
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5. Discussion 
In this study, we provided the first report of Spindly upregulation in cancer, namely 
in OSCC cell lines and OSCC tissue specimens. Overexpression of Spindly was 
significantly associated with tumor cell proliferation and, interestingly, was inversely 
correlated with the survival time of OSCC patients, highlighting the potential of Spindly 
as an independent marker of poor prognostic in OSCC. Moreover, we found that 
Spindly depletion significantly enhanced the chemosensitivity of OSCC cells to 
clinically relevant doses of cisplatin, pointing to Spindly as a potential target in a drug 
combination strategy to circumvent resistance to cisplatin treatment. 
Chromosomal instability (CIN) plays a key causative role in many malignancies and 
is often found in OSCC, with complex structural and numerical variations [401, 402]. 
Abnormal karyotype in OSCC cells arises from defects in chromosome segregation, 
frequently in the form of lagging chromosomes [403]. Spindly is a transient kinetochore 
protein required for efficient chromosome attachment to microtubules and plays a key 
role in SAC silencing [114, 396]. Indeed, depletion of Spindly by RNAi induces 
chromosome misalignment and caused cells to arrest in prometaphase [187]. It may be 
possible that overexpression of Spindly affects proper chromosome attachments and 
occasionally leads to lagging chromosomes thereby contributing to CIN. Changes in 
karyotype through CIN appear to confer proliferative advantages as a result of massive 
gene dosage imbalances [404]. Strikingly, in the present study, Spindly overexpression 
was strongly associated with increased cellular proliferation, suggesting a function of 
Spindly upregulation in the pathogenesis of OSCC. Thus, the link between the 
biological function of Spindly, CIN, and the pathogenesis of OSCC disease deserves to 
be investigated. 
Cisplatin is currently used as a potent chemotherapeutic agent in a wide variety 
of malignant solid tumors including OSCC [405]. However when used as a single 
agent is limited by intrinsic or acquired resistance. While the molecular 
mechanisms of such resistance remain poorly understood, cisplatin-based 
combination therapy has been the focus of intense research. As a consequence, 
combinatorial therapy has been applied as novel therapeutic strategy and has 
proven to be more effective while minimizing cisplatin resistance [406]. Our in 
vitro data suggests therapeutic implications for Spindly. We found that 
cytotoxicity of low doses of cisplatin was strongly increased in OSCC cells 
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depleted of Spindly. This suggests Spindly as suitable target in a combination 
strategy to sensitize OSCC to low doses of cisplatin, thus providing therapeutic 
benefits by overcoming problems of resistance and side effects. Further study is 
needed to clarify the detailed mechanism regulating cell growth by a combination 
of Spindly inhibition and cisplatin. 
In conclusion, in this study, Spindly was found to be overexpressed in OSCC. 
This upregulation was correlated with tumor proliferation and shown to be an 
independent poor prognosis factor. Depletion of Spindly sensitized OSCC to 
clinically relevant doses of cisplatin. We thus propose Spindly inhibition as 
promising strategy in rational combination with cisplatin for OSCC therapy.  
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7. Supplementary table 
 
Table 4.S1. Clinicopathological characteristics of the OSCC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: SG= surgery; RT=radiotherapy; CT=chemotherapy. 
a
 Not available in the 8 cases. 
b 
Not available in the 7 cases. 
 
Characteristic N (%) 
All cases 61 (100) 
Gender   
    Female  16 (26.2) 
    Male 45 (73.8) 
Age    
    <62 years 26 (42.6) 
    ≥62 years 35 (57.4) 
Consumption habits
a
   
    No habits 16 (26.2) 
    Alcohol 5 (8.2) 
    Tobacco 12 (19.7) 
    Alcohol + tobacco 20 (32.8) 
Tumor location   
    Lip mucosae 7 (11.5) 
    Floor of the mouth 5 (8.2) 
    Tongue 26 (42.6) 
    Buccal mucosa  4 (6.6) 
    Retromolar trigone  6 (9.8) 
    Hard palate 7 (11.5) 
    Gingiva 6 (9.8) 
Tumor size   
    T1 17 (27.9) 
    T2 27 (44.3) 
    T3 3 (4.9) 
    T4 14 (23.0) 
N status   
    N0 37 (60.7) 
    N1 11 (18.0) 
    N2 11 (18.0) 
    N3 2 (3.3) 
Stage   
    I 12 (19.7) 
    II 21 (34.4) 
    III 12 (19.7) 
    IV 16 (26.2) 
Treatment modality   
    SG 33 (54.1) 
    SG + RT 18 (29.5) 
    CT + other 10 (16.4) 
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Table 4.S1. (continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: SG= surgery; RT=radiotherapy; CT=chemotherapy. 
a
 Not available in the 8 cases. 
b 
Not available in the 7 cases. 
 
 
Characteristic N (%) 
Tumor grade  
    G1 37 (60.7) 
    G2 22 (36.1) 
    G3 2 (3.3) 
Margin status
b
  
    Free of tumor 32 (52.5) 
    Tumor proximity 13 (21.3) 
    With tumor 9 (14.8) 
Vascular invasion  
    Absent 57 (93.4) 
    Present 4 (6.6) 
Perineural permeation  
    Absent 52 (85.2) 
    Present 9 (14.8) 
Lymphatic invasion  
    Absent 48 (78.7) 
    Present 13 (21.3) 
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In present work we have achieved the main goals we had set up in the beginning, 
namely (1) to shed light into the function and regulation of the SAC mechanism and (2) 
to explore its potential as therapeutic target for cancer therapy.  
 
Concerning SAC function and regulation we proposed:  
(i) To establish a relationship between the SAC protein Bub3 and the microtubule 
motor dynein in regulating kinetochore-microtubule attachment and 
chromosome congression and 
(ii) To elucidate the role of dynein-mediated transport of SAC components off 
kinetochores to promote SAC silencing.  
Interestingly, we found a functional and antagonistic relationship between Bub3 and 
dynein to ensure stable KT-MT attachments and chromosome congression, establishing 
a link between SAC signaling and KT-MT binding machinery. Indeed, several studies 
have contributed to unveil a number of proteins involved in SAC signaling pathway and 
in mediation of KT-MT interactions and some of them were shown to participate in 
more than one functional activity. Here, beside dynein, the function of Bub3 in the 
regulation of KT-MT attachments might involve other interactors that define the 
molecular context in which this regulation is performed at the KT-MT interface. Hence, 
a possible further approach is to perform a proteomics-based analysis to identify novel 
partners of Bub3 to arrive to a better mechanistic understanding of Bub3’s role in the 
regulation of KT-MT attachments during mitosis.  
We also showed that the core SAC proteins Mad1, Mad2, Bub1, BubR1, and Bub3 
and a pool of KMN components Hec1 and Mis12 are poleward transported in a dynein-
dependent manner, after successful chromosome attachment, contributing to extinguish 
the inhibitory SAC signal and to allow cell cycle progression. These results contributed 
to clarify which proteins are truly dynein cargoes and to unveil new proteins subjected 
to the poleward transport, namely KMN components, providing first insights into the 
contribution of the KMN network to SAC silencing. Moreover, we found that dynein-
inhibited cells did not retain SAC proteins on kinetochores of aligned chromosomes. 
Instead, these proteins accumulated only on misaligned kinetochores, supporting the 
existence of a dynein-independent mechanism of protein stripping from attached 
kinetochores during SAC silencing. Indeed, in human cells, unlike direct dynein 
inhibition, depletion of Spindly (that abolishes kinetochore dynein localization) does not 
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block the removal of Mad2 SAC protein from attached kinetochores [114], suggesting 
additional mechanisms for SAC silencing. To the other hand, in Drosophila Spindly-
depleted cells, high levels of Mad2 and RZZ were found on bi-oriented and stretched 
metaphase kinetochores [112]. Further studies, conducted by Gassmann et al., using 
Spindly motif mutants, that target normally to kinetochores but prevent dynein 
recruitment, indicated that kinetochore dynein is essential for SAC silencing in the 
presence of Spindly but a second mechanism silence the checkpoint in their absence 
[186]. In fact, dynein-dependent removal of checkpoint proteins from kinetochores does 
not appear to be a conserved mechanism for SAC silencing, as no obvious Spindly/RZZ 
homologs are present in lower eukaryotes such as yeast and the reason for these 
discrepancies might be due to different kinetochore structures in the different species. In 
line with this, it would be interesting for future progress to explore the probably 
alternative SAC silencing mechanism operating when dynein is absent. Overall, these 
results contribute to expand the scientific knowledge about SAC mechanism, based on a 
fundamental research which constitutes a fuel for applied research.   
 
Focusing on SAC targeting in a therapeutic perspective, we proposed: 
(i) To highlight the potential of Spindly, a kinetochore regulator of dynein, as a 
target for cancer therapy; 
(ii) To explore the therapeutic benefit of combining Spindly inhibition with 
currently used chemotherapeutic drugs. 
First, we found Spindly overexpression both in human tumor cell lines and in 
patient samples from oral cancer. Importantly, Spindly overexpression was significantly 
correlated with tumor proliferation and worse prognosis, making Spindly expression 
pattern an independent prognostic indicator for cancer-specific survival and a marker of 
cell proliferation. Since Spindly is involved both in chromosome attachment and in 
SAC silencing we hypothesize that potentiate chromosome attachment errors and block 
mitotic exit, through Spindly inhibition, could result in improvement of cytotoxicity 
mediated by current chemotherapeutic drugs, namely paclitaxel and cisplatin. We found 
that Spindly inhibition plus low doses of paclitaxel or cisplatin co-treatment potentiates 
cell death, pointing Spindly inhibition as valid and valuable strategy in rational 
combination cancer therapy. Given the disappointed results in clinical trials from the 
new generation of antimitotics and in light of our results, we believed that the drug 
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concentration is a crucial factor in the response to antimitotics. For instance, although 
taxanes have been widely used in the clinic for over a decade, a divergence between in 
vitro and in vivo data exists on this drug’s therapeutic action [407]. It is probably related 
with the selected drug concentration used in cell culture experiments, forgetting the 
availability of drug in vivo. It is possible that the clinical efficacy of paclitaxel is not in 
fact due to mitotic arrest, but an enhancement of aneuploidy related with drug 
concentration used. In response to paclitaxel treatment, abnormal DNA contents and 
cell death were found at low drug concentrations, where a robust mitotic arrest was not 
apparent [408], suggesting that antimitotic agents that elicit their effect via prolonged 
mitotic arrest are only cytotoxic at a high concentration. Moreover, the percentage of 
mitotic cells in tumors is significantly lower than the percentage found in cell cultures 
but the number of aneuploid cells is higher. So, potentiates chromosome missegregation 
and aneuploidy could be a more efficient strategy to induce tumor cells killing rather 
than an exclusive mitotic arrest. Our results showed effectively that Spindly inhibition 
enhance the chromosome missegregation, in cells treated with paclitaxel, leading to cell 
death. Different from paclitaxel, a microtubule-targeting agent, cisplatin interfere 
with DNA replication which kills the fastest proliferating cells. Although the final 
result from Spindly and paclitaxel or cisplatin co-treatment was transversal, since 
induces cell death, further studies are needed to clarify the detailed mechanism 
regulating cell growth by a combination of Spindly inhibition and cisplatin.   
The promising our in vitro results lead us to believe that the in vivo experiments on 
mouse xenografts models would strengthen our findings towards a future therapeutic 
use. Accordingly, it would be relevant to assess the ability of siRNA-mediated Spindly 
inhibition to inhibit tumor progression, in a murine subcutaneous tumor model, and to 
evaluate the effect of Spindly inhibition as an adjuvant of paclitaxel and cisplatin. This 
combination would minimize undesired toxicity to normal cells, as low doses of drugs 
would be used. Importantly, since siRNAs offers some restrictions due to its specific 
delivery to target cells/tissues and high toxicity, the use of functionalized carriers such 
as nanoparticles or therapeutic polymers would represents an attractive alternative for 
efficient intracellular release of siRNAs to specific tumor locations. Overall, our 
findings validate Spindly as a suitable therapeutic target and justify its combination with 
conventional anticancer drugs in order to enhance their efficacy and potentially 
overcome resistance, which would represent a promising concept for cancer therapy. 
Moreover, the results reinforce the concept of exploiting the genomic instability of 
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tumor cells through therapeutic inhibition of mitotic checkpoints could be a viable 
strategy. We believe that this strategy has a high likelihood of success given its potential 
to enhance therapeutic index by targeting tumor-specific vulnerabilities.  
In conclusion, the work presented in this thesis contributed to increase the current 
knowledge concerning the function and regulation of spindle assembly checkpoint and 
to highlight the potential of Spindly as a therapeutic target for cancer therapy, as an 
enhancer of paclitaxel and cisplatin-mediated cytotoxicity, making the aims initially 
proposed fulfilled and, at the same time, opening new lines of research.  
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CHAPTER 3. SHEDDING LIGHT ON SPINDLE ASSEMBLY CHECKPOINT 
REGULATION AND FUNCTION 
Dynein-dependent transport of spindle assembly checkpoint proteins off 
kinetochores toward spindle poles 
Movie 3.1. Control (Saline G) HeLa cells stably expressing EGFP-Bub3 showed normal 
mitosis timing and normal localization pattern of Bub3. Maximum projections of 7 Z-
stacks at 1 μm intervals are displayed. Time is shown in hours:minutes. 
Movie 3.2. ATP reduction induced relocalization of EGFP-Bub3 to spindle poles in 
metaphase-arrested cells. HeLa cells stably expressing EGFP-Bub3 were treated with 
MG132 and filmed for 30 minutes, then AZ/DOG was added and the cells were further 
filmed for 60 minutes. EGFP-Bub3 relocalized to spindle poles within minutes of 
adding AZ/DOG. Maximum projections of 7 Z-stacks at 1 μm intervals are displayed. 
Time is shown in hours:minutes. 
 
CHAPTER 4. EXPLORING THE POTENTIAL THERAPEUTIC IMPLICATIONS OF 
SPINDLE ASSEMBLY CHECKPOINT FOR CANCER THERAPY  
Spindly Delays Mitotic Exit and Exacerbates Cell Death Response of Cancer Cells 
Treated with Low Doses of Paclitaxel 
Movie 4.1. Time-lapse imaging (DIC microscopy) of a typical mitosis in untreated 
NCI-H460 cells. Time is shown in hours:minutes. 
Movie 4.2. Time-lapse imaging (DIC microscopy) showing a typical Spindly-depleted 
cell undergoing death in mitosis after >13 h spent in mitosis. Time is shown in 
hours:minutes. 
Movie 4.3. Time-lapse imaging (DIC microscopy) showing a typical mitosis in 10 nM 
paclitaxel-treated NCI-H460 cells. Time is shown in hours:minutes. 
Movie 4.4. Time-lapse imaging (DIC microscopy) of Spindly-depleted plus 10 nM 
paclitaxel-treated cells; the cell at the middle of field arrests in mitosis, initiates mitotic 
exit at 11h:00min, and dies at 26h:10min. Time is shown in hours:minutes. 
  
